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ABSTRACT
STUDY OF THE ENHANCEMENT EFFECT OF CYCLOPENTADECANOLIDE 
ON PROTEIN PERMEATION THROUGH LIPID MEMBRANES
By
Zhengmao Li 
University of New Hampshire, September 2004
Intranasal drug delivery has been a topic of increasing interest for a 
decade as a convenient and reliable method for the systemic administration of 
drugs. The low bioavailability of simple formulation of protein drugs, such as 
insulin, can be greatly improved by using permeation enhancers. We studied the 
effect of cyclopentadecanolide (CPE-215®) as a permeation enhancer in protein 
release through lipid bilayer membranes. We successfully designed a novel in- 
vitro membrane permeability model using liposomes and performed a series of 
transmembrane protein release experiments. These were carried out under a 
wide range of conditions in the presence of different permeation enhancer 
combinations. The experimental results showed that CPE-215® is an effective 
membrane permeation enhancer for proteins and a phase transfer agent, for 
example, cyclodextrins, can further enhance the effect of CPE-215®.
Besides the release experiments, studies on insulin solution properties 
(self-diffusion and self-association states), the interaction between insulin and
xiii
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liposome and the interaction between CPE-215® and liposomes were carried out. 
Based on the mechanistic study and release data, we hypothesized that CPE- 
215® can form transient “pores” in the lipid bilayer that dissolve when CPE-215® 
distributes homogeneously within the bilayer and restore the barrier function of 
the lipid bilayer. We performed several experiments that corroborate our 
hypothesis.
A mathematical model was developed based on our hypothesized release 
mechanism. A semi-empirical nonlinear equation involving four parameters 
effectively fits the protein release profiles. The quality of the data fit with this 
model is good supporting evidence for the validity of our mechanistic model. 
Finally we used a neural network approach to correlate the different release 
condition parameters and the four semi-empirical fitting parameters based on our 
limited data sets. Reasonable neural networks were formed for the three major 
parameters of the mathematical model and provided acceptable prediction 
results.
xiv
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CHAPTER 1
INTRODUCTION
Since our research is related to the mucosal delivery of protein/peptide 
drugs, an overview of protein/peptide drug delivery is given at the beginning of 
this chapter, then the topic is narrowed down to our research -  protein transport 
though natural membranes with permeation enhancers. Structure and major 
components of natural membranes, and different in vitro membrane permeability 
models (Caco-2, PAMPA, and liposomes) are discussed. Since liposomes were 
selected as our in vitro membrane model, detailed preparation and purification 
methods for different kinds of liposomes are presented.
1.1. Objective of Thesis
Cyclopentadecanolide (Figure 1), trademarked as CPE-215® is one 
permeation enhancer with proprietary ownership to Bentley Pharmaceuticals, Inc. 
Bentley Pharmaceuticals, Inc is using CPE-215® to help protein, peptide, and low 
molecular weight therapeutic drugs transport through natural membranes for 
delivery to the blood stream. This thesis aims to understand the process behind 
the permeation effect of CPE-215®. Pharmaceutical formulations are always 
challenged with a need for appropriate animal or human tests. These tests are
1
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typically costly and time consuming, and reproducibility is always difficult. To 
effectively develop formulations, it is advantageous to construct in vitro tests to 
optimize formulations, before in vivo testing. The goal of this thesis is to establish 
an in vitro membrane model for protein transmembrane transport, to understand 
the release mechanism of CPE-215®’ and to test intranasal formulations.
Figure 1 Molecular structure of Cyclopentadecanolide (CPE-215®).
1.2. Protein/Peptide Drug Delivery
1.2.1. Proteins and peptides as pharmaceuticals
The use of peptides and proteins for systemic treatment of certain 
diseases is now well accepted in medical practice. Peptide/protein drugs are 
increasingly becoming a very important class of therapeutical agents as a result 
of our gaining more understanding of their role in physiology and pathology as 
well as the rapid advances in the field of biotechnology and genetic engineering.
2
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Many of these peptides are endogenous molecules that play an important role in 
maintaining organ function and metabolic homeostasis.
Peptide and protein pharmaceuticals are different than conventional low 
molecular weight drugs; they are structurally more challenging and complicated; 
they are often unstable, have large molecular weights and have charges on the 
outer surface. The last two properties lead to poor permeability through biological 
membranes and consequently peptides and protein material are difficult to 
administer except by injection.1
1.2.2. Protein/Peptide Delivery- A Booming Research Area
There is presently an urgent need to find new ways to deliver peptides and 
protein drugs and to control their absorption and distribution in the body. In an 
editorial in 1998, Rakesh Jain2 stated that the delivery of therapeutics can be 
considered as the next frontier of molecular medicine research. He commented 
that extraordinary advances in molecular biology and biotechnology have helped 
identify novel targets and develop a vast array of therapeutic agents. However,
(in his view), our understanding of the delivery of therapeutic agents has lagged 
behind.
In the past, when developing new products, drug delivery scientists have 
often em ployed delivery strategies to enhance a property, such as the controlled 
release of the therapeutic agent. However, for the case of peptides and proteins, 
drug delivery systems must play a more critical role in enabling a viable product. 
In doing so, a detailed knowledge of the properties of the compound needs to be
3
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Figure 2 Number of published research papers (journal, letter and patent 
only) on protein/peptide drug delivery every year from 1985 to 2003.
Usually the number of publications on a research topic shows the 
magnitude of people’s interest in the topic. A publication search on 
protein/peptide drug delivery using SciFinder Scholar in early 2004, shows that 
this is really a booming research area. Figure 2 highlights the number of 
published research papers (journal, letter and patent only) on protein/peptide 
drug delivery every year from 1985 to 2003. Researchers’ interest in 
protein/peptide drug delivery started in the mid 1980s; for the first decade, there
4
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was a steady and slow increase in the number of publications. However, after the 
mid 1990s, the number of yearly publications increased drastically, from around 
50 a year in 1995 to almost 1300 a year in 2003. There are several key academic 
researchers in this booming field, such as Dr. Robert Langer (MIT), Dr. Nicholas 
Peppas (U Texas), Dr. Francis Szoka (UCSF), Dr. William Pardridge (UCLA), Dr. 
Jacobus Verhoef (Leiden U, Netherlands), Dr. Andreas Bernkop-Schnurch (U 
Vienna, Austria), Dr. Allan Hoffman (U Washington), and Dr. Lisbeth Ilium (U 
Nottingham, UK), to cite only the most published principal investigators.
1.2.3. Delivery Routes
The choice of delivery routes for drugs is wide (parenteral,3 oral,4,5 
pulmonary,67 intranasal,8,9 transdermal,10,11 buccal,12,13 ocular,14,15 rectal,16 
vaginal,17 etc.). The clinical application, drug properties, patient convenience, and 
required “performance” (e.g. bioavailability), are all key selection factors. The 
next sections (1.2.3.1 to 1.2.3.6) are an overview of these delivery routes, recent 
development and their pros and cons.
1.2.3.1. Injectable Systems
Injections are inevitably associated with some degree of pain, irrespective 
of their route of delivery, whether intramuscular, intravenous, or subcutaneous. 
The inherent advantages of injectable systems need to be weighed against their 
disadvantages.
5
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Currently, proteins and peptides are mostly delivered by parenteral 
administration. Because they are extremely short-acting, repeated injections are 
often required. Parenteral delivery can be used to target compounds to specific 
sites (via blood or lymphatic systems), as well as to provide precise 
pharmacokinetic and phamacodynamic profiles. Exciting developments have 
shown how formulation technologies can be used to provide improved parenteral 
delivery (e.g. nanoparticles, liposomes, PEGylation).18,19 Engineering based 
systems, such as insulin pumps and injection pen systems (for insulin and 
human growth hormone), have gained considerable success in the market. 
Needleless injection systems currently under development should have better 
patient acceptance.20 These include systems employing liquid or powder 
technologies.
Polymer implants and microspheres based on polylactide-coglycolide 
(PLGA) have been very successful clinically.21 Flamel Technologies developed a 
self-assembled poly-aminoacid nanoparticles system for parenteral delivery of 
proteins. However, polymer microspheres are not without problems in terms of 
loading, drug stability and release profiles. Processing, particularly sterilization, 
remains an issue. New implant systems based on alternative concepts are 
currently under investigation including an implantable titanium device.22
1.2.3.2. Oral Delivery
Oral delivery is the most preferred method for the introduction of 
therapeutic agents. In 2002, oral delivery technologies accounted for 39% ($14
6
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billion) of the world market ($38 billion).23 This field has been the subject of many 
peptide and protein delivery attempts, particularly with insulin; but, as yet, few 
oral polypeptide products have reached the market.
Peptides and proteins are inherently unstable in the harsh conditions of 
the gastrointestinal tract (pH, enzymes, adsorption to solids); but, even if 
instability can be avoided, good absorption is not guaranteed. The work of Drew 
et al. on octreotide is instructive.24 Octreotide is a cyclic polypeptide (a 
somatostatin analogue) that is very stable even in the small intestines. When 
orally given to human as a simple solution, the bioavailability is 0.6%. This can 
increase to 3.3% by using a non-ionic surfactant (polyoxyethylene 24-cholesterol 
ether). Therefore, for oral administration, it is important to be realistic about 
potential product performance. If stability is an issue, then enteric coating and 
enzyme inhibitors can be used.25 Absorption can be improved by selecting a 
permeation enhancer that can improve transcellular or paracellular transport.
Also of importance is the selection of a preferential absorption site. The small 
intestine and large intestine have both advantages and disadvantages.
Therefore, before developing a delivery strategy, it can be important to evaluate 
the absorption of a candidate biopharmaceutical. Today it is possible to deliver 
drugs into different regions of the human gastrointestinal tract using “smart” 
capsules.26 This avoids the highly invasive method of intubation.
Various methods to increase the absorption of challenging molecules from 
the gastrointestinal tract have been tried. These include permeation enhancers 
such as surfactants, chitosan (and derivatives thereof), chelating agents, as well
7
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as carriers and complexation systems.27 Some of these strategies use known 
pharmaceutical excipients (GRAS (Generally Recognized As Safe) status) which 
can alter cell permeability, usually by modification of the paracellular pathway. 
Non-covalent complexation strategies have also been reported.28 The 
modification of peptides and proteins chemically by lipidzation or the attachment 
of hydrophilic and hydrophobic polymeric functions has also been described.29,30 
Clearly, such modifications result in a new chemical entity and the associated 
regulatory issues. The covalent attachment of moieties that permit the 
biopharmaceutical to exploit biological transporters is also an active area of 
research.31,32 Here again, there is the disadvantage of covalent chemistry, but 
these approaches could offer exciting opportunities in the exploitation of natural 
pathways. A recent report by Morris et al. could open up new approaches.33 They 
found that a 21 residue peptide that had hydrophilic and hydrophobic regions 
forms stable non-covalent complexes with peptides and proteins. They were able 
to use this system to deliver a model protein into various cell lines. The system 
was claimed to have low toxicity but as yet, no in vivo data have been reported.
Alternatively, one may use nanoparticles for the delivery of peptide and 
protein drugs into the systemic circulation from the gastrointestinal tract. It is well 
known that certain specialized cells (M-cells) in the gastrointestinal tract can take 
up and transport particles.34 The size and surface properties of the particles are 
key factors. This process is important for the development of oral vaccine 
systems. However, the quantities of material transported are low, even with 
systems with specific surface markers that provide enhanced interaction between
8
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particles and cells. Some clinical phase II trials suggested that particle uptake 
resulted in less than 0.1% of the administered dose being sequestered.35 This 
could be sufficient for a beneficial immune response when developing an oral 
vaccine but will surely be of no benefit for the oral delivery of peptides.
1.2.3.3. Pulmonary Delivery
Patton has claimed that the lung is a logical target for non-invasive drug 
delivery.36 It should provide rapid onset of action and a variety of delivery devices 
(Metered Dose Inhalers (MDI), Dry Powder Inhalers (DPI), nebulizers). Good 
absorption, even of polar drugs, can be achieved, if the drug is delivered to the 
deep lung. Good patient compliance is to be expected provided that the device 
and delivery system are properly engineered. Similarly, good reliability should 
also be attainable. Understandably, insulin has been the molecule of choice and 
a number of different companies are pursuing novel pulmonary delivery systems 
using liquid and powder systems. Reported bioavailabilities, versus s.c. 
(subcutaneous) injection, range from 10-20% and reliability would appear to be 
as good as or better than for injectable insulin (s.c.). Various products are now in 
Phase ll/Phase III clinical evaluation and the results look to be encouraging. 
However, some concerns over safety (lung function, cough) and increased 
antibody levels have been raised recently, but it is likely that inhaled products for 
insulin (and other therapeutic peptides) will reach the market soon. One great 
advantage of the lung is that it is possible to obtain reasonable absorption (i.e. 
50% of the dose delivered) across the mucosal surfaces of the deep lung-
9
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alveolar region using simple formulations. Long term effect of pulmonary delivery 
has yet to be investigated.
1.2.3.4. Nasal Delivery
The nose is an alternative part of the respiratory system that can be 
exploited for the delivery of therapeutic peptides and proteins. Nasal products for 
peptide delivery are on the market, but with low bioavailability.37 Nasal delivery 
can provide rapid onset of action and good deposition can be achieved readily for 
both liquid and powder systems. However, using simple formulations, the 
absorption of biopharmaceuticals from the nose of animal models and human is 
less than 1%. Therefore, in order to improve reliability and to address cost of 
goods issues, absorption enhancers may be required. Various materials have 
been studied over the years. While many are effective, most are associated with 
problems of irritation and regulatory acceptance.38 Often an increase in 
absorption (e.g. bioavailability) is associated with a direct effect of membrane 
damage. However, some materials such as certain phospholipids can provide 
good absorption with low toxicity; the polysaccharide material chitosan was found 
to provide increased drug absorption with no evidence of toxic manifestations.39
The nasal route also provides a unique delivery opportunity. The olfactory 
region of the nose can be exploited to provide direct delivery of drugs into the 
brain.40 Recent studies by Frey et al. have demonstrated that polypeptide 
materials such as nerve growth factor can reach the CSF and brain tissues 41 In 
addition, exciting clinical studies by Fehm and Born42 have demonstrated that
10
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materials such as arginine vasopressin, angiotensin II, and insulin can be 
transported from nose to brain in humans, in low quantities. This could be a novel 
way to avoid the blood-brain barrier and to provide a novel means of access to 
the brain.
1.2.3.5. Buccal Delivery
The mouth has been examined as a delivery route for biopharmaceuticals 
by various groups using animal models and also in humans. The pivotal clinical 
studies of de Groot and colleagues using sublingual oxytocin suggest a low 
bioavailability of less than 1%.43 Therefore, the results recently reported on the 
buccal administration of insulin using a spray device (MDI) are both surprising 
and potentially exciting. Reported clinical studies in diabetic subjects have 
demonstrated good efficacy with bioavailabilities in the range of 5-10%.44
1.2.3.6. Transdermal Delivery
The transdermal delivery of polypeptides has been evaluated by many 
groups, but the results so far are not encouraging.45 Good results in animal 
models do not translate well to human (usually because the chosen animal 
model has little relevance to the human skin). The skin of human provides a good 
barrier. Novel approaches to “driving” polypeptides across the skin, such as 
iontophoresis and ultrasound, have been explored but clinical results have been 
disappointing 46,47 Insulin is an interesting case where physiological pH is a
11
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problem when considering iontophoresis. The charge on the molecule changes 
with pH gradient across the skin. Under electrophoresis, the molecule can be 
forced into the skin; but, as the pH changes from the skin surface to tissue, the 
charge on the molecule reverses and the molecule is forced to back out!
A novel transdermal system using “transferosomes" (ultraflexible 
liposomes with low pore resistance) has been proposed by Cevc.48 It is claimed 
that the system can transport therapeutic amounts of insulin across intact 
mammalian skin but detailed clinical results are awaited. Alternative engineering 
approaches, such as microneedles produced by photolithography, could well 
provide a more reliable transdermal system 49
1.3. Membrane Permeation Enhancers
To minimize the health hazard of repeated injection, there is a need to 
search for another systemic delivery route as a non-invasive alternative to 
injection. Mucosal delivery routes, such as pulmonary, intranasal and oral routes, 
will deliver the drugs through the mucosa and reach the general blood circulation 
via numerous capillary vessels present underneath the mucosa.
In mucosal delivery, therapeutic agents need to go through mucous 
membranes first; but mucous membranes are not designed to let foreign subjects 
go through and into the blood system—on the contrary, one of the critical 
functions of the mucus membranes is the barrier function. Some small and 
neutral molecules, such as glycerin and vitamins can go through natural 
membranes easily. But large molecules, for example protein/peptide drugs,
12
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cannot go through mucous membranes and into the blood by themselves, in 
another words, mucous membranes are not permeable to them. Therefore, 
improving the bioavailability of the therapeutic agents is the major task for 
protein/peptide mucosal delivery. In order to go through barrier membranes, 
protein/peptide drugs need the help of membrane permeation enhancers.
Membrane permeation enhancers are usually small molecules used to 
interact with the membranes and increase the permeability of membranes. The 
main concerns with membrane permeation enhancers are safety issues: they can 
cause irritations and can break the integrity of the membrane. Many molecules 
have been studied and used as membrane permeation enhancers. Generally 
speaking, permeation enhancers have experienced three generations.50 The first 
generation is represented by bile salts and surfactants. The second generation is 
represented by salicylates, enamines, fusidate derivatives, acylcarnitines and 
phospholipids. Nutrients, hormones and antioxidants form the main force of the 
third generation of the membrane permeation enhancers. CPE-215® may fall in 
the second generation in this category.
1.4. Membrane Structure
In order to study the permeation property of biological membranes, one 
must know the structure of the mem branes. Despite the variable compositions of 
biological membranes, the basic structural unit of virtually all biomembranes is 
the phospholipid bilayer, with embedded proteins (Figure 3). This bilayer is a 
sheet like structure composed of two layers of phospholipid molecules whose
13
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polar head groups face the surrounding water and whose fatty acyl chains form a 
continuous hydrophobic interior of 4 nm thick. Each phospholipid layer in this 
lamellar structure is called a leaflet. The major driving force for the formation of 
phospholipid bilayers is hydrophobic interaction between the fatty acyl chains of 
glycolipid and phospholipid molecules. Van der Waals interactions among the 
hydrocarbon chains favor close packing of these hydrophobic tails. Hydrogen 
bonding and electrostatic interactions between the polar head groups and water 
molecules also stabilize the bilayer. Therefore, the membrane has a relatively 
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Membrane proteins are embedded in the lipid bilayer. Some may pass 
through the bilayer as transmembrane proteins. Transmembrane proteins are
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amphipathic, which means they have hydrophobic and hydrophilic regions that 
are oriented in the same regions in the lipid bilayer. Another name for them is 
“integral proteins”. Other types of proteins may be linked only at the cytoplasmic 
surface by attachment to a fatty acid chain, or at the external cell surface 
attached by an oligosaccharide. In other cases, these non-transmembrane 
proteins may be bound to other membrane proteins. Collectively these are called 
“peripheral membrane proteins”.
Membrane lipids are numerous and diverse, such as phosphatidylcholine, 
phosphatidylserine, sphingomyelin, cholesterol, etc. The lipid components of 
biological membranes in animal cells consist predominantly of phospholipids. 
The phospholipids have two fatty acyl chains esterified to glycerol and a 
hydrophilic “head group”. In animal cells phosphatidylcholine (PC) is the major 
phospholipid.
15
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Figure 4 Molecular structure of some common membrane lipids. 52
Cholesterol is a particular type of lipid. It is a membrane constituent widely 
found in biological systems which serves the unique purpose of modulating 
membrane fluidity, elasticity, and permeability. It literally fills in the gaps created 
by imperfect packing of other lipid species when proteins are embedded in the 
membrane. Cholesterol serves much the same purpose in model membranes. 
The cholesterol molecule inserts itself in the membrane with the same orientation 
as the phospholipid molecules. Figure 5 shows phospholipid molecules with a 
cholesterol molecule inserted. Note that the polar head of the cholesterol is 
aligned with the polar head of the phospholipids.
16
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Figure 5 Cholesterol molecules in lipid bilayer.49
Different lipids can have different conformations in water when they gather 
together, and those conformations are usually determined by their molecular 
shapes (Figure 6). Lipids with a big hydrophilic anionic “head” and a small 
hydrophobic hydrocarbon “tail”, for example common detergents, have the shape 
of an inverted cone, and will form micelles in water. Lipids with a hydrophilic 
“head” and two hydrophobic “tails”, for example most lipids in natural 
membranes, have a cylindrical shape, and will form lipid bilayers in water. These 
lipid bilayers are thermodynamically stable.
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Figure 6 Polymorphic phases, molecular shapes, and the critical packing 
parameter for some membrane lipids.53
1.5. In Vitro Membrane Permeability Models
It costs pharmaceutical companies hundreds of millions of dollars to test 
drugs in Phase II & III. This makes a compound that demonstrates low 
bioavailability during clinical trials unacceptable. To prevent this problem, drug 
candidates are screened for their absorption potential early in the discovery and 
development phase, when investment in a compound is low, as a filter to remove 
poor performers and identify candidates that need to be potentially modified.
18
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Initially, in silico methods were favored. But computational models based 
on molecular properties typically fail when large sets of diverse compounds are 
analyzed. This is particularly a problem when conformationally flexible 
compounds are used. Membrane retention is also an important phenomenon. 
Two compounds can have the same permeability but different membrane 
retention characteristics. This retention is often misunderstood or neglected, 
which leads to incorrect membrane permeability estimates and calculations. The 
failure of physiochemistry-based predictions led to the development of simple 
assays to evaluate compound absorption. As a result, two permeability assays 
have become prevalent in the past five years: the Caco-2 cell permeability assay 
and the parallel artificial membrane permeability assay (PAMPA). These assays 
have risen to play important roles in industry, and most companies perform at 
least one of them in their research programs.
Figure 7 Caco-2 and PAMPA. Caco-2 uses compartments of different 
volumes separated by a monolayer of cell grown on a filter. PAMPA uses 
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Liposomes are usually used as model membranes to study the properties 
of pure lipids and lipid mixtures. In the drug delivery field, they are mostly used 
as drug delivery carriers. However, we found that they can also be used as 
membrane permeability models due to their lipid bilayer structure.
1.5.1. Caco-2
First described in the early 1990s, cell permeability studies came to 
industry from academia, where several groups worked to develop cell-based 
assays that mimicked the passage of drugs through the intestinal mucosa54,55— 
the Caco-2 assay was the result.
In typical experiments, a monolayer of cells is grown on a filter separating 
two stacked microwell plates. The permeability of compounds through the cells is 
determined after the introduction of a drug on one side of the filter. The entire 
process has been automated, and when used in conjunction with LC-MS 
detection, it enables any compound’s permeability to be determined. It is 
recognized by the FDA as one of the few means to measure permeability as part 
of the bioequivalence waiver process. Since its introduction, Caco-2 has been 
championed as a standard for measuring permeability, but it is not without some 
shortcomings.
Caco-2 experiments require up to 20 days for the preparation of stable 
monolayers, and the cells must be maintained in protective environments, free 
from contamination, and examined for tight-junction formation prior to use. The
20
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method requires careful sample analysis to calculate permeability correctly. 
Interlaboratory variation is a problem because of differences in cell line strains. 
Caco-2 cells also contain endogenous transporter and efflux systems, the latter 
of which work against the permeability process and can complicate data 
interpretation for some compounds. In addition, test compound solubility appears 
to be a problem in Caco-2 assays because of the assay conditions.
1.5.2. PAMPA
As a less expensive alternative to Caco-2, Manfred Kansy et al. developed 
PAMPA.56 A “PAMPA sandwich” is prepared from two plates that are similar to 
those used for traditional Caco-2 experiments (Figure 7). One plate contains a 
porous filter disk at the bottom of each well. The other one is a reservoir plate 
that is precisely molded to sit under the filter plate so that contact between the 
two occurs at the filter. The filter is coated with a solution of lipid material in inert 
organic solvent to prepare the artificial membrane. The wells of one plate are 
then filled with donor solution (i.e., drug), and the other with acceptor solution 
(i.e., buffer); the plates are then stacked to create the sandwich and are 
incubated. The drug concentration in the donor and acceptor wells is then 
determined by UV or LC-MS methods, and permeability is calculated.57 The 
whole PAMPA process is easily automated and commercially available.
The lipid choice is flexible and often varies by research group, ranging 
from mixtures that reflect the lipid composition of mammalian cell membranes to
21
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simple synthetic phospholipids.58 Some even forgo the lipid altogether and use 
non-polar organic solvents.59
With PAMPA, the emphasis is on simplicity. Because the membrane has 
no transporters or efflux systems, only passive permeability is observed. And 
because there is no growth period, the analysis can be set up quickly from 
standard stock supplies without concern about contamination. This allows 
PAMPA to be run without restructuring laboratories to create sterile 
environments, making PAMPA experiments easier, faster, and much less 
expensive to run than Caco-2 assays.
1.5.3. Liposome
Due to the lack of experience with cell culture and uncertainty with cell 
lives, we did not use Caco-2 as the membrane permeability model. As to 
PAMPA, its artificial membrane is a filter coated with a solution of lipid materials 
in inert organic solvent, which is quite different from the lipid bilayer structure of 
biological membranes. In that case, PAMPA will not be a good membrane analog 
for us to study the interaction of our hydrophobic permeation enhancer with 
biological membranes.
Liposomes have a spherical lipid bilayer structure, which is very similar to 
the lipid bilayer structure in biological membranes. Since liposomes can 
encapsulate solutions inside and separate the inside solution from the outside, 
we found that liposome can be used as a passive membrane permeability model. 
By encapsulating the drug solution inside of liposomes and detecting the drug
22
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concentration in the outside solution, we can monitor the drug transport across 
the lipid bilayer.
The research on liposomes is mostly focused on using liposomes as drug 
delivery carriers,60,61 and structural model membranes. However, no one has yet 
reported using liposomes as passive membrane permeability models before.
More information about liposomes will be introduced in the following 
section.
1.6. Liposome as an Artificial Membrane Model
The term “liposome” can be defined as any lipid bilayer structure which 
encloses a volume (Figure 8).62,63,64 Many phospholipids, when dispersed in 
water, spontaneously form a heterogeneous mixture of vesicular structures which 
contain multiple bilayers forming a series of concentric shells.
Lipid* auikt butUtiny 
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Figure 8 Liposome structure (half).65
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There are different kinds of liposomes (vesicles): multilamellar vesicles 
(MLV), large unilamellar vesicles (LUV) and small unilamellar vesicles (SUV, < 
100 nm in diameter). Practical applications of liposomes have been explored in 
three main areas of research, namely in model membrane studies, in controlled 
and targeted drug delivery in vivo, and in transfer of genetic and other material 
into cells in culture.
One important property of liposome is its thermal phase transition. The 
phase transition temperature (Tc) is defined as the temperature required to 
induce a change in the lipid physical state from the ordered gel phase, where the 
hydrocarbon chains are fully extended and closely packed at low temperature, to 
the disordered liquid crystalline phase, where the hydrocarbon chains are 
randomly oriented and fluid at more elevated temperature. There are several 
factors which directly affect the phase transition temperature including 
hydrocarbon length, unsaturation, charge, and headgroup species. As the 
hydrocarbon length is increased, van derWaals interactions become stronger 
requiring more energy to disrupt the ordered packing, thus the phase transition 
temperature increases. Likewise, introducing a double bond into the acyl group 
puts a kink in the chain which requires much lower temperatures to induce an 
ordered packing arrangement. This property will be the object of a specific study 
in Chapter 4.2.
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1.6.1. Preparation of Liposomes
When considering the preparative methodology of liposomes, it has to be 
recognized that different applications require different types of liposomes.
1.6.1.1. Multilamellar Vesicles (MLV)
Multilamellar liposomes were first described by Bangham et al.66 The 
procedure used by them still remains the simplest and the most widely used. This 
involves the deposition of a thin lipid film from an organic solvent medium on the 
walls of a container, followed by agitation with an aqueous solution of the 
material to be encapsulated. Provided the agitation is carried out at temperatures 
above the characteristic gel-liquid crystal phase transition temperature of the 
phospholipid and the lipid film is indeed thin, MLV should form spontaneously 
with little effort. However, the degree of agitation required to form a good 
dispersion of MLV (without poorly hydrated lipid globules) will depend upon the 
thickness of the lipid film. With relatively thicker films produced by more 
concentrated lipid solutions and/or smaller evaporation vessels, more vigorous 
agitation is required.
The MLV appear to be attractive because of the ease of their preparation 
and relative stability on storage. However, the disadvantages include low 
encapsulation efficiency and inconsistency of properties.
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1.6.1.2. Large Uni- or Oligolamellar Vesicles
Relatively large liposomes with either one or a few lamellae, as for 
example the reverse-phase-evaporation vesicles (REV), occupy an intermediate 
position between the MLV and small unilamellar vesicles (SUV). Some common 
large unilamellar liposome preparation methods will be briefly introduced below.
1.6.1.2.1. Ether Infusion
Ether infusion techniques67,68 can be used to prepare large unilamellar 
liposomes. The basic principle is the injection of a solution of lipids in ether into 
an aqueous solution of the material to be encapsulated at a temperature high 
enough for the rapid evaporation of the solvent. Large molecules such as 
proteins and DNA have been encapsulated into liposomes using this technique. 
Although the encapsulation efficiency is very low, relatively large aqueous space 
volumes have been reported 69 Additionally, the size distribution of the liposomes 
is heterogeneous.
1.6.1.2.2. Calcium-Induced Fusion
This method, developed by Papahadjopoulos et al.70 relies on the effect of 
calcium ions on acidic phospholipids to form initially cochleate cylindrical 
structures, which are then transformed into large unilamellar vesicles (LUV) by 
the addition of the chelating agent EDTA. Although the preparative procedure 
and efficiency of encapsulation are attractive,71 the presence of calcium ions and 
the sequestrant during the formation of the liposomes and consequent
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contamination of the liposomes with these may be unacceptable. Furthermore, 
this rather specialized technique is valid only for acidic lipids.
1.6.1.2.3. Reverse-Phase-Evaporation (REV)
This method was introduced by Szoka and Papahadjopoulos72 for the 
preparation of large uni- or oligolamellar liposomes incorporating a variety of 
drugs and biologically active materials. The efficiency of drug encapsulation, 
generally around 50%, is very good. The method appears suitable for use with a 
variety of lipids and lipid mixtures and for the encapsulation of even large 
macromolecular materials. The aqueous space in these liposomes is 7 to 10 
l/mol lipid, which is very high in comparison to MLV and SUV.8 Liposomal 
dispersions prepared in this manner are said to be mixtures of large unilamellar 
and oligolamellar liposomes with the size and number of lamellae being 
dependent upon the nature of the lipid mixture, and possibly the exact 
procedure.6,73
The relatively high encapsulation efficiency for a variety of compounds 
and the basic principle of going from an emulsion to a liposomal dispersion are 
very attractive from scale-up and processing considerations. Greater 
reproducibility of liposome size range and drug encapsulation can be expected 
due to the absence of the “dry lipid” stage. O ne of the disadvantages of this 
method is the need for sonication of the mixture of the lipid solution and the 
aqueous drug solution to form an “adequate” emulsion. This step would be 
difficult to operate on a large scale in a reproducible manner. Although Szoka
27
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
and Papahadjopoulos6 stressed the need for sonication in order to ensure a 
homogeneous emulsion, and thus a primarily unilamellar liposomal dispersion, 
other emulsification techniques may be equally effective. Other drawbacks of this 
procedure include the presence of the organic solvent in contact with the material 
to be encapsulated and the temperature needed for the evaporation of the 
solvent under reduced pressure. These conditions may be too severe for 
peptides and proteins.
1.6.1.2.4. Rapid Extrusion through Polycarbonate Filter
Lipid extrusion is a technique in which a lipid suspension is forced under 
pressure through polycarbonate filters with defined pore sizes to yield particles 
with a mean diameter that reflects that of the filter pore.74 Prior to extrusion 
through the final pore size, LMV suspensions are disrupted either by several 
freeze-thaw cycles or by prefiltering the suspension through a larger pore size. 
This method helps prevent the membranes from fouling and improves the 
homogeneity of the size distribution of the final suspension. As with all 
procedures for downsizing LMV dispersions, the extrusion should be done at a 
temperature above the Tc of the lipid. Attempts to extrude below the Tc will be 
unsuccessful as the membrane has a tendency to foul with rigid membranes 
which cannot pass through the pores.
Preparing liposomes by extrusion allows the size of the liposomes to be 
specified by selecting a polycarbonate membrane filters with a specific pore size.
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Mean particle size is quite reproducible from batch to batch. Liposomes made 
from extrusion process usually have narrow size distributions.
1.6.1.3. Small Unilamellar Liposomes (SUV)
Small unilamellar liposomes (SUV) are of great interest in drug delivery 
because of their potential for controlled drug release in the blood stream and for 
targeting to non-reticuloendothelial cells and tissues. The slow clearance of SUV 
from circulation after i.v. administration75 offers these possibilities. SUV also have 
a potential for fusion with target cell membranes. Methods for the preparation of 
SUV are examined in the following sections.
1.6.1.3.1. Sonication
The most widely used procedure for the preparation of SUV consists of 
sonicating MLV using either a probe or a sonication bath.76,77 Electron 
microscopic techniques are used to visualize the unilamellar structure and to 
estimate the size, typically about 50 nm as the mean diameter. In general, 
adequate ultrasonic treatment leads to a homogeneous preparation in terms of 
size. One of the consequences of the small size of the SUV is the limited 
aqueous space inside the liposomes and the low encapsulation efficiency.9 
Application of ultrasonic energy as a means of converting MLV to SUV is unlikely 
to be a reliable and consistent operation in large-scale manufacture.
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1.6.1.3.2. Ethanol Injection
This procedure, introduced by Batzri and Korn,78 is reported to produce 
relatively small unilamellar liposomes. Although this technique is, in principle, 
similar to the ether injection method,3 the size and degree of heterogeneity of the 
liposomes are dependent upon the concentration of the lipids and the relative 
volumes of the alcoholic and the aqueous phases. The basic procedure is 
amenable to scale-up and needs to be examined further. Two major drawbacks 
of this method are the low drug encapsulation levels and the yield of liposomes 
as a very dilute dispersion at the end of the process. An additional concentration 
step is required to produce an adequate liposomal dispersion.
1.6.1.3.3. Detergent Dialysis
The detergent dialysis procedure was developed by Milsmann et al.79 In 
this method, mixed micelles are first formed by dispersing a phospholipid and a 
surfactant in an aqueous solution of the material to be encapsulated. This 
dispersion of mixed micelles is then dialyzed extensively, when the surfactant is 
gradually removed and the phospholipid assumes a unilamellar liposome 
structure. Homogeneous dispersions of SUV are formed by this technique. An 
additional advantage is the absence of an evaporation step and elevated 
temperatures. This allows encapsulation of labile materials under mild conditions.
The degree of encapsulation is, however, very low because of the loss of 
material during dialysis (while the liposomes are being formed), except in the 
case of encapsulation of macromolecular compounds. Another disadvantage of
30
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this method is the presence of considerable amounts of residual surfactant in the 
final liposomal dispersion at the end of dialysis.
1.6.1.3.4. Reverse Micelle Method
The reverse micelle method was described in a patent by the Battelle 
Memorial Institute.80 In this method, a small quantity of an aqueous solution of 
the material to be encapsulated is initially dispersed in a volatile organic solvent 
containing the lipid mixture. The inverted micellar dispersion is then redispersed 
in an aqueous buffer medium to form a water-in-oil-in-water type emulsion. Upon 
evaporation of the solvent under reduced pressure or by means of a stream of 
nitrogen, unilamellar liposomes are obtained.
Very high degrees of drug encapsulation, in terms of the encapsulated 
drug as a percentage of the total drug used, are claimed. However, it should be 
pointed out that the drug solution only forms the interior aqueous phase of the 
emulsion. Consequently, the final liposomal dispersion is dilute with respect to 
the encapsulated drug, although the apparent degree of encapsulation is high. 
This technique has potential for large-scale application and should be explored 
further.
1.6.2. Removal of Unbound Drug
When lipophilic drugs of appropriate structure are associated with 
liposomes by inclusion in the bilayer phase, the degree of “encapsulation” is
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dependent upon the saturation of the lipid phase. Under these circumstances, it 
is possible to achieve degrees of encapsulation of over 90%, making it 
unnecessary to remove the unbound drug. However, in the case of water-soluble 
drugs, the encapsulated drug is only a fraction of the total drug used. An 
additional process step is required to remove the unbound drug from the drug- 
loaded liposomes in dispersion. Dialysis, centrifugation, and gel filtration have 
been used for this purpose.
1.6.2.1. Dialysis
Dialysis is probably the simplest and most widely used procedure for the 
removal of the unbound drug, except when macromolecular compounds are 
involved.81 It is a technique requiring no complicated or expensive equipment and 
is capable of being scaled up. Dialysis is effective in removing nearly the entire 
free drugs with a sufficient number of changes of the dialyzing medium. Dialysis 
is, however, a slow process. Typically, removal of over 95% of the free drug in a 
liposomal dispersion might require a minimum of 3 changes of the external 
medium over 10 to 24 hr at room temperature. Additionally, the volume of the 
liposomal dispersion will alter during dialysis, unless care is taken to balance the 
osmotic strengths of the liposomal dispersion and the dialyzing medium. It is also 
possible that the presence of the external dialyzing medium in equilibrium with 
the liposomal dispersion might induce leakage of the encapsulated drug.
32
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
1.6.2.2. Centrifugation
Centrifugation at various g values is an effective means of isolating 
various kinds of liposomes from the free drug in the suspending medium.82 Two 
or more resuspension and centrifugation steps are usually included to effect a 
complete removal of the free drug. The centrifugal force required to pull 
liposomes down into a pellet is dependent upon the size of the liposomes, and to 
a certain extent, on the flocculation state of the dispersion. The lowest speed 
possible to achieve pelleting is best since higher speeds could induce 
deformation and/or fusion of liposomes. High g values and conditions of 
refrigeration are required for liposomes in the small to medium size ranges.
Clearly, the use of refrigerated centrifuges operating at high speeds with 
large volumes of liposomal dispersions is energy intensive and expensive, when 
feasible. Therefore, this method may not be suitable for the isolation of small 
liposomes. For relatively large liposomes, low speed centrifugation offers the 
advantages of a short time scale of operation and an opportunity to concentrate 
or dilute the original dispersion to the required extent. It is essential to ensure 
that the osmotic strength of the resuspending medium is matched with that of 
original liposomal dispersion in order to avoid osmotic shock and rupture of 
liposomes.
1.6.2.3. Gel Filtration
Gel permeation chromatographic technique is used extensively both to 
separate liposomes from unbound drug and also to fractionate heterogeneous
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liposomal dispersions.83 The technique is very effective and rapid at the 
laboratory level. Although gel filtration is used in the purification of biological 
materials such as insulin on a large scale, the technique is difficult and 
expensive. Additionally, dilution of the liposomal dispersion with the eluting 
medium may necessitate another concentration step. Much remains to be 
established in regard to recovery levels and lipid losses on the column materials.
Centrifugation is the fastest way to remove unbound drugs from liposomes 
among the three; it works fine with large liposomes, but not very well with small 
liposomes (<100 nm). Dialysis takes longer time, but it is easier and cheaper 
than gel filtration. Gel filtration is a universal method to remove unbound drugs 
from liposomes, but it involves gel column packing and may dilute the liposome 
suspension after the process.
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CHAPTER 2
METHODOLOGY
In this chapter, the focus is on the design and development of a novel and 
valid in vitro membrane release model for protein/peptide drugs. We selected the 
kind of lipid that would be used to prepare liposomes and the model proteins, and 
determined the protocol for the release experiments. Then improvements on the 
liposome preparation, protein detection, and release experiment procedure are 
discussed.
2.1. Release Concept “In Vivo” Vs. “In Vitro”
In a conventional intranasal drug delivery configuration, the peptide drug 
and the permeation enhancer are formulated together to achieve delivery across 
the natural membrane. In our model, we encapsulate the peptide inside the 
liposome, and use the formulated permeation enhancer to “free” the peptide from 
the liposome. This simple permutation of location is illustrated in Figure 9.
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Figure 9 Contrast between in vivo and in vitro formulation testing.
Indeed, our liposome model differs from the mechanism of in vivo 
intranasal delivery. In in vivo intranasal delivery, the peptide drug is in the vicinity 
of the permeation enhancer and diffuses into the biological membrane. In the 
present liposome model, the peptide is encapsulated inside the liposome, while 
the permeation enhancer is added outside. The outside peptide concentration is 
measured to quantify the permeation enhancing effect. In both instances the 
peptide is required to travel across the membrane. In both situations, the 
“assistance” of the permeation enhancer is necessary to achieve faster release 
(or permeation) rates. If the peptide release is faster with the addition of a 
specific formulation of permeation enhancers, then we know this formulation can 
effectively interact with the loaded liposome to let the peptide cross through the
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bilayer. The methodology needed to test the efficiency of a permeation enhancer 
formulation is less complex and expensive compared to an in vivo test.
2.2. In Vitro Release Protocol Design
The concept is to encapsulate the protein/peptide drugs inside liposomes, 
separate the liposomes from the unencapsulated drugs, then add the permeation 
enhancer outside of the liposomes and monitor how fast the encapsulated drugs 
can release out of the liposomes. In the following sections, the choice of 
liposome lipid, protein and release probes will be discussed.
2.2.1 Liposome
In order to make full use of the lipid, obviously unilamellar liposomes are 
more desirable than multilamellar liposomes. During the liposome encapsulation 
process of an aqueous solution of drugs, lipids form spherical lipid bilayers and 
encapsulate part of the solution inside; after the formation of the liposomes, the 
concentrations of the aqueous solutions inside and outside of liposomes are the 
same. To increase the liposome encapsulation efficiency, or to encapsulate the 
maximum amount of solution with a given amount of lipids, one must answer the 
question of how to occupy the maximum total volume with the same total surface 
area. The answer to this question is to make one giant unilamellar liposome, but 
there is no practical value to make a liposome that big. The practical way to get 
high encapsulation efficiency is to make narrow size distribution of large
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unilamellar liposomes, instead of small unilamellar liposomes. What size of 
unilamellar liposome is appropriate? Due to the structural strength of the lipid 
bilayer sphere, it is hard to make large unilamellar liposomes even at the micron 
scale. We think unilamellar liposomes with 400 nm in diameter should be both 
large enough to reach high encapsulation efficiency, and strong enough to 
maintain their shape. Considering the thickness of unilamellar lipid bilayer is 
about 5 nm,84 selecting 400 nm as liposome diameter can also reduce the 
curvature effect on the permeation study.
CH, O
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Figure 10 Molecular structure of dipalmitoyl phosphatidylcholine (DPPC).
At first we used only one phospholipid, dipalmitoyl phosphatidylcholine 
(DPPC), to prepare the simplest liposome model. Figure 10 shows the molecular 
structure of DPPC. DPPC was selected because of its popular usage in liposome 
related research and its high concentration and occurrence in natural 
membranes.
As seen before, cholesterol is a membrane constituent widely found in 
animal systems, which serves a unique purpose of modulating membrane fluidity, 
elasticity, and permeability. It literally fills in the gaps created by imperfect 
packing of other lipid species when proteins are embedded in the membrane. In
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order to make our liposome model a better analog of natural membrane, later we 
made 4:1 (w/w) DPPC: Cholesterol liposomes for the release study.
The total inner aqueous volume ratio V , (liters per 1.0 liter of liposome 
suspension) of the unilamellar liposomes can be determined by the following 
equations. The total number of lipid molecules N p was expressed as the function 
of the initial concentration of the lipid, C (mole-liter'1),
N p =  N 0 - C , [2.1]
where N 0 was Avogadro’s number. A/j, the number of lipid molecules composing 
one unilamellar liposome with radius r  (A), was expressed as 
N , =  4 x ( r 2 + ( r - d ) 2) / S ,  [2.2]
where S and of were the average surface area per lipid molecule in square 
angstroms and the thickness of the bilayer membrane in angstrom, respectively. 
N,  the number of liposomes with radius r in the solution containing C (mole-liter'1) 
lipids, was therefore expressed as
W =  N >- C -s  ,2 .3 ,
N t 4 n ( r 2 +  { r - d ) 2)
The total inner aqueous volume (V)  was defined as
V  =  N - % 7 r ( r - d ) 3 x l 0 ~ 27 [2.4]
In the case of 400 nm unilamellar DPPC liposomes, where C = 3.4 * 10'3 
mole-litter'1 (= 0 .25  w t% ), r =  2 000  A, S = 58 A2, and d  =  37  A ,85-86 the total inner 
volume was calculated to be 3.8 x 10'2 (liter per 1.0 liter of liposome 
suspension), i.e., 3.8% by volume.
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2.2.2 Model Proteins
This project focuses on quantifying the permeation of proteins/peptides 
through membranes and characterizing the enhancement effect of CPE-215®. 
Insulin (Figure 11) was selected as the protein model for this study because it is 
one of the least expensive low molecular weight small proteins available, and 











Figure 11 The primary structure of human insulin. The black residues 
designate the amino acids which are invariant among species of insulin. 
The letters indicate the residues involved in association of the molecule. 
D, dimer formation. H, hexamer formation.87
Insulin, the hormone that regulates blood glucose levels, is a small protein 
(MW 5.8 KDa) comprising two peptide chains connected by disulfide bonds, A 
(21 amino acids) and B (30 amino acids). Due to the functional groups on the 
chain ends, insulin dissolves in water only at pH below 4.5 and above 7.0. When 
insulin concentration is high in solution, with or without the help of zinc, it forms
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dimers or even higher association states, such as tetramers and hexamers. 
Monomeric insulin is observed only at low concentration (< 0.1 pM, -0 .6  |jg/ml).87
Bovine serum albumin (BSA) is one of the most widely studied proteins 
with a high solubility in water around 5g/100ml. BSA was used as a second 
model protein for its higher molecular weight, about 66 KDa, which is about 10 
times the molecular weight of insulin.
2.2.3 Release Protocol Flow Chart
The general strategy behind our release studies is illustrated in Figure 12. 
We first prepared an insulin buffer solution, and then used the extrusion method 
to prepare narrow size distribution large unilamellar liposomes to encapsulate 
some of the insulin solution inside, and then separated the liposomes from the 
unencapsulated insulin with a gel filtration column at 4 °C. Then liposomes were 
collected for the release study. After adding the permeation enhancer 
formulation, the liposome solution was held at 37 °C, and small amount of 
liposome samples were periodically taken out and released insulin was 
separated from liposomes. Finally we measured the insulin concentration outside 
the liposomes.
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Although insulin is one of the smallest proteins, it is still a large molecule 
compared to lipids. The lipid DPPC has a molecular weight of only 734 Da, while 
insulin in monomeric form has more than 50 amino acids with a molecular weight 
near 6000 Da, not taking into account the insulin that may be present in the 
hexameric form. There is an equilibrium between insulin monomers, dimers and 
tetramers (possibly hexamers) in solution. Since small and neutral molecules, 
such as water, glycerol and vitamins, can go through biological membranes fairly 
easy, at first we suspected the protein membrane permeation process is size and 
charge controlled. We assumed that the smaller the protein, the easier it could 
go through the lipid bilayer. In that case, we would like to use the lower 
association states of insulin, such as monomers or dimers, to do the release 
experiments, then we need very dilute insulin solution (insulin monomer 
concentration limit is 0.1 pM, ~0.6 pg/ml)87.
Such very dilute insulin concentrations make detecting insulin a challenge 
in itself. The UV technique is not sensitive enough at such low concentration.
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Fluorescence is much more sensitive, and insulin has intrinsic fluorescence 
signal due to its tyrosine and phenylalanine amino acid residues, but that is not a 
strong fluorescence signal.
To improve the detection sensitivity of insulin molecule, we decided to 
attach a fluorescent label to insulin. Amine-reactive reagents may be conjugated 
with virtually any protein or peptide. After consideration of many possibilities, an 
amine-reactive fluorescent analog, fluorescein-5-isothiocyanate (Figure 13), was 
selected because it has a relatively high smax (77 ,000  at pH 9) with a relatively 
low price. The isothiocyanate group reacts with basic amine groups at high pH 
and forms a covalent bond to derivatize the protein. Besides the two amine 
groups at the two N-terminals, insulin has two basic amine groups from the side 
chains of lysine and arginine; therefore, there should be no more than 4 
fluorescence probes on each insulin molecule after the labeling reaction. The 
labeling reaction is done in a mild condition: mix the insulin in a pH 9 bicarbonate 
buffered solution using dimethyl formamide (DMF) as a solvent with the reagents 
and stir at room temperature for an hour. Excess reagent is used to react with 
insulin, and labeled insulin can be easily separated using a gel filtration column.
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Figure 13 Molecular structure of the fluorescent probe, fluorescein-5-
isothiocyanate.
Based on the manufacturer’s data, the derivative has an excitation and 
emission wavelength of 494 nm and 518 nm respectively. In practice, in the SLM 
AMINCO Bowman® Series 2 luminescence spectrometer, the maximum 
excitation and emission wavelengths are 492 nm and 516 nm respectively. After 
the labeling, the detection limits were determined to be 1 ng/ml_.
Although the labeling conditions were mild, there was some concern 
whether the process breaks the bonds within protein, especially the disulfide 
bonds. Obviously we do not want to see protein degradation due to the 
fluorescence labeling process. We use the aqueous GPC (Gel Permeation 
Chromatography) with the Wyatt® light scattering detector (DAWN EOS) and 
refractive index detector to compare the protein samples before and after the 
labeling process to see if there is a decrease of protein molecular weight after the 
labeling.
When a polarized, monochromatic laser beam passes through a solvent 
containing proteins, the light scattered by the molecules at an angle to the 
incident beam over the light scattered by the solvent alone is directly proportional
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to the molecular weight multiplied by the concentration of the molecule. This 
characteristic of static light scattering is used for determining the absolute 
molecular weight of eluting biomolecules.88 Therefore, light scattering is not very 
sensitive to low molecular weight proteins. Since the molecular weight of insulin 
is small (less than 6 KDa), we used BSA (MW 66 KDa) instead to test the 
potential degradation effect of the labeling process. Since proteins with higher 
molecular weight are more complicated and more sensitive to outer environment 
changes, using BSA to test the labeling process is conceptually more relevant.
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Figure 14 Aqueous GPC trace of 4.3 mg/ml BSA, eluant 100 mM KCI 10 
mM BTP pH 6.5 buffer. The upper trace is from the 90° angle light 
scattering detector, the lower trace is from the refractive index detector. 
Four interesting peaks in the right 90° angle light scattering trace were 
selected and the average molecular weights of each peak were given out. 
The GPC column was TSK G3000SWXL column.
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Figure 15 Aqueous GPC trace of 4 mg/ml tagged BSA, eluant 100 mM 
KC110 mM BTP pH 6.5 buffer. The upper trace is from the 90° angle light 
scattering detector, the lower trace is from the refractive index detector. 
Four interesting peaks in the right 90° angle light scattering trace were 
selected and the average molecular weights of each peak were given out. 
The GPC column was TSK G3000SWXL column.
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Figure 14 and 15 show the aqueous GPC traces of BSA before and after 
the fluorescence labeling process. In each figure, the upper left trace is from the 
90° angle light scattering detector, and the lower left trace is from the refractive 
index detector; the right one is the enlarged trace from the 90° angle light 
scattering detector, four interesting peaks on the trace were selected, and the 
average molecular weights for each peak were computed. In Figure 14 and 15, 
the light scattering traces of tagged BSA and original BSA are almost identical, in 
number of peaks, peak positions and peak shapes. In both figures, peak #1 (from 
4.2 min to 4.7 min) is a tiny bump, the major peaks are peak #2 (from 5.0 min to 
5.7 min) and peak #3 (from 5.9 min to 6.5 min), peak #4 (from 7.6 min to 8.1 min) 
is also a tiny bump in the light scattering traces. The peak after 9 min in the 
refractive index trace is the solvent peak -- the original solvent for the BSA 
sample came out. Because light scattering is more sensitive to bigger 
molecules/particles, while refractive index detector only focuses on 
concentrations, the relative peak area of BSA dimer/trimer (peak #2) comparing 
to BSA monomer (peak #3) is bigger in the trace of light scattering detector than 
in the trace of refractive index detector.
From the peak position and the average molecular weight given by the 
program, peak #3 is identified as the BSA monomer peak, and peak #2 as the 
peak for the higher association state of BSA. In Figure 14, the molecular weight 
of original BSA monomer given by the Wyatt® program is 80 KDa, which is a little 
more than the real number (66 KDa) and may be due to some incorrect 
parameters in the program. Actually the relative numbers are more important to
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us. The molecular weight of higher association state BSA given by the program is 
about 220 KDa, which is about 2.75 times the molecular weight of monomer and 
means that is the mixture of BSA dimers and trimers. In Figure 15, the molecular 
weight of tagged BSA monomer is about 91 KDa, which is more than that of the 
original BSA monomer and means some fluorescent probes have attached to 
BSA. The molecular weight of higher association state tagged BSA given by the 
program is about 230 KDa, which means attached fluorescent probes did not 
affect the self-association of BSA, tagged BSA can still have higher association 
states and that is still a mixture of dimers and trimers of tagged BSA.
Every peak in Figure 15 can find its corresponding peak in Figure 14 at 
almost the same retention time and with almost the same shape, and there is no 
additional low molecular weight peak appearing in Figure 15 that would indicate 
BSA degradation by the labeling process. Based on the analysis, this fluorescent 
probe labeling process is efficient and safe for proteins, no protein degradation is 
detected after the process and the fluorescence tagged proteins still have self­
association ability.
Since a fluorescence signal was used to monitor the insulin release, it was 
necessary to determine the relationship between the fluorescence signal and 
tagged insulin concentration; the fluorescence stability of the tagged insulin is 
also important for long term release studies. Fluorescence measurements of 
different tagged insulin concentrations at pH 7 in phosphate buffer were carried 
out. Figure 16 shows the calibration curve of fluorescence signal verse insulin 
concentration. The data indicate a linear relationship between the fluorescence
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signal and concentration. In order to make sure of the fluorescence long-term 
stability, we stored the tagged insulin solutions with different concentrations at 4 
°C and performed fluorescence signal measurement over 90 days. The result 































Figure 16 Tagged insulin fluorescence calibration and stability data at pH 
7 in phosphate buffer.
2.4. Liposome Synthesis and Size Measurement
The extrusion method can prepare desired size liposomes with relatively 
narrow size distribution by extruding lipid suspension through a fixed pore size 
polycarbonate membrane filter at a temperature higher than the transition
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temperature of the lipid. Due to obvious advantages over other liposome 
preparation methods, we chose the extrusion method to prepare liposomes.
The working mechanism of a liposome extruder is not complicated as it 
only needs a high pressure system, a sample reservoir, a filter holder and a 
temperature control. Figure 17 shows the design of my custom-made liposome 
extruder. Valve 1 is a three-way valve, it can connect either A or B to C, or totally 
closed. Valve 2 is identical to Valve 1, and it can let DE or DF be connected, or 
close the lines between DE and DF. A is connected to a nitrogen gas cylinder to 
provide high pressure for the extrusion. B is used to add liposome samples to the 
sample reservoir loop. E is used to release the high pressure inside the sample 
reservoir loop after the extrusion making the sample loading/reloading from B 
possible (without DE open to air, it is impossible to load/reload liposome samples 
to the reservoir loop from B). The components within the dashed line are 
submerged in a water bath when the extrusion process begins. The membrane 
filter is hydrated before it is placed inside the membrane holder. When loading 
the liposome samples, Valve 1 and 2 are adjusted so that B, C, D, E are 
connected. A syringe is used to load the raw liposomes from B to the reservoir 
loop. After the loading, Valve 1 and 2 are adjusted so that A, C, D, F, G are 
connected, then the reservoir loop and membrane filter holder are submerged in 
the water bath, then the gas pressure is established to start the extrusion.
Multiple extrusions are needed to make narrow size distribution liposomes, so 
the liposomes need to be reloaded in the reservoir loop after each extrusion.
After the extrusion is performed, the high pressure gas inlet is closed, and the
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extruder is removed from the water bath. Valve 2 is turned to connect DE and 
release the remaining pressure inside of the sample reservoir loop. Then Valve 1 
is turned to connect BC and the liposomes are loaded for the next extrusion.
Since the phase transition temperature of DPPC is 41 °C and the water 
bath temperature should be higher than the lipid phase transition temperature, 
we selected 50 °C as the water bath temperature.
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Figure 17 Block diagram of the custom-made liposome extruder. Valve 1 
is a three-way valve, it can either let AC connected or BC connected, or 
totally close the lines of AC and BC. Valve 2 is the same as Valve 1, and it 
can let DE or DF connected, or close the lines of DE and DF. A is 
connected to a nitrogen gas cylinder to provide high pressure for the 
extrusion. B is used to add liposome samples to the sample reservoir 
loop. E is used to release the high pressure inside the sample reservoir 
loop after the extrusion and make the sample loading/reloading from B 
possible. The components within the dashed line will be submerged in the 
water bath when the extrusion process begins.
52
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
Figure 18 Custom-made liposome extruder (without showing the water bath 
and high pressure gas inlet).
We chose a 400 nm pore size polycarbonate membrane filters to make 
large unilamellar liposomes. The thickness of one lipid bilayer is about 5 nm, and 
using 400 nm diameter large unilamellar liposome can greatly reduce the 
curvature effect of the liposome, so that the liposome leakage profile is similar to 
that of a planar lipid bilayer.
We used a light scattering instrument (Microtrac S3000) to measure the 
liposome size and distribution after extrusion. Figure 19 shows one example of 
DPPC liposome size distribution after extrusion through a 400 nm membrane 
filter. This shows an essentially monodispersed distribution: volume-average 
diameter 354 nm, area-average diameter 351 nm, number-average diameter 345 
nm.
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Figure 19 DPPC liposome size distribution measured by Microtrac S3000 
after extrusion through a 400 nm polycarbonate membrane filter. This 
shows a very narrow distribution: volume-average diameter 354 nm, area- 
average diameter 351 nm, number-average diameter 345 nm.
2.5. Permeation Enhancer Combinations
CPE-215® is the permeation enhancer Bentley uses for the intranasal 
emulsion formulations, but its melting point makes a problem for emulsion 
formulation. CPE-215® has a melting point of 34 °C, which makes it a solid at 
room temperature. Figure 20 shows the thermal property of CPE-215® by 
Differential Scanning Calorimeter (Q100 series modulated DSC from TA 
Instrument, Inc). In Figure 20, CPE-215® was equilibrated at -20 °C first, then 
heated at 3 °C /min to 100 °C, and then cooled at 3 °C /min back to -20 °C. The 
top trace shows the cooling process, and the large exothermal peak indicates
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crystallization which starts at 33.5 °C. The bottom trace shows the heating 
process, and the large endothermal peak indicates melting process which starts 
at 34 °C. In order to make a practical formulation, we need to be sure that CPE- 
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Figure 20 DSC trace of CPE-215® (exo up). The sample was equilibrated 
at -20 °C first, then heated at 3 °C/min to 100 °C, and then cooled at 3 °C 
/min back to -20 °C. The top trace shows the cooling process, and the 
large exothermal peak indicates crystallization. The bottom trace shows 
the heating process, and the large endothermal peak indicates melting 
process.
We tried to use different additives, such as sesame oil, cottonseed oil, and 
soybean oil, to lower the melting temperature of CPE-215®, and found that 
cottonseed oil could successfully lower the melting and crystalline temperature of 
CPE-215®. Figure 21 shows the thermal property of 3:1 (w/w) CPE-215®:
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cottonseed oil by DSC (Q100 series modulated DSC from TA Instrument, Inc). In 
Figure 21, the mixture was equilibrated at -20 °C first, then heated at 3 °C /min to 
100 °C, and then cooled at 3 °C /min back to -20 °C. The top trace shows the 
cooling process, and the crystallization peak shows that the mixture does not 
crystallize until cooled to 5 °C. The bottom trace shows the heating process, it is 
hard to identify the exact temperature at which the mixture starts to melt, but it 
appears around 5 °C. The mixture only has one melting/crystalline peak at much 
lower temperature compared to pure CPE-215®, which shows complete 
miscibility between CPE-215® and cottonseed oil. In our study, all the CPE- 
215®/cottonseed oil mixture we used were 3:1 (w/w) oil mixtures.
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Figure 21 DSC trace of 3:1 (w/w) CPE-215®: Cottonseed oil. The sample 
was equilibrated at -20 °C first, then heated at 3 °C/min to 100 °C, and 
then cooled at 3 °C /min back to -20 °C. The top trace shows the cooling 
process, and the large exothermal peak indicates crystallization. The 
bottom trace shows the heating process, and the large endothermal peak 
indicates melting process.
2.6. Liposome Cleaning
After the extrusion, narrow size distribution large unilamellar liposomes 
are made, but there are insulin molecules remaining both inside and outside of 
the liposomes. Separating the outside free insulin molecules from the liposomes 
is the last step before release studies.
At first we used gel filtration to separate the outside insulin from 
liposomes. However, after we collected the liposomes by gel filtration and 
preformed the insulin release experiment, at the beginning of the release
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experiment, the fluorescence signals of free insulin in solution at time “zero” were 
much higher than we expected. We assumed it could be due to the adsorption of 
insulin on the outside surface of the liposomes. During the gel filtration, the 
adsorbed insulin eluted with the liposomes; after gel filtration, the outside insulin 
concentration was so low that the adsorbed insulin desorbed from the liposomes 
and went into the solution, which produced the high fluorescence signal at the 
starting points. Further gel filtrations might be a way to solve that problem, but 
that could also further dilute the liposome suspension, and the gel filtration 
process involved more labor and time.
Since it was found that our liposomes had a slightly higher density than 
water, a centrifuge technique was studied to make the outside of liposomes 
“insulin free”. For this to be accomplished, the liposome suspension after 
extrusion was centrifuged at 650 g at 4 °C for 30 minutes, then the supernatant 
was taken out and fresh buffer was added; then the same procedure was 
repeated. This may be called centrifugal extraction, which is similar to dialysis but 
faster and does not require a membrane.
After each cycle of centrifugal extraction, some clear supernatant was 
taken out for fluorescence measurement to detect the free insulin concentration 
in the supernatant. Figure 22 shows the result of the measurement and the effect 
of centrifugal extraction on the free insulin concentration outside of the 
liposomes. After 10 cycles of centrifugal extraction, the requirement of 
“substantially insulin free” outside the liposome could be reached.
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Figure 22 Effect of centrifugal extraction on the concentration of free 
insulin outside of the liposomes.
During the insulin release experiment, after taking out the liposome 
samples from the release tubes and before the fluorescence measurement for 
the released insulin concentration, free insulin molecules outside need to be 
separated from liposomes again. This time the outside insulin is what we need 
and the insulin concentration should not be changed after the separation. 
Therefore, this time we used centrifugal filtration.
The process of centrifugal filtration uses semi-permeable membrane filters 
and centrifugal force to separate molecular species on the basis of size and 
shape. The disposable centrifugal units consist of a sam ple filter unit and a 
filtration collection tube. A sample is loaded in the filter unit that is then put into 
the collection tube. Together the filter unit and collection tube are put in a 
centrifuge and spun at the appropriate speed. Since the size of our liposomes is
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around 400 nm in diameter and the size of hexamer insulin is less than 10 nm in 
diameter, a membrane filter with the nominal molecular weight limits (NMWL) of 
50 KDa can retain the liposomes and let insulin molecules go through without 
any problems. However, liposomes do not have a solid surface, therefore, the 
centrifuge conditions need to be adjusted to make sure the liposomes will not 
break during the process of centrifugal filtration. We did a test by performing the 
centrifugal filtration at different speed at 4 °C with 400 nm DPPC liposomes and 
found that filtration at 500 g not only did not break the liposomes, but also 
provided reasonable separation times. Another concern is that too many 
liposomes might clog the filter membrane. To solve this problem, before placing 
the liposomes into the sample filter unit, we centrifuge them at 500 g at 4 °C for 
20 minutes and only take the supernatant to perform the centrifugal filtration 
process. In this case, fewer liposomes have a chance to contact the filter 
membrane.
2.7. Drug Release with Shaker Table
Once we obtain “clean” liposomes with insulin solution inside, we can start 
the release experiments. In order to keep the liposome samples at controlled 
temperature, we use 15ml centrifuge tubes to contain the liposome samples and 
fit the tubes in the necks of the three-neck jacketed flasks, which are connected 
to a temperature controlled water bath (Figure 23). Both the inside and jacketed 
flasks are filled with water; in this case the temperature inside the flask is 
controlled by the water bath, and the sample temperature is controlled by the
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water inside of the flask. We found that once they reached temperature 
equilibrium, there was almost no temperature difference between water bath and 
liposome samples. A shaker table is used to give gentle shaking to the liposome 
samples so that there is no concentration gradient in each tube to affect the 
insulin release.
Figure 23 Protein release experiment setup. The release liposome 
samples are in the red-capped centrifuge tubes. The tubes are inserted in 
the necks of the three-neck jacketed flasks, and the flasks are used as 
water baths to control the sample temperature. The shaker table is used 
to give gentle steering to the liposome samples.
61
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
2.8. Animal Test Validation
All the experiments we designed and performed were membrane 
permeation in vitro tests, and needed in vivo animal tests to validate the model. If 
the in vitro test results were significantly different from those of the in vivo animal 
tests, then it would mean some of our assumptions were incorrect.
Bentley Pharmaceuticals, Inc. used pigs to perform the in vivo tests for 
intranasal insulin delivery with CPE-215® formulations. The results showed that 
right after the spray of certain intranasal insulin formulations into the pigs’ noses, 
the body glucose level in the pigs dropped quickly, which indicated the insulin did 
go through the nasal membranes with the help of CPE-215® and into the blood 
system. CPE-215® is an effective membrane permeation enhancer for insulin. 
Formulation lacking the enhancer showed no alterations in blood insulin level.
Since the animal test is not the object of this thesis and the test results are 
proprietary of Bentley Pharmaceutical, we will not talk about it in detail here.
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CHAPTER 3
PROTEIN RELEASE FROM LIPOSOMES
In order to study the property and function of CPE-215® as a permeation 
enhancer for natural membranes, we performed some insulin release 
experiments with our liposome model under different conditions.
As described in the last chapter, liposomes are used to contain the 
fluorescein-tagged insulin solutions, then different CPE-215® formulations are 
added externally, and external insulin fluorescence is measured. Different 
formulations provided insight on factors causing release.
3.1. General Procedure for One Release Experiment
First, about 0.1 g of lipid mixture (sometimes DPPC lipid only, sometimes 
mixture of 4:1 (w/w) DPPC/cholesterol) was dissolved in 4 ml of chloroform to 
assure a homogeneous mixture of lipids. Once the lipids were thoroughly mixed 
in chloroform, the chloroform was removed by rotary evaporation yielding a thin 
lipid film on the side of a 50-ml round bottom flask. The lipid film was thoroughly 
dried to remove residual chloroform by placing the flask under vacuum overnight 
at room temperature. Then 8 ml 0.2 mg/ml fluorescein-tagged insulin pH 7 
phosphate buffer solution was added into the flask to hydrate the dry lipid film at
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50 °C, which allowed the lipid to hydrate in its fluid phase with adequate 
agitation. A ten-second bath-type sonication was found to greatly reduce the 
hydration time, making the sizing process easier and improving the homogeneity 
of the size distribution. The product of hydration was a suspension of large, 
multilamellar liposomes analogous in structure to an onion, with each lipid bilayer 
separated by a water layer.89 Typically liposome suspensions were extruded five 
times through a 400 nm pore size polycarbonate membrane filter at 50 °C 
(Attempts to extrude below the Tc of lipids were unsuccessful as the membrane 
has a tendency to foul with rigid membranes which cannot pass through the 
pores).
After extrusion, centrifugal extraction was carried out to remove the 
unencapsulated tagged insulin molecules. To make sure the liposomes were free 
of external insulin, 6 ml of liposome suspension was centrifuged at 650 g for 30 
minutes at 4 °C, then the supernatant was taken out and fresh 50 mM pH 7 
phosphate buffer was added, and then the same procedure was repeated. Ten 
cycles of centrifugal extraction were performed.
The process of liposome extrusion and centrifugal extraction can result in 
some lipid loss. We did one blank run (extrude liposome suspension without 
insulin, after 10 cycles of centrifugal extraction, dry the remaining liposome 
suspension to determine the dry lipid content) to determine how much lipid was 
left after the process of liposome extrusion and centrifugal extraction, and found 
that 70% of lipid content was left after the process.
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After the centrifugal extraction, the “cleaned” liposomes were evenly 
distributed into six 15-ml plastic centrifuge tubes, which were used as the 
containers for the release experiments. According to the requirement of the 
experiment, buffer (most of the time, it was 50 mM pH 7 phosphate buffer) and 
different excipients were added to the tubes. Usually one of the tubes was used 
as blank release (no permeation excipient added). Finally each tube had 4 ml of 
liposome suspension inside, and an aliquot sample was taken from each tube for 
the release value at time=0. The centrifuge tubes were fit in the necks of the 
three-neck jacketed flasks, which were on a shaker table and connected to the 
temperature controlled water bath. The shaker table was set to 150 rpm 
arbitrarily, and the influence of this shear parameter was not studied, though it 
would be expected to have influence on the release results.
At various times, 400 pi of liposome sample was taken from each tube. 
After 20 minutes’ centrifuging at 500 g at 4 °C, 200 pi supernatant of each 400 pi 
sample was taken for the centrifugal filtration process at 500 g at 4 °C for another 
30 minutes. A membrane filter with the nominal molecular weight limits (NMWL) 
of 50 KDa was usually used to retain the liposomes and let insulin molecules go 
through. 40 pi of the filtrate was diluted with the 50 mM pH 7 phosphate buffer to 
400 pi for the final fluorescence measurement.
Finally, 100% release was achieved by sonicating the remaining 
liposomes in the presence of Triton X-100 to break the lipid bilayers. Triton X-100 
(Figure 24) is a strong water-soluble surfactant, which disrupts the bilayer 
packing of liposomes and makes them leak.
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Figure 24 Chemical structure of Triton X-100.
The reproducibility of the release data has been improved over the course 
of this study. Release data were estimated to have a reproducibility error of 10% 
for Section 3.2 to 3.3. This error was reduced to 3-5% in Section 3.4 to 3.6. Only 
a very limited data set was reproduced in Section 4.4.3 towards the end of this 
study and the error was found to be less than 2%. The relative trend of the 
release data (i.e. which sample had the faster/slower release rate) was 
reproducible.
Point #0 for each sample was taken right after the emulsion/suspension 
was added into the release tubes (before that, everything inside each tube was 
identical), so theoretically their signals should be identical. However, practically 
the liposomes release insulin even at low temperature. Only after centrifugal 
filtration is complete, the outside insulin concentration is constant. The centrifugal 
filtration process for each sample took about half an hour, from the time taking 
the samples out to the end of the centrifugation. The signal difference of the
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Point #0 between the various formulations partially indicates the membrane 
permeation enhancing effects of different formulations during the first 30 minutes.
3.2. Insulin Release from DPPC Liposomes at Different Temperatures
At first, we used only DPPC to prepare the liposomes. The transition 
temperature of DPPC lipid bilayer is 42 °C. Below this temperature, the lipid is in 
the rigid gel state; above it, the lipid is in the so called liquid crystalline state, with 
freedom of motion in 2 dimensions without true melting. The liquid crystalline 
state is the structural basis allowing mobility of membrane components within an 
organized framework. The dynamic properties of membranes rely on the fluid 
environment within the plane of the membrane, which means in the natural 
membranes the overall transition temperature of the lipids is below 37 °C. In 
order to make our liposome system more closely resemble the natural membrane 
situation, higher release temperatures were used.
3.2.1. Insulin Release from DPPC Liposome at 47 °C At pH 7
An insulin release experiment of DPPC liposome at 47 °C was conducted, 
which is 5 °C higher than the phase transition temperature of DPPC. Equal 
amount and same concentration of DPPC liposomes in 50 mM pH 7 phosphate 
buffer were put in three 15-ml plastic centrifuge tubes; pH 7 phosphate buffer, 
cottonseed oil emulsion and CPE-215®/cottonseed oil emulsion were added into 
three tubes respectively. The amount of CPE-215® is based on the molar ratio of
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CPE-215®: DPPC = 1:2, the weight ratio of CPE-215®: cottonseed oil = 3:1. The 
tubes were placed into the 47 °C water bath on a shaker table at 150 rpm.
Figure 25 shows that the insulin release from DPPC liposome at 47 °C 
was so fast that most of the insulin came out in 6 hours; and the temperature was 
so high that there was almost no difference between the insulin release rates 















Figure 25 Insulin release from DPPC liposomes at 47 °C at pH 7. In the 
“Blank” sample, there were only DPPC liposomes encapsulating insulin 
solution. In “Cottonseed oil” sample, besides DPPC liposomes, there was 
some cottonseed oil added. In “CPE&Cottonseed oil” sample, besides 
DPPC liposomes, there was some mixture of 3:1 (w/w) CPE- 
215®/Cottonseed oil added.
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This was the first insulin release experiment. Therefore, there were some 
flaws in it. I did not expect the release rates to be that fast, and I did not take 
samples in the first 6 hours and missed most of the information at the beginning. 
In later release experiments, the sampling rate was increased at early times. In 
Figure 25, although the trend of the data points was increasing with time, for one 
sample (either “Blank”, or “Cottonseed oil”, or “CPE&Cottonseed oil”), some 
release points at later time even had lower fluorescence signals than the earlier 
ones. Theoretically, since those points were taken from the same release tube at 
different times, the later sample points should not have lower fluorescence 
signals than the earlier ones. That problem might be due to my sample handling 
techniques, which needed to be improved. However, from this experiment, we 
did know that 47 °C was too high for the DPPC liposome release experiments, 
and we needed to use lower temperature for the future release experiments.
3.2.2. Insulin Release from DPPC Liposome at 42 °C at pH 7.4
Since we did not want to perform D PPC  liposome release experiments at 
temperature below the phase transition temperature of D P P C , and 47 °C  was 
proven to be too high, we decided to carry out the release experiment at the 
phase transition of D P P C  (42 °C). This time we would like to see the individual 
effect of cottonseed oil and CPE-215® on the insulin release from D P P C  
liposomes at pH 7.4.
DPPC liposomes were made with pH 7.4 tagged insulin phosphate buffer 
solution. Three different release samples were made -  one at pH 7.4 with CPE-
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215® suspension only, one at pH 7.4 with cottonseed oil suspension only, the last 
one at pH 7.4 was the blank control. In each 15-ml plastic centrifuge tube, there 
was 4 ml DPPC liposome buffer suspension with 0.0076 g DPPC inside; 1 g of 
different emulsion/suspension was added later. CPE-215® was handled in a 
warm water bath so that it was in the liquid state (mp 34 °C). This time the CPE- 
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Figure 26 Insulin release from DPPC liposome at 42 °C at pH 7.4. In the 
“Blank" sample, there were only DPPC liposomes encapsulating insulin 
solution. In “Cottonseed oil” sample, besides DPPC liposomes, there was 
some cottonseed oil added. In “CPE-215” sample, besides DPPC 
liposomes, there was some CPE-215® added. The amount of CPE-215® 
added was based on the molar ratio of CPE-215®: DPPC = 125:1. 
Cottonseed oil amount was based on CPE-215®: cottonseed oil (w/w) = 
3:1.
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The release tubes were placed in a 42 °C water bath on a shaker table at 
150 rpm. In the “CPE215” sample, most of the CPE-215® was on the top of the 
solution; phase separation was due to its low solubility in water and its low 
density. Oil-water phase separation happened in “Cottonseed oil” sample, too.
In Figure 26, those Point #0s are different, which partially indicates that 
CPE-215® and cottonseed oil do have permeation enhancing effects on the 
DPPC liposome release capacity. The sequence of initial fluorescence signals 
from high to low is “Cottonseed oil”, “CPE215”and “Blank”.
Insulin release in “Cottonseed oil” was the fastest at the beginning, while 
insulin release in “CPE215” was the slowest. But the release rate of “Cottonseed 
oil” slowed down after it reached certain point, and finally was caught up by 
“CPE215” and “Blank”. In this group, it seems that the sample releasing the 
fastest (“Cottonseed oil”) at the beginning had the lowest data point in the end, 
while the slowest one at the beginning (“CPE215”) had the highest data point. It 
seems that cottonseed oil can help make a burst release at the beginning while 
CPE-215® can keep the release from liposome at a higher rate. According to the 
literature90, cottonseed oil is a mixture of triglycerides. 18-carbon fatty acids with 
two unsaturated double bonds count for 53% of the total amount of fatty acids in 
cottonseed oil. Cottonseed oil is a mixture of lipids, similar to DPPC. Therefore, it 
can have good interactions with the lipids in the liposomes, which may account 
for its membrane permeation enhancing effect.
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3.3. Insulin Release from DPPC Liposomes with Phase Transfer Agent
CPE-215® is a crystalline solid at room temperature, and cottonseed oil is 
added to lower its melting point. The CPE-215®/cottonseed oil mixture is very 
hydrophobic and not soluble in aqueous solutions. During the release 
experiments, most of the CPE-215®/cottonseed oil mixture was phase-separated 
from the aqueous buffer solution and floating on the top, which means most of 
the CPE-215® added into the system did not have the chance to make contact 
with liposomes, let alone help the release of insulin. In order for the permeation 
excipient to take effect, how much and how fast CPE-215® can interact with the 
liposomes and be incorporated in the lipid bilayer is more important than how 
much CPE-215® emulsion is added to the system. Only the soluble portion of 
CPE-215®, which is very limited, counts. This is the interpretation of why the 
release enhancement effect of CPE-215® was so small in previous experiment.
Getting more CPE-215® into the lipid bilayer may be the key for faster 
release rate. We need a phase-transfer carrier to transport more CPE-215® from 
the oil phase through the water phase to the liposome membrane to facilitate the 
release of insulin out of the liposomes. Cyclodextrins are well-known for their 
phase transport properties.
Structurally, Cyclodextrins consist of 6 , 7, or 8 (a, |3 and y respectively) D- 
glucopyranosyl units connected by alpha-(1,4) glycosidic linkages. Figure 27 
shows the molecular structure of a-cyclodextrin. The most stable three 
dimensional molecular configuration for these non-reducing cyclic 
oligosaccharides takes the form of a toroid with the upper (larger) and lower
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(smaller) opening of the toroid presenting secondary and primary hydroxyl 
groups, respectively, to the solvent environment. The interior of the toroid is 
hydrophobic as a result of the electron rich environment provided in large part by 
the glycosidic oxygen atoms, which can be used to carry or encapsulate small 
water-insoluble molecules.
HOCH,
Figure 27 Molecular structure of a-cyclodextrin.
Table 1 Physical properties of various cyclodextrins91
Alpha Beta Gamma
Molecular weight 972 1135 1297
Glucose monomers 6 7 8
Internal cavity diameter (angstroms) 5 6 8
Water solubility (g/100ml, at 25 °C) 14.2 1.85 23.2
Melting rang (°C) 255-260 255-265 240-245
Water molecules in cavity 6 11 17
According to the information from Table 1, one more glucose unit in 
cyclodextrin can result in huge cavity volume increase, it is surprising that the
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water solubility of p-cyclodextrin is only about 1/10 of that of a- or y-cyclodextrin. 
y-Cyclodextrin has the largest internal cavity, but it is much more expensive than 
the other two and not economical to use. p-Cyclodextrin is the cheapest among 
the three and has a larger cavity than a-cyclodextrin, so P-cyclodextrin was used 
as the promising phase transfer candidate.
V
N»
Figure 28 Molecular model of a-cyclodextrin (left) and CPE-215® (right) in 
the same scale. Hydrogen atoms are white, carbon atoms are grey, and 
oxygen atoms are red. a-Cyclodextrin is in a rod model, and CPE-215® is 
in a stick-and-ball model.
Figure 28 shows the molecular model of a-cyclodextrin and CPE-215® at 
the same scale. It seems that the internal cavity of a-cyclodextrin is large enough 
for a CPE-215® molecule.
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3.3.1. Insulin Release from DPPC Liposome at 42 °C with Cyclodextrins at 
p H  7
We decided to add cyclodextrins to our release formulations to see if they 
can work as phase transfer carriers as we expected. First we would like to know 
if cyclodextrin can further enhance the permeation effect of CPE-215® and 
cottonseed oil, then we would like to know if cyclodextrin itself has permeation 
enhancing effect, and determine which cyclodextrin is better (alpha or beta).
We used a release tube with only DPPC liposomes inside as the blank 
control; p-cyclodextrin buffer solution was added in one DPPC liposome 
suspension as the “B-CD” sample to see the membrane permeation enhancing 
effect of p-cyclodextrin itself; CPE-215®/Cottonseed oil mixture emulsion was 
added to one DPPC liposome tube as the “CPE&CSO” sample to see the 
membrane permeation enhancing effect of CPE-215®/Cottonseed oil mixture; 
CPE-215®/Cottonseed oil mixture in p-cyclodextrin buffer solution was added into 
one DPPC liposome tube as the “B-CD+CPE&CSO” sample to see if the 
presence of P-cyclodextrin can further boost the effect of CPE-215®/Cottonseed 
oil mixture; CPE-215®/Cottonseed oil mixture in a-cyclodextrin buffer solution 
was added into one DPPC liposome tube as the “a-CD+CPE&CSO” sample to 
see if a-cyclodextrin is better than p-cyclodextrin.
Phosphate buffer at pH 7 was used to make liposomes and prepare 
different release samples. Five different 1 g emulsion/suspension formulations 
were added to the identical liposome suspension in five release tubes, each with 
4 ml DPPC liposome buffer suspension and 0.0063 g DPPC inside: one was the
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blank control buffer solution, one was the p-cyclodextrin buffer solution, one was 
the p-cyclodextrin buffer solution with mixture of CPE-215® & cottonseed oil, one 
was the simple mixture of CPE-215® & cottonseed oil, one was the a-cyclodextrin 
buffer solution with mixture of CPE-215® & cottonseed oil.
The amount of CPE-215® added was based on a molar ratio of CPE-215®: 
DPPC = 125:1. The amount of cyclodextrin was planned to be added according 
to the weight ratio of CPE-215®: cyclodextrin = 2:1, but unfortunately, neither a- 
cyclodextrin nor p-cyclodextrin could be dissolved to that extent in the buffer 
solution, so saturated cyclodextrin solutions were used (a-cyclodextrin is much 
more water soluble than p-cyclodextrin).
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Figure 29 Insulin release from DPPC liposomes with cyclodextrins at 42 
°C at pH 7. Sample tube with DPPC liposomes only was the “Blank”; P- 
cyclodextrin buffer solution was added in one DPPC liposome suspension 
as the “B-CD” sample; CPE-215®/Cottonseed oil mixture emulsion was 
added to one DPPC liposome tube as the “CPE&CSO” sample; CPE- 
215®/Cottonseed oil mixture in P-cyclodextrin buffer solution was added 
into one DPPC liposome tube as the “B-CD+CPE&CSO” sample; CPE- 
21 5®/Cottonseed oil mixture in a-cyclodextrin buffer solution was added 
into one DPPC liposome tube as the “a-CD+CPE&CSO” sample.
The release tubes were placed in a 42 °C water bath on a shaker table at 
150 rpm. Figure 29 shows the result of this insulin release experiment with 
cyclodextrins at pH 7.
All samples showed similar release pattern: insulin release rates were 
very fast at the very beginning (ideal for intranasal drug delivery), followed by 
slower rate after 10 hours, but different samples showed different starting points.
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The experimental data showed that the sample with a-cyclodextrin buffer 
solution and mixture of CPE-215® & cottonseed oil had the highest starting point 
and the fastest release rate at the beginning; the next one was the one with (3- 
cyclodextrin and mixture of CPE-215® & cottonseed oil. The blank control one 
had the lowest starting point and the slowest release rate, as expected. For the 
ones with only P-cyclodextrin or mixture of CPE-215® & cottonseed oil, it is hard 
to tell which one is faster; they have almost the same effects on the release of 
insulin.
All the samples with cyclodextrin show obvious permeation enhancement 
effects, and saturated a-cyclodextrin solution has better effect than saturated p- 
cyclodextrin solution due to the big difference in water solubility. Cyclodextrin 
itself has just a small permeation enhancing effect; it mainly acts as a phase 
transfer carrier.
Finally, CPE-215® is an effective permeation enhancer, but needs a phase 
transition carrier like cyclodextrin; otherwise it can reach the membrane only with 
great difficulty due to its limited water solubility.
3.3.2. Insulin Release from DPPC Liposome at 42 °C with Different Amount 
of Cyclodextrins at pH 7
W e  have known that cyclodextrin can further enhance the m em brane  
permeation effect caused by CPE-215® and cottonseed oil, now we would like to 
know how much cyclodextrin is needed and what the proper ratio of CPE-215® to 
cyclodextrin is.
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This time, we added the same amount of CPE-215®/Cottonseed oil 
mixture with different amount of a-cyclodextrin into each liposome suspension to 
determine the best ratio of cyclodextrin to CPE-215®. In the previous experiment, 
saturated a-cyclodextrin showed better permeation enhancing effect with CPE- 
215® than saturated P-cyclodextrin, but in that case, much more a-cyclodextrin 
was added than P-cyclodextrin due to higher solubility of a-cyclodextrin, so it is 
difficult to determine which one is better. This time we compared a-cyclodextrin 
with p-cyclodextrin at the same molar ratio of CPE-215®.
Similar amount of 3:1 (w/w) CPE-215®/Cottonseed oil mixture were added 
to every release tube. The amount of CPE-215® added was based on the molar 
ratio of CPE-215®: DPPC = 20:1. A 50 mM pH 7 phosphate buffer was used to 
make liposomes and prepare different release samples. Three liposome samples 
were used to see the effect of different amount of a-cyclodextrin on the insulin 
release rate. In “C&C+1x a-CD” sample, molar ratio of a-cyclodextrin: CPE-215® 
= 1:100; in “C&C+5x a-CD” sample, molar ratio of a-cyclodextrin: CPE-215® = 
1:20; in “C&C+20x a-CD” sample, molar ratio of a-cyclodextrin: CPE-215® = 1:5. 
In “C&C+20x B-CD” sample, molar ratio of P-cyclodextrin: CPE-215® = 1:5.
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Figure 30 Insulin release from DPPC liposomes at 42 °C at pH 7 with 
different ratio of cyclodextrin over CPE-215®. Same amount of 3:1 (w/w) 
CPE-215®/Cottonseed oil mixture was added to every release tube. The 
amount of CPE-215® added was based on the molar ratio of CPE-215®: 
DPPC = 20:1. In “C&C+1x a-CD” sample, molar ratio of a-cyclodextrin: 
CPE-215® = 1:100; in “C&C+5x a-CD” sample, molar ratio of a- 
cyclodextrin: CPE-215® = 1:20; in “C&C+20x a-CD” sample, molar ratio of 
a-cyclodextrin: CPE-215® = 1:5. In “C&C+20x B-CD” sample, molar ratio 
of (3-cyclodextrin: CPE-215® = 1:5.
The release tubes were placed in a 42 °C water bath on a shaker table at 
150 rpm. Figure 30 showed the results of this insulin release experiment with 
different amounts of cyclodextrin at 42 °C at pH 7. The shapes of the four insulin 
release curves were similar: the release rate was very fast at the very beginning, 
then the insulin release rate slowed down and after 6 hours reached a gentle 
slope. The starting points for each release curve were not the same. We could
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almost predict which sample would have the maximum final insulin release by 
looking at the insulin fluorescence signals at Time Zero -  the higher the 
fluorescence signal at Time Zero, the more final released insulin for that sample.
By comparing the release curves, we can see that the more cyclodextrin, 
the more insulin released from DPPC liposomes; at the same molar ratio to CPE- 
215®, P-cyclodextrin is better than a-cyclodextrin, which makes sense because P- 
cyclodextrin has a bigger hydrophobic cavity than a-cyclodextrin.
3.3.3. Insulin Release from DPPC Liposome at 42 °C with Beta-Cyclodextrin 
at pH 7
In order to know the effect of p-cyclodextrin on different components of the 
intranasal formulation, such as CPE-215®, cottonseed oil and mixture of CPE- 
215® and cottonseed oil, we carried out another insulin release experiment.
“Cleaned” DPPC liposomes encapsulating insulin pH 7 phosphate buffer 
solution were evenly divided into four plastic centrifuge tubes. As usual we used 
one tube of DPPC liposomes as the “Blank” sample. In “CSO+B-CD” sample, 
cottonseed oil in pH 7 p-cyclodextrin buffer solution was added; in “CPE+B-CD” 
sample, CPE-215® in pH 7 P-cyclodextrin buffer solution was added; in 
“CPE+CSO+B-CD” sample, CPE-215®/Cottonseed oil mixture in P-cyclodextrin 
buffer solution was added. We used 2% p-cyclodextrin buffer solution, which is 
almost its saturation concentration. The amount of CPE-215® added was based 
on the molar ratio of CPE-215®: P-cyclodextrin =1:1, molar ratio of DPPC: CPE-
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215® = 1:5. The 50 mM pH 7 phosphate buffer was used to prepare liposomes 
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Figure 31 Insulin release from DPPC liposomes at 42 °C with (3- 
cyclodextrin at pH 7. In “Blank” sample, there was only DPPC liposomes, 
as the blank control for insulin release. In “CSO+B-CD” sample, 
cottonseed oil in pH 7 P-cyclodextrin buffer solution was added into 
liposomes: in “CPE+B-CD” sample, CPE-215® in pH 7 P-cyclodextrin 
buffer solution was added into liposomes; in “CPE+CSO+B-CD” sample, 
CPE-215®/Cottonseed oil mixture in p-cyclodextrin buffer solution was 
added into liposomes. The amount of CPE-215® added was based on the 
molar ratio of CPE-215®: P-cyclodextrin =1:1, molar ratio of DPPC: CPE- 
215® = 1:5.
The release tubes were placed in a 42 °C water bath on a shaker table at 
150 rpm. Figure 31 showed the insulin DPPC liposome release result of p- 
cyclodextrin with different formulation components. There was also a very fast
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release rate at the very beginning, then the rate slowed down and reached a 
plateau. The insulin released from liposomes in “Blank” sample was the smallest, 
as expected. Although the “Blank” here was different from the “Blank” in Figure 
26 , which meant we had some reproducibility issue, the relative trends of them 
were similar. The amounts of insulin released in “CPE+B-CD” and 
“CPE+CSO+B-CD” samples were average; the “CSO+B-CD” sample had the 
maximum insulin release. It is interesting to see that cottonseed oil showed better 
membrane permeation enhancing effect than CPE-215® in this experiment. In 
comparison with previous results of insulin release experiments, we can say (3- 
cyclodextrin can further enhance the insulin release from DPPC liposomes.
Based on the structure of cyclodextrins and the results of the insulin 
release experiments, we confirmed that cyclodextrins increased the availability of 
CPE-215® and cottonseed oil to the liposomes. Cyclodextrins and the 
hydrophobic CPE-215®/ cottonseed oil formed inclusion complexes by 
hydrophobic interaction and when the cyclodextrins collided with the liposomes, 
CPE-215® and cottonseed oil could be released into the hydrophobic lipid 
bilayers of liposomes. The direct conclusion out of this hypothesis is that 
cyclodextrin could greatly increase the apparent solubility of CPE-215® in water. 
However, in a simple solubility test of CPE-215® in (3-cyclodextrin solution, even 
when the molar ratio of (3-cyclodextrin: CPE-215® reached to 10:1, we could still 
see some CPE-215® floating on the aqueous surface. Probably (3-cyclodextrin did 
increase the solubility of CPE-215® in water, maybe by 10 or 100 fold, but not as 
much as we thought (we thought by forming an inclusion complex with CPE-
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215®, one p-cyclodextrin could take one CPE-215® into the aqueous phase). I did 
a literature search on cyclodextrins, and found that cyclodextrins were widely 
used to increase the water solubility of hydrophobic molecules by forming a 1:1 
inclusion complex; but not every cyclodextrin molecule could form a complex with 
those hydrophobic molecules, there were different formation constants for 
different molecules. In one recent paper on the use of P-cyclodextrin to increase 
the solubility of a highly hydrophobic drug, furosemide, the drug solubility was 
increased by 11 fold with the help of cyclodextrin.92
3.4. Incorporating Cholesterol into DPPC Liposome
Cholesterol is a membrane constituent widely found in animal systems 
which serves a unique purpose of modulating membrane fluidity, elasticity, and 
permeability. In order to make our liposome model more similar to natural 
membrane, cholesterol was incorporated with DPPC to prepare the liposomes. 
The fluid-phase behavior of binary mixtures of cholesterol with 
phosphatidylcholines was well studied.93,94 When cholesterol content is higher 
than 30 mol%, there is only one phase in DPPC and cholesterol mixture from 20 
°C to 55 °C. In order to make cholesterol evenly distributed in the lipid bilayer, the 
weight ratio of DPPC to cholesterol in our new membrane model was 4:1, in 
which cholesterol counts for 32 mol% of total lipid. With this adjustment to the 
liposome model, the insulin release temperature was adjusted to the human body 
temperature of 37 °C.
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3.4.1. Insulin Release at 37 °C from DPPC/Cholesterol Liposomes with 
Different Formulation Components and Simple Combinations
After we decided to incorporate cholesterol into DPPC liposomes, we 
wanted to see if the change in the liposome model and temperature could result 
in a change of the insulin release profile. We wanted to see the effect of CPE- 
215® only, cottonseed oil only and with (3-cyclodextrin combination on this 
improved membrane model. Therefore, we did a similar insulin release 
experiment for this DPPC/Cholesterol liposome at 37 °C.
We used a high molar ratio of P-cyclodextrin: CPE-215®, which was 1:1. 
Due to the solubility limitation of P-cyclodextrin, the molar ratio of CPE-215®: 
DPPC turned out to be 4:1. Cottonseed oil is a mixture of triglycerides with the 
average molecular weight of 275. In this experiment, the molar ratio of (3- 
cyclodextrin: cottonseed oil was also 1:1. A 50 mM pH 7 phosphate buffer was 
used to prepare these liposomes.
“Cleaned” DPPC/Cholesterol liposomes encapsulating insulin phosphate 
buffer solutions were evenly divided into six plastic centrifuge tubes, with 2 ml of 
DPPC/Cholesterol liposomes in each tube. We added 2 ml of pH 7 buffer into 
one tube of liposomes and used it as the “Blank” control sample. In the “CPE-215 
only” sample, CPE-215® and 2 ml of pH 7 phosphate buffer were added to the 2 
ml liposomes; in the “Cottonseed oil only” sample, cottonseed oil and 2 ml of pH 
7 phosphate buffer were added to the liposomes; in the “1:1 B-cyclodextrin: CPE- 
215” sample, CPE-215® and 2 ml of 2% (3-cyclodextrin pH 7 phosphate buffer 
solution were added to the 2 ml liposomes; in the “1:1 B-cyclodextrin: CSO”
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sample, cottonseed oil and 2 ml of 2% p-cyclodextrin pH 7 phosphate buffer 
solution were added to the 2 ml liposomes.
In this experiment, we also wanted to see the effect of different oil droplet 
size of cottonseed oil on the insulin release profile. In “Cottonseed oil only” and 
“1:1 B-cyclodextrin: CSO” samples, cottonseed oil was added as droplets. 
However, in the “CSO emulsion” sample, cottonseed oil was added to the 
liposomes in the form of emulsion made with a high shear mixter (Ultra Turrex®).
Table 2 Samp e information in Section 3.4.1
Sample Content Note
Blank 2 ml liposome +2 ml phosphate 
buffer
The amount of 
CPE-215® used in 
different samples 
was the same, so 
was cottonseed oil. 
The amount of 
CPE-215® and 
cottonseed oil used 
was based on 1:1 
molar ratio to P-CD.
CPE-215 only 2 ml liposome +2 ml phosphate 
buffer+CPE-215®
Cottonseed oil only 2 ml liposome +2 ml phosphate 
buffer+ cottonseed oil drop








2 ml liposome +2ml 2% P-CD buffer 
solution + cottonseed oil drop
Before the experiment, we thought since CPE-215® crystal started to melt 
at 34 °C, it would be in liquid state at 37 °C. But during the release experiment at 
37 °C, in the samples containing CPE-215®, we could see some solid CPE-215® 
floating on the aqueous surface, which further decreased the availability of CPE- 
215® to the liposomes. Consequently, in all the further release experiments at 37
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Figure 32 Insulin release from DPPC/Cholesterol liposomes at 37 °C at 
pH 7. In the “Blank” sample, there was only DPPC/Cholesterol liposomes, 
as the blank control for insulin release. Molar ratio of (3-cyclodextrin: CPE- 
215®: cottonseed oil = 1:1:1.
Figure 32 showed the result of insulin release from DPPC/Cholesterol 
liposomes at 37 °C at pH 7. The release data were good and as expected—the 
data curve of the “Blank” sample was the lowest among all the sample release 
curves, and the released insulin signals increased with time in all the samples. All 
the insulin release data points are independent, which means that there is no
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guarantee for fluorescence signal of the next point to be higher than the one 
before, although it should be—any mistakes can result in unreasonable curves. 
Therefore, a reasonable curve (the fluorescence signals increase with time and 
the “Blank” curve shows the slowest release) not only shows the insulin release 
information, but also shows that the experimental procedures (sample handling, 
liposome separation and fluorescence signal measurement, etc.) were done 
properly. The reproducibility of our data was also good.
From Figure 32, we can establish a list of samples from the minimum 
amount of released insulin from DPPC/Cholesterol liposomes to the maximum 
amount of released insulin, and comes in order “Blank”, “CPE-215 only", 
“Cottonseed oil only”, “CSO emulsion”, “1:1 B-cyclodextrin: CPE-215” and “1:1 B- 
cyclodextrin :CSO”. The difference between “Cottonseed oil only” and “CSO 
emulsion” samples was really small, which shows that the difference in the oil 
droplet size of cottonseed oil did not make a difference in the insulin release 
profile. Since adding oil droplets is much easier than making oil emulsions, in the 
following experiments, cottonseed oil and mixture of CPE-215®/Cottonseed oil 
were added into DPPC/Cholesterol liposomes as large oil droplets.
This experiment showed again that adding (3-cyclodextrin could further 
enhance the insulin release from liposomes and cottonseed oil had better 
membrane permeation enhancing effect than CPE-215®. CPE-215® is a good 
permeation enhancer, but needs a phase transfer carrier to increase its 
availability to the liposomes.
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3.4.2. Insulin Release at 37 °C from DPPC/Cholesterol Liposomes with 
Different amount of CPE-215®
From the results of previous insulin release experiments with 
cyclodextrins, it seemed that the insulin release was controlled by the availability 
of CPE-215® to the liposomes, not by the amount of CPE-215® added into the 
release tube. If that conclusion is true, then under the same conditions, adding 
more CPE-215® into the release tube will not make the insulin release rate from 
liposomes faster, since the water is already saturated with CPE-215®. In order to 
test this theory, we designed a new release experiment.
This time, we used six release tubes. One was still used as blank control; 
one was used to see the permeation enhancing effect of (3-cyclodextrin only, 
without CPE-215®; two were used to compare the insulin release rate with 
different amount of CPE-215®/Cottonseed oil mixture; the last two were used to 
compare the insulin release rate with different amount of CPE-215®/Cottonseed 
oil mixture with the same amount of (B-cyclodextrin present.
In DPPC/Cholesterol liposome, weight ration of DPPC: cholesterol was 
still 4:1. The weight ratio of CPE-215®: cottonseed oil was still 3:1. In the “1X 
CPE&CSO” sample, molar ratio of CPE-215®: DPPC was 4:1; in the “3X 
CPE&CSO” sample, molar ratio of CPE-215®: DPPC was 12:1. In the 
“1 XCPE&CSO+B-CD”, molar ratio of (3-cyclodextrin: CPE-215®: DPPC was 4: 
4:1; in the “3XCPE&CSO+B-CD” sample, molar ratio of (3-cyclodextrin: CPE- 
215®: DPPC was 4:12:1. In the “B-CD only” sample, molar ratio of (3-cyclodextrin:
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DPPC was 4:1. A 50 mM pH 7 phosphate buffer was used to prepare these 
liposomes.
Table 3 Sample information in Section 3.4.2





B-CD only N/A 0:1:4
1X CPE&CSO 3:1 4:1:0
3X CPE&CSO 3:1 12:1:0
1 XCPE&CSO+B-CD 3:1 4:1:4
3XCPE&CSO+B-CD 3:1 12:1:4
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Figure 33 Insulin release at 37 °C from DPPC/Cholesterol liposomes with 
different amount of CPE-215®/Cottonseed oil at pH 7. The weight ratio of 
CPE-215®: cottonseed oil was still 3:1. In the “1X CPE&CSO” sample, 
molar ratio of CPE-215®: DPPC was 4:1; in the “3X CPE&CSO” sample, 
molar ratio of CPE-215®: DPPC was 12:1. In the “1 XCPE&CSO+B-CD”, 
molar ratio of (3-cyclodextrin: CPE-215®: DPPC was 4: 4:1; in the 
“3XCPE&CSO+E3-CD” sample, molar ratio of (3-cyclodextrin: CPE-215®: 
DPPC was 4:12:1. In the “B-CD only” sample, molar ratio of (3- 
cyclodextrin: DPPC was 4:1.
Figure 33 showed the result of insulin release from DPPC/Cholesterol 
liposomes with different amount of CPE-215®/Cottonseed oil mixture at pH 7. 
The “Blank" sample showed a steady intrinsic insulin leakage rate from 
DPPC/Cholesterol liposomes. The other samples all showed a much higher 
insulin release rate than the “Blank” sample at the beginning, then the release 
rates decreased and finally the insulin release rates were similar to the blank
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control. The “B-CD only” sample showed that p-cyclodextrin itself also had 
membrane permeation enhancing effect, but the faster release rate only lasted 
for about an hour, then went back down to the blank control rate. The 
“1XCPE&CSO” sample had almost the same starting release rate as the “B-CD 
only” sample, but lasted for a longer time, about 3 hours, then the rate went back 
down to the blank control rate. The “3XCPE&CSO” sample had a little bit faster 
stating release rate than the “1XCPE&CSO” sample, but not much. The 
“1 XCPE&CSO+B-CD” sample and the “3XCPE&CSO+B-CD” sample had almost 
the same release profiles, though the amount of CPE-215®/Cottonseed oil in 
these two samples was different; their insulin release rate was much faster than 
the other samples. Obviously the fast insulin release rate was not due to the 
simple effects of (3-cyclodextrin and CPE-215®/Cottonseed oil, but showed the 
synergy between p-cyclodextrin and CPE-215®/Cottonseed oil on the membrane 
permeation effect.
This experiment successfully supported the assumption that the insulin 
release was controlled by the availability of CPE-215® to the liposomes, not by 
the amount of CPE-215® added into the release tube. P-Cyclodextrin could 
increase the availability of hydrophobic CPE-215® to the aqueous phase, which 
resulted in great insulin release rate increases from “1XCPE&CSO” to 
“1 XCPE&CSO+B-CD”, and from “3XCPE&CSO” to “3XCPE&CSO+B-CD”. With 
the same amount of P-cyclodextrin in the solution, which meant with the same 
amount of “transporters” available, different amount of CPE-215® results in the 
same insulin release rate.
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3.5. Insulin Release from DPPC/Cholesterol Liposomes at Different pH
Twenty different amino acids are the elementary constituents of all natural 
proteins. Those amino acids can be grouped according to the characteristics of 
the side chains, such as acidic, basic, polar, and non-polar. Changing pH 
changes the charges on the acidic and basic amino acid side chains, and results 
in changes in the total charge of the protein: the higher the pH value, the more 
negative charge on the protein. For human insulin, the isoelectric point is aroud 
pH 5.3.95 We wished to see the effect of pH on the insulin release rate from 
DPPC/Cholesterol liposomes. The change of pH could also affect the charge on 
the lipids and the liposome structure, but the charge on DPPC does not change 
in the pH range from 4 to pH 10.
3.5.1. Insulin Release from DPPC/Cholesterol Liposome at 37 °C with Small 
pH Gradient
We wanted to see what the insulin release profile would be when there is 
a pH gradient across the membrane (the insulin solution inside of liposomes at 
different pH value from the outside buffer solution). In this experiment, we tested 
three gradients (inside to outside of liposome): pH 7 to pH 5.7, pH 7 to pH 7, pH 
7 to pH 8.2. There were two samples for each gradient: one as the blank release 
control, the other was added CPE-215®/cottonseed oil mixture and (3-
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cyclodextrin. However, the result was not what we expected. Finally we realized 
that it is hard to keep a pH gradient across the lipid bilayer.
When we prepared the 4:1 (w/w) DPPC/Cholesterol liposomes, 50 mM pH 
7 phosphate buffer was used, so that the insulin solution inside of liposome was 
pH 7. When we did the centrifugal extractions at 4 °C, 50 mM pH 7 phosphate 
buffer was also used. Then 3 ml of concentrated liposomes were evenly 
distributed into six 15-ml plastic centrifuge tubes. In “pH 5.7 Blank”, 3.5 ml of pH 
5 phosphate solution was added to 0.5 ml of pH 7 liposomes, the final pH turned 
out to be 5.7. In “pH 7 Blank”, 3.5 ml of pH 7 phosphate buffer was added to 0.5 
ml of pH 7 liposomes. In “pH 8.2 Blank”, 3.5 ml of pH 9 phosphate solution was 
added to 0.5 ml of pH 7 liposomes, the final pH turned out to be 8.2. In “pH 5.7 
C&C+B-CD”, 3.5 ml of 2% (3-cyclodextrin pH 5 phosphate solution and mixture of 
CPE-215®/Cottonseed oil were added to 0.5 ml of pH 7 liposomes. In “pH 7 
C&C+B-CD”, 3.5 ml of 2% p-cyclodextrin pH 7 phosphate solution and mixture of 
CPE-215®/Cottonseed oil were added to 0.5 ml of pH 7 liposomes. In “pH 8.2 
C&C+B-CD”, 3.5 ml of 2% p-cyclodextrin pH 9 phosphate solution and mixture of 
CPE-215®/Cottonseed oil were added to 0.5 ml of pH 7 liposomes.
The weight ratio of CPE-215®: cottonseed oil was still 3:1. The molar ratio 
of CPE-215®: P-cyclodextrin: DPPC was 4:4:1.
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Figure 34 Insulin release at 37 °C from DPPC/Cholesterol liposomes at 
different pH gradients, inside pH is 7. The 100% insulin release point was 
0.0045 mg/ml. We tested three gradients (inside to outside of liposome): 
pH 7 to pH 5.7, pH 7 to pH 7, pH 7 to pH 8.2. There were two samples for 
each gradient, one for the blank release control, the other was added 
CPE-215®/cottonseed oil mixture and P-cyclodextrin. The weight ratio of 
CPE-215®: cottonseed oil was still 3:1. The molar ratio of CPE-215®: P- 
cyclodextrin: DPPC was 4:4:1.
Figure 34 showed the result of insulin release from DPPC/Cholesterol 
liposomes at different pH gradients. To our surprise, it seemed that the pH 
gradients had no effect on the insulin release rate from liposomes: no matter at 
what pH gradient, all the blank control samples seemed to have the same insulin 
release rate, and all the samples with CPE-215®/Cottonseed oil and P- 
cyclodextrin had the same insulin release rate, too. The samples with CPE- 
215®/Cottonseed oil and P-cyclodextrin showed much faster insulin release rates 
at the beginning, similar to the previous release experiments at pH 7.
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In Figure 34, instead of showing the percent of total insulin release in the 
Y-axis as before, insulin concentration was used as the Y-axis. The 100% insulin 
release point corresponded to the insulin concentration of 0.0045 mg/ml.
After some literature search on the membrane permeability to protons, I 
found that lipid bilayers are remarkably permeable to protons.96 It is clear that 
proton permeability is at least 106 greater than for the other simple ions, and this 
is true for biomembranes as well as for model membranes.97 Therefore, in our 
experiment, due to the great permeability of protons through membrane, there 
might not be a pH gradient between the inside and outside of liposomes, though 
we tried to establish one; the release results are likely to have shown the insulin 
release rates at pH around 6 , 7 and 8 , without pH gradients.
3.5.2. Insulin Release from DPPC/Cholesterol Liposome at 37 °C at pH 10
In order to find out how pH affects insulin release, we performed the 
insulin release from 4:1 (w/w) DPPC/Cholesterol liposomes at pH 10. At pH 10, 
insulin has a negative overall charge of about -5.
We did the liposome extrusion and the centrifugal extraction both at pH 
10, so that we were certain there was no pH gradient from the inside to the 
outside of the liposome. The liposomes were evenly distributed into three 15-ml 
plastic centrifuge tubes. O ne tube was used as blank release control, one 
received a CPE-215®/Cottonseed oil mixture, the other one received a CPE- 
215®/Cottonseed oil mixture and (3-cyclodextrin. The weight ratio of CPE-215®:
96
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Figure 35 Insulin release at 37 °C from DPPC/Cholesterol liposome at pH 
10. The 100% insulin release point was 0.003 mg/ml. The weight ratio of 
CPE-215®: cottonseed oil was still 3:1. The molar ratio of CPE-215®: P- 
cyclodextrin: DPPC was 4:4:1.
Figure 35 showed the result of insulin release from DPPC/Cholesterol 
liposomes at pH 10. Insulin concentration was used as the Y-axis. The 100% 
insulin release point corresponded to the insulin concentration of 0.003 mg/ml. 
Insulin release at pH 10 showed a similar trend: CPE-215®/Cottonseed oil 
mixture could make more insulin come out of liposomes; adding P-cyclodextrin
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could further enhance the permeation effect of CPE-215®. However, compared 
with the release data at pH 7 (Figure 33), insulin release at pH 10 seems more 
difficult: slower release rate with low insulin blank release rate.
3.5.3. Insulin Release from DPPC/Cholesterol Liposome at 37 °C at pH 4
We also performed the insulin release from 4:1 (w/w) DPPC/Cholesterol 
liposomes at pH 4. At pH 10, insulin has a positive overall charge, about +3.
We carried out the liposome extrusion and the centrifugal extraction at pH 
4, so that we were certain that there was no pH gradient. The liposomes were 
evenly distributed into three 15-ml plastic centrifuge tubes. One tube was used 
as blank release control; “C&C” received a CPE-215®/Cottonseed oil mixture; 
“C&C+B-CD” received a CPE-215®/Cottonseed oil mixture and P-cyclodextrin. 
The weight ratio of CPE-215®: cottonseed oil was 3:1. The molar ratio of CPE- 
215®: p-cyclodextrin: DPPC was 4:4:1.
98
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
0.003 n
0.0025 -I









0   ■--------1-------------------------I I I I I I I I I




C & C + B -C D
Figure 36 Insulin release at 37 °C from DPPC/Cholesterol liposome at pH 
4. The 100% insulin release point was 0.003 mg/ml. The weight ratio of 
CPE-215®: cottonseed oil was 3:1. The molar ratio of CPE-215®: p- 
cyclodextrin: DPPC was 4:4:1.
Figure 36 showed the result of insulin release from DPPC/Cholesterol 
liposomes at pH 4. Insulin concentration was used as the Y-axis. The 100% 
insulin release point corresponded to the insulin concentration of 0.003 mg/ml. 
Insulin release curve of “C&C” was only a little higher than the release curve of 
“Blank”, but “C&C+B-CD” still showed much faster insulin release from 
liposomes. Comparing the release data at pH 4 (Figure 36) and pH 7 (Figure 33), 
we can see it is much harder for insulin to permeate through lipid bilayers at pH 4 
than at pH 7, even with the help of CPE-215®/cottonseed oil and P-cyclodextrin.
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3.6. BSA Release at 37 °C from DPPC/Cholesterol Liposomes at pH 7
Previously we used insulin molecules, which were tagged with 
fluorescence probes, to do the release experiments from liposomes with CPE- 
215®, and found that liposomes are a good membrane model and CPE-215® is a 
good membrane permeation enhancer. To see if CPE-215® is protein kind and 
size specific, we used a larger protein instead of insulin (MW 6 KDa) to do 
another release experiment. Bovine serum albumin (BSA, MW 66 KDa) was 
selected to be the other model protein. In order to improve the detection 
sensitivity, again we used the fluorescence labeling process to attach a 
fluorescence probe to BSA.
We performed both the liposome extrusion and the centrifugal extraction 
at pH 7. The 4:1 (w/w) DPPC/Cholesterol liposomes were evenly distributed into 
three 15-ml plastic centrifuge tubes. One tube was used as the blank release 
control; in the “CPE” sample, CPE-215® solid was added; in the “CPE&CSO” 
sample, CPE-215®/Cottonseed oil mixture was added. The weight ratio of CPE- 
215®: cottonseed oil was 3:1. The molar ratio of CPE-215®: DPPC was 4:1.
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Figure 37 BSA release at 37 °C from DPPC/Cholesterol liposomes at pH 
7. The 100% BSA release point was 0.007 mg/ml. The weight ratio of 
CPE-215®: cottonseed oil was 3:1. The molar ratio of CPE-215®: DPPC 
was 4:1. In the “CPE” sample, CPE-215® solid was added; in the 
“CPE&CSO” sample, CPE-215®/Cottonseed oil mixture was added.
Figure 37 showed the result of BSA release at 37 °C from 
DPPC/Cholesterol liposomes at pH 7. BSA concentration was used as the Y- 
axis. The 100% BSA release point was 0.007 mg/ml. The BSA release data 
showed that CPE-215® can also enhance the release of big proteins, for example 
66 KDa BSA, through lipid bilayers. CPE-215®/Cottonseed oil mixture gave better 
result than CPE-215® alone, maybe because at 37 °C, most of CPE-215® is still a 
solid, making it less available to the liposomes than CPE-215®/Cottonseed oil 
mixture. The BSA release rate with CPE-215®/Cottonseed oil was slow at the 
beginning when compared with the insulin release data, which might be due to 
the larger size of BSA.
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CHAPTER 4
RELEASE MECHANISM STUDY
The experiments of insulin release from liposomes have proved that CPE- 
215® is an effective membrane permeation enhancer. The next step is to 
investigate the mechanism behind the fact that CPE-215® facilitates the insulin 
transport through lipid bilayers. Studies focusing on the properties of our system 
were carried out, such as the insulin solution properties (self-diffusion and self­
association states of insulin), the interaction between insulin and liposome and 
the interaction between CPE-215® and liposomes. Based on these studies and 
the experimental data, a hypothesis was proposed and the result of a special 
testing experiment proved the validity of the hypothesis for the protein release 
profile from liposomes.
4.1. Insulin Solution Properties
4.1.1. Insulin Diffusion Coefficient Measurement by NMR
Nuclear M agnetic Resonance (N M R ) is a common non-destructive 
technique, which is widely used to obtain information on functional group analysis 
(chemical shifts), bonding connectivity and orientation (J coupling), through 
space connectivity (Overhauser effect), molecular conformations, DNA, peptide
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and enzyme sequence and structure, etc. It can also be used to determine the 
self-diffusion coefficient by the spin-echo technique with pulsed field gradient.98,99
Molecules in liquid or solution states move. This translational motion is, in 
contrast to rotational motion, known as Brownian molecular motion and is often 
simply called diffusion or self-diffusion. It depends on a lot of physical parameters 
such as size and shape of the molecule, temperature and viscosity. Assuming a 
globular or spherical shape for the molecule, the diffusion coefficient, D, is 
described by the Stokes-Einstein equation
n  k T
6^ .  1411
where k  is the Boltzman constant, T  the temperature, q  the viscosity of the liquid 
and rsthe hydrodynamic radius of the molecule.
Pulsed field gradient NMR spectroscopy can be used to measure the 
translational diffusion coefficient of molecules and is sometimes referred to as q- 
space imaging. Through the use of a gradient, molecules can be spatially 
labeled, i.e. marked depending on their spatial position in the sample tube. If they 
move after this encoding during the following diffusion time A, their new position 
can be decoded by a second gradient. The measured signal is the integral over 
the whole sample volume and the NMR signal intensity is attenuated depending 
on the diffusion time A and the gradient parameters (g, 6) .  This intensity change 
is described by
r _  j  „ - D r 2g 2s 2( A - s / Z )
1 ~  1 o e  [4.2]
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where I is the observed intensity, lo the reference intensity (unattenuated signal 
intensity), D the diffusion coefficient, ythe gyromagnetic ratio of the observed 
nucleus, g  the gradient strength, 6  the length of the gradient, and A the diffusion 
time. If bipolar gradients are used for dephasing and rephasing, a correction for 
the time t  between those bipolar gradients has to be applied:
T T - D y 2g 2S 2 ( A - S / Z - T / 2 )I =  I0 'e [4.3]
Briefly, a spin echo pulse sequence is used in combination with a pair of 
gradients on both sides of the 180° pulse. The echo amplitude decay was 
measured and the value of the self-diffusion coefficient was determined from that 
signal.
Usually in NMR experiments, the higher the concentration, the better the 
signal/noise. We used low pH to dissolve more insulin in the NMR tube: 
deuterated hydrochloride acid was used to adjust D2O to pH 3, which was near 
the pH value of the intranasal insulin formulations of Bentley Pharmaceuticals, 
and then insulin was dissolved to reach 2 mg/ml solution.
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Figure 38 Insulin diffusion coefficient measurement by pulsed field 
gradient NMR at pH 3 at 37 °C. The X-axis shows the chemical shifts of 
TH NMR spectrum; the Y-axis shows the diffusion coefficient, the unit is 
10‘10 m2/s, i.e. 10’6 cm2/s.
Figure 38 shows the insulin diffusion coefficient measured by pulsed field 
gradient NMR at pH 3 at 37 °C. It is a 2D NMR spectrum: the X-axis shows the 
1H NMR spectrum, the value in the Y-axis corresponds to the diffusion coefficient 
of the molecule for that specific proton. This 2D NMR spectrum shows the 
diffusion coefficients of different protons in the solution; therefore, even if there 
are different molecules in the solution, as long as the chemical shifts can be 
identified individually, the diffusion coefficients of different molecules can be
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obtained from the 2D DOSY NMR spectrum at the same time. In Figure 38, most 
protons have the diffusion coefficient of 1.4 x 10'10 m2/s, the other proton with a 
chemical shift at 4.7 ppm has a much faster and broader diffusion coefficient. 
Based on its chemical shift position and diffusion coefficient, the peak at 4.7 ppm 
should be due to the proton of water molecules. Insulin consists of 51 amino 
acids and should have a 1H NMR spectrum with numerous peaks. Therefore, the 
remaining peaks in Figure 38 should belong to insulin, and insulin diffusion 
coefficient at pH 3 at 37 °C is 1.4 x 10’10 m2/s, or 1.4 x 10‘6 cm2/s.
Assuming the insulin molecule is a globular protein, from the Stokes- 
Einstein equation (Eq. [4.1]), 
kT
The viscosity for a dilute aqueous is approximately equal to that of water, which 
is approximately, 1.0 centipoise (cP) or 1.0 * 10*3 Pa s. Thus, the hydrodynamic 
radius of insulin
(1.38x 10”2 3 AT-1)(310A') ^  1A_9 ^
r  = ------------------- r-------------------------—  ----- — = 1.6 x 10 m  = \  .6 n m
6;r • (1.0 x 10 Pa • s ) ( l.40x 10  m  - s~ l )
We calculate that the insulin at pH 3 at 2 mg/ml concentration at 37 °C 
behaves like a globular protein with a radius of 1.6 nm or with a diameter of 3.2 
nm.
Lin, et al. studied the insulin aggregates with pulsed-field gradient nuclear 
magnetic resonance spectroscopy at pH 9.4 at 25 °C. 100 They found that at 4 
mg/ml, the insulin dimer is the predominant species in the solution, the 
hydrodynamic diameters calculated for the dimer is 3.6 nm, and the diffusion
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coefficient detected for the dimer by PFG NMR is 1.38 * 10"6 cm2/s at 25 °C, 
which is similar to our result at pH 3.
4.1.2. Using the Analytical Ultracentrifugation to Determine the Insulin 
Association State
Human insulin exists in different association states, from monomer to 
hexamer, depending on the conditions.101,102,103 In the presence of zinc, the 
"normal" state is a hexamer. Zinc ions are not involved in dimer formation but are 
involved in the association of dimers to give the hexamer.104 Zinc-free insulin can 
have different aggregation levels, six monomers *-*■ three dimers <-»■ one 
hexamer, or monomer <-► dimer tetramer <-+ hexamer.105 We would like to 
identify the insulin association state under our release condition for the modeling 
work; and we used the Analytical Ultracentrifugation to do so.
Analytical Ultracentrifugation (AUC) is a very versatile and powerful 
technique for characterizing the solution-state behavior of macromolecules. It 
provides a primary method to determine protein molecular weight and size. Using 
ultracentrifuge to determine protein molecular weight can be traced back to 
1920s.106 The concentration dependence of the molecular weight can provide the 
same thermodynamic information as light scattering. The rate of movement of 
molecules provides hydrodynamic size information. The subunit stoichiometry of 
a protein complex can be calculated from the determined molecular weight. 
Depending on the quality of the data, this determination can be very accurate; for 
example, it can be easily established whether the native conformation of a
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protein is a dimer, trimer or tetramer. Information about the shape and the 
conformation of a protein as well as the interaction between macromolecules can 
be obtained from the sedimentation and diffusion coefficients obtained from a 
sedimentation velocity experiment.
An analytical ultracentrifuge can be viewed as a combination of a 
preparative ultracentrifuge and an optical detection system that is capable of 
directly measuring the sample concentration inside the centrifuge cell during 
sedimentation. The analytical ultracentrifuge at UNH is a Beckman Optima XL-A. 
The instrument spins the protein sample at a controlled speed and temperature 
while at set times recording the spatial concentration distribution. Depending on 
the rotor, the speed may be as high as 60,000 rpm (which is equivalent to 
250,000 x g).
One common type of experiment performed in an analytical ultracentrifuge 
is sedimentation velocity. Sedimentation velocity is a hydrodynamic technique 
and is sensitive to the mass and shape of the macromolecular species. In a 
sedimentation velocity experiment, an initially uniform solution is placed in the 
cell and a high speed is used to cause rapid sedimentation of solute towards the 
cell bottom. This produces a depletion of solute near the top solution meniscus 
and the formation of a sharp boundary between the depleted region and the 
uniform concentration of sedimenting solute (the plateau) (Figure 39). The rate of 
movement of this boundary can be measured, which leads to the determination 
of the sedimentation coefficients.
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Figure 39 Schematic representation of the solute concentration 
distribution in the centrifuge cell in a sedimentation velocity experiment.
At their isoelectric points, proteins have the lowest solubility; from their 
isoelectric points, either raising or lowering the pH, the protein solubility 
increases. Insulin does not have good solubility at neutral pH, but the 
ultracentrifugation experiment usually requires a protein concentration of 1 
mg/ml. Therefore, we prepared a 1 mg/ml insulin in 50 mM citric acid buffer with 
100 mM KCI at pH 3.3, which was also the pH value Bentley Pharmaceutical, Inc. 
used for their intranasal insulin formulations. Before the ultracentrifugation, the 
insulin sample was dialyzed for 10 hours with the pH 3.3 citric acid buffer, which 
was used to dilute the insulin solution later on, to make sure the ionic strengths in 
the insulin sample and citric acid buffer were the same. Part of the 1 mg/ml 
insulin sample was diluted to make a 0.5 mg/ml insulin sample (1:2 dilution) and 
a 0.25 mg/ml insulin sample (1:4 dilution). Then we used the Beckman Optima
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Figure 40 Result of insulin sedimentation velocity experiment of analytical 
ultracentrifugation at 20 °C. The three curves show the molecular weight 
distribution of different insulin species in 1 mg/ml, 0.5 mg/ml (1:2 dilution) 
and 0.25 mg/ml (1:4 dilution) insulin buffer solutions at pH 3.3. The buffer 
was 50 mM citric acid buffer with 100 mM KCI.
Figure 40 shows the result of the insulin sedimentation velocity 
experiment. Due to the complex nature of analytical ultracentrifugation, the result 
shall be interpreted carefully. Peaks in sedimentation velocity diagram have no 
meanings, and multiple peaks only indicate that the stoichiometry of insulin is
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larger than two, which indicates the presence of higher association states of 
insulin than insulin monomer.
4.2. CPE-215® Interaction with Liposome (Membrane)
4.2.1. Introduction
CPE-215® is a general-purpose membrane permeation enhancer for 
protein delivery, which means it is not focusing on specific proteins but 
interacting with the lipid phase of membranes in general. CPE-215® is a 




Figure 41 Molecular structure of DPPC, Cholesterol and CPE-2151
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Figure 41 shows the structure of the three molecules that we focused on 
in the interaction study between CPE-215® and liposome: DPPC was the 
phospholipid used to form lipid bilayers and liposomes, cholesterol was inserted 
into the DPPC lipid bilayer to change the fluidity of the lipids, CPE-215® was the 
membrane permeation enhancer.
Lipid bilayers have different phases. The lamellar gel phase is formed at 
low temperature; the molecules are packed tightly together and the acyl chains 
are highly ordered, corresponding to the all- t ra n s  configuration found in the 
structure of lipid crystals. In lamellar liquid crystalline phase, there is two- 
dimensional order, but there is considerable disorder in the acyl chains, 
characterized by g a u c h e  conformation.107 The lipid phase transition between the 
lamellar gel and liquid crystalline phases can be thermally induced, and the 
phase transition temperature (Tc) is unique to each lipid.
Figure 42 Phosphatidyl Choline lipid bilayer phase transition108.
The technique commonly applied to determine the lipid phase transition 
temperature is differential scanning calorimetry (DSC).109,110,111,112 It is used to
112
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monitor and characterize changes in physical state in polymorphic lipids and also 
to characterize the perturbations on pure lipids by the interactions with other 
materials, such as other lipids, proteins, ions, or small hydrophobic molecules. In 
DSC, a sample and inert reference are heated independently to maintain an 
identical temperature in each. The endothermic gel-to-liquid crystalline bilayer 
transition requires an excess heat over the heat required to maintain the same 
temperature in the reference. Differential heat flow is then plotted as a function of 
temperature.
Modulated DSC™ (MDSC®) is a new technique which provides not only 
the same information as conventional DSC, but also provides unique information 
not available from conventional DSC by overcoming most of the limitations of 
conventional DSC.113,114 In MDSC, the same “heat flux” cell design is used; 
however, a different heating profile is applied to the sample and reference. 
Specifically, a sinusoidal modulation (oscillation) is overlaid on the conventional 
linear heating or cooling ramp to yield a profile in which the average sample 
temperature continuously changes with time. The heat capacity (reversible) 
component of the total heat flow follows the oscillation and can be separated 
from the kinetic (non- reversible) component of the total heat flow by Fourier 
Transform. Therefore, more accurate phase transition information can be 
obtained by MDSC. Furthermore, different from traditional DSC, MDSC can give 
increased resolution of transitions without loss of sensitivity.
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4.2.2. Experiment Design
Earlier, we showed that CPE-215® does have a permeation enhancing 
effect helping insulin go though lipid bilayers. In absence of the permeation 
enhancer, insulin is not likely to go easily through the membrane by itself. As the 
membrane permeation enhancer, CPE-215® is supposed to interact with the 
membrane in order to facilitate the crossing of insulin. We wanted to better 
understand what happens to the membrane in the presence of CPE-215®.
For a thermal study, the size of the liposome does not need to be narrowly 
distributed. In that case, all the liposomes used here were made by bath-type 
sonication at 50 °C for 5 minutes, not by extrusion.
CPE-215® is a hydrophobic molecule, and it must interact with the lipid 
bilayers in order to act as a permeation enhancer. We would like to know if CPE- 
215® molecules formed CPE-215® domains inside the lipid bilayers or if they 
were evenly distributed in the DPPC liposomes and formed a new kind of 
liposome. First, we mixed CPE-215® with DPPC before preparing the liposome, 
and then we compared the thermal property of this new DPPC/CPE liposome 
with standard DPPC liposome. We also mixed CPE-215® with DPPC and 
cholesterol before preparing the liposome and compared the thermal property of 
this DPPC/Cholesterol/CPE-215® liposome with the DPPC/Cholesterol 
liposomes. For convenience, DPPC liposome was called Liposome D,
DPPC/CPE liposome was called Liposome DC, DPPC/Cholesterol liposome was 
called Liposome DH, and DPPC/Cholesterol/CPE-215® liposome was called 
Liposome DHC.
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In our insulin release experiment, CPE-215® was added outside of the 
liposomes containing insulin. Therefore, in another experiment, we made 
Liposome D first and then put CPE-215® together with Liposome D and let the 
MDSC perform multiple heating-cooling cycles. Although CPE-215® is 
hydrophobic, it still has some minimal solubility in water and its solubility 
increases with temperature. With the increase of temperature, more and more 
CPE-215® can go into the aqueous phase; while when the temperature cools 
down, super-saturated CPE-215® needs to come out of the aqueous phase, and 
some will reach the liposomes and enter inside the hydrophobic bilayers. With 
multiple cycles of heating and cooling, conceptually we can see the change of 
the DPPC liposome thermal properties with CPE-215® slowly diffusing into these 
liposomes. CPE-215® has a melting point of 34 °C, which is very close to the 
liposome phase transition temperature; in order to reduce such interference, we 
used 2:1 (w/w) mixture of CPE-215®/cottonseed oil instead of pure CPE-215® 
(Figure 45), which had no thermal transition above 20 °C. We also run the same 
experiment with the Liposome DH.
4.2.3. Experimental Section
The DSC instrument was a Modulated DSC Q100 from TA Instruments, 
Inc. Liposomes were made by sonication. Lipids (DPPC, cholesterol, CPE-215®) 
were mixed and dissolved in chloroform in 50-ml flask, and then dried at reduced 
pressure with a Rotavapor at room temperature for 6 hours to form a lipid film on 
the flask wall. The lipid film was hydrated with 10 ml of 50 mM pH 7 phosphate
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buffer at 50 °C and then sonicated for 5 minutes in the bath-type sonicator to 
make liposomes. Then the liposomes were concentrated by centrifugation at 900 
g for 30 minutes.
The liposomes were sealed in an aluminum pan to measure the liposome 
phase transition. After the DSC experiment, a hole was punched in the pan cover 
and the pan was kept at 70 °C for 5 hours to let the inside water evaporate, 
finally the weight of dry lipid was obtained. Four different liposomes were 
characterized for their phase transitions. Table 4 shows the compositions of 
these four liposomes.














Weight (mg) 5.9 7.5 14.6 12.9
Weight after 
drying (mg)
1.5 2.8 3.1 3.9
Lipid
content
25% 37% 21% 30%
The MDSC in our lab is a Modulated DSC Q100 from TA Instruments, Inc. 
The following MDSC sequence was used for the purpose of measuring the lipid 
bilayer phase transition temperature:
1. initial temp at 25 °C
2. equilibrium at 5 °C
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3. modulate ± 1 °C/60 sec
4. isotherm for 7 min
5. ramp 5 °C/min to 100 °C
6. isotherm for 2 min
For the multiple heating-cooling experiment of liposomes with CPE- 
215®/cottonseed oil mixture, concentrated liposomes and 2:1 (weight) CPE- 
215®/cottonseed oil mixture were sealed in an aluminum pan and heated from 5 
°C to 90 °C for several times. Table 5 shows the different liposomes for the multi- 
heating-cycle experiment.
Table 5. Different liposomes for multiple-heating-cycle experiment.
Liposome D 
only
Liposome D with oil Liposome DH with 
oil
CPE/cottonseed 
oil 2:1 (w/w) (mg)
N/A 2.9 1.6
Liposome (mg) 23.1 19.2 10.1
# of heating 
cycles
4 25 8
The multiple-heating-cooling program is listed below:
1. initial temp at 25 °C
2. equilibrate at 5 °C
3. modulate ± 0.796 °C/60 sec (heat only)
4. isotherm for 6 min
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5. ramp 5 °C/min to 90 °C
6. isotherm for 2 min
7. Repeat from Step 2
In order to see the effect of 2:1 CPE-215®/cottonseed oil on the DPPC 
liposome phase transition DSC curve, 11.9 mg 2:1 CPE-215®/cottonseed oil 
mixture was sealed in an aluminum pan and the thermal scan from 10 °C to 80 
°C (modulation ± 1 °C/60 sec, ramp 5 °C/min) was recorded.
4.2.4. Results and Discussion
The modulated DSC experiments were done for different types of 
liposomes: Liposome D (DPPC liposome), Liposome DC (DPPC/CPE-215® 
liposome), Liposome DH (DPPC/Cholesterol liposome) and Liposome DHC 
(DPPC/Cholesterol/CPE-215® liposome). Figure 43 and 44 showed the resulting 
curves. The lipid bilayer phase transition is a reversible, first-order transition; 
therefore the figures in this section (Figure 43 to Figure 51) show only the 
reversible heat flow by removing the kinetic (non- reversible) component from the 
total heat flow.
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Figure 43 DSC of Liposome D (DPPC liposome) and Liposome DC 
(DPPC/CPE-215® liposome) (exothermal up).
The DSC of Liposome D showed a phase transition temperature at 42 °C 
(we conveniently took the peak temperature as the phase transition 
temperature), which was similar to the literature value.108 The phase transition of 
highly purified DPPC should be sharp, but in Figure 43, the phase transition peak 
seemed a little broad, which may be due to minor impurities in the lipid.
The reversible heat flow of Liposome DC (4:1 (w/w) DPPC/CPE-215®) 
showed one broad endothermic peak with the peak value of 34  °C  (in our 
Liposome DC, the molar ratio of DPPC: CPE-215® was 1.3). Compared with the 
reversible heat flow curve of Liposome D, the phase transition temperature of 
Liposome D was lowered by incorporating CPE-215® with DPPC in the
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liposomes. Since there was no endothermic peak at 42 °C in the reversible heat 
flow curve of Liposome DC, there should be no DPPC domains in Liposome DC, 
or at least the gathering of DPPC in Liposome DC was not significant enough to 
initiate an endothermic peak in the DSC heat flow curve. As to the question of 
whether CPE-215® formed domains in Liposome DC, unfortunately this could not 
be answered based on Figure 44 alone because the CPE-215® itself has a 
melting point of 34 °C, the same temperature as the phase transition temperature 
of Liposome DC. Even if there were CPE-215® domains inside, the CPE-215® 
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Figure 44 DSC of Liposome DH (DPPC/Cholesterol liposome) and 
Liposome DHC (DPPC/Cholesterol/CPE liposome) (exothermal up).
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Cholesterol is a common lipid in natural membranes. Therefore, we also 
used Liposome DH (4:1 (w/w) DPPC/cholesterol) as the membrane model and 
incorporated CPE-215® inside to see if the phase transition temperature was also 
lowered after the addition of CPE-215®. Figure 44 showed the modulated DSC 
reversible heat flow curves of Liposome DH and Liposome DHC (4:1:1 (w/w/w) 
DPPC/cholesterol/CPE-215®), and the phase transition temperatures were 46 °C 
and 37 °C respectively. Cholesterol made the phase transition of DPPC liposome 
broader an increased its average value, while CPE-215® lowered the liposome 
phase transition temperature. Figure 44 also showed that there were no CPE- 
215® domains in the final liposome, CPE-215® and cholesterol were evenly 
distributed in the DPPC liposome and formed a liposome with new thermal 
property.
Among the phase transition peaks of Liposome D, Liposome DC and 
Liposome DH, the phase transition of Liposome DH was the broadest, the phase 
transition of Liposome D was the narrowest, while the broadness of the phase 
transition peak of Liposome DC was intermediate. This might be due to the 
structure of cholesterol and CPE-215® molecules. Cholesterol is a compact, rigid 
hydrophobic entity with a polar hydroxyl group. With cholesterol in the liposome 
bilayer, it is difficult for the DPPC lipid to pack the hydrocarbon chains next to the 
rigid sterol moiety. In the liquid crystalline state, the sterol results in 
conformational constraints on the phospholipid chain, whereas in the gel state 
the sterol inhibits optimal packing of the all- t r a n s  chain configuration. The result 
is that lipid-cholesterol mixtures behave as intermediate between the gel and
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liquid crystalline states of the pure phospholipid, which explains the broadness of 
the phase transition of Liposome DH. Basically, cholesterol acts as a “spacer” 
and reduces the attractive forces between the lipid hydrocarbon chains. 
Compared to cholesterol, CPE-215® is a more flexible lactone o f  a  16-membered 
ring and can cooperate better with phospholipid hydrocarbon chains. In the gel 
phase, the CPE-215® can change its conformation so that the phospholipid 
hydrocarbon chains can pack mostly as t r a n s  conformation; in the liquid 
crystalline phase, CPE-215® can also change its conformation to minimize the 
interference with the g a u c h e  packing of the phospholipid hydrocarbon chains. 
This can explain why the phase transition of DPPC/CPE-215® liposome is 
narrower than that of Liposome DH. Cholesterol’s rigidity and CPE-215®’s 
flexibility may also account for the phase transition temperature change of the 
liposomes.
In our insulin release experiments, we started with DPPC (or 
DPPC/Cholesterol) liposomes and CPE-215® was added outside of liposomes; 
with CPE-215® continuously contacted with liposomes and went into the lipid 
bilayer, Liposome D (or DH) became Liposome DC (or DHC). From Figure 44 
and 44, we only learned that the phase transition temperature of Liposome DC 
(4:1 (w/w) DPPC/CPE-215®) was lower than that of Liposome D, but we would 
also like to know how the DPPC liposome phase transition temperature changed 
while CPE-215® was gradually incorporated inside (Did the phase transition 
temperature decrease continuously? Or did the phase transition temperatures 
not change, just the old peak decreasing and the new peak increasing?) It is
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similar to the situation that after we discovered the starting point A and the end 
point B, we would also like to know how to get to B from A.
In order to make CPE-215® go into the liposome gradually, we planed to 
seal the Liposome D with CPE-215® inside a 50-pl aluminum pan with a cover 
and heat it from 5 °C to 90 °C for multiple cycles with the modulated DSC. 
Although CPE-215® is hydrophobic and has little solubility in water, its solubility 
can increase with temperature. With the increase of temperature, more and more 
CPE-215® can go into the aqueous phase; while when the temperature cools 
down, super-saturated CPE-215® needs to get out of the aqueous phase, and 
some will find the liposomes and go inside of bilayers. With multiple cycles of 
heating and cooling, CPE-215® will gradually transport into the lipid bilayers, and 
we will monitor this continuous change by the modulated DSC. In this 
experiment, we did not want the sealed mixture to have any thermal phase 
change, except the liposome phase transition itself, from 20 °C to 60 °C. Due to 
the melting point of CPE-215® at 34 °C, we could not use the pure CPE-215® 
with Liposome D. We found that the mixture of 2:1 (w/w) CPE-215®/cottonseed 
oil did not have thermal phase change from 20 °C to 60 °C (Figure 45), so that 
we used 2:1 CPE-215®/cottonseed oil instead.
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Figure 45 DSC of 2:1 (w/w) CPE-215®: cottonseed oil (exothermal up).
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Figure 46 Four heating cycles of Liposome D (DPPC liposome) 
(exothermal up).
Figure 46 was the reversible heat flow of modulated DSC of four heating 
cycles of Liposome D. This showed that the phase transition of Liposome D was 
reversible, transition peak size and position did not change with the number of 
heating cycles if there was no outside interference. In other words, if the lipid 
bilayer structure/composition did not change, the phase transition peak size and 
temperature would not change; if the phase transition size and temperature 
changed, then there must be changes in the lipid bilayer structure or 
composition.
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Figure 47 25 heating cycles of Liposome D (DPPC liposome) with CPE- 
215®/cottonseed oil mixture.
Figure 47 shows the result of the multiple heating and cooling of Liposome 
D and 2:1 (w/w) CPE-215®/cottonseed oil mixture. The reduction of the heat of 
the phase transition and the decrease of the transition temperature are 
interpreted to be due to CPE-215® gradually diffusing inside of DPPC lipid 
bilayers. Since there was no endothermic peak increasing around 34 °C (mp of 
CPE-215®) and only the whole liposome phase transition peak shifted to low 
temperature during the cyclic process, we concluded that CPE-215® was evenly 
distributed in liposomes from the beginning, which was thermodynamically 
favored. If we looked at Figure 47 in detail, we could find that with the number of 
heating cycles increasing, the starting temperature of the phase transition
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decreased, while the ending temperature of the phase transition almost did not 
change. This meant with more and more CPE-215® gradually inserted into the 
DPPC liposome, lower temperature was required to make the system deviate 
from ordered packing state, but the same high temperature was still needed to 
get the whole system away from ordered packing. CPE-215® is a small flexible 
molecule, its gradual insertion into the DPPC lipid bilayer disturbed the a \\- tra n s  
ordered packing of phospholipid hydrocarbon chains in the gel state, which 
resulted in lower starting temperature of the liposome phase transition. However, 
since the majority was still DPPC lipid, each time the same high temperature was 
still needed to get all the DPPC chains in the g a u c h e  conformation to reach the 
liquid crystalline state.
Figure 48 showed how the liposome phase transition temperature 
changed with the number of heating cycles, which decreased almost linearly at 
the beginning and reached a plateau in the end.
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Figure 48 Change of phase transition temperature of Liposome D with the 
number of heating cycles.
In order to see if CPE-215® could only reduce the phase transition 
temperature of Liposome D, we did the same multi-heating-cycle experiment with 
Liposome DH. Figure 49 was the DSC result, which also showed that the phase 
transition temperature of Liposome DH decreased with continuous insertion of 
CPE-215®. Although the phase transition for Liposome DH was very broad, the 
peak shift with number of heating cycles was still quite noticeable. We took the 
lowest point of the curve as the phase transition temperature. Figure 50 showed 
the phase transition temperature decreased with number of heating cycles. The 
decrease was almost linear with the number of heating cycles.
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Figure 49 Eight heating cycles of Liposome DH (DPPC/Cholesterol 
liposome) with CPE-215®/cottonseed oil mixture (exothermal up).
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Figure 50 Change of phase transition temperature of Liposome DH with 
number of heating cycles.
We also looked at the enthalpy change of liposomes during the lipid 
bilayer phase transitions. Since the phase transitions of cholesterol-containing 
liposomes are too broad, it is hard to tell the starting and ending points of those 
transitions and accurately obtain the enthalpy change; in that case, here we only 
discuss the phase transition of the DPPC liposomes. According to the thermal 
data of Figure 43, the enthalpy change during the Liposome D phase transition is 
37 kJ/mol, which is similar to the literature value.108 However, the enthalpy 
change in the phase transition of Liposome DC is only 20 kJ/mol, assuming only 
DPPC molecules in the liposomes accounted for the enthalpy change, not CPE-
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215®. The big difference between the enthalpy change of Liposome D and 
Liposome DC can be explained from the different molecular conformation of 
DPPC molecules in those two liposomes. As we have discussed before, during 
the phase transition of Liposome D from lamellar gel phase to lamellar liquid 
crystalline phase, the conformation of the acyl chains of DPPC molecules are 
changed from all- t ra n s  to g a u c h e , and the enthalpy change is related to the 
energy needed to convert the DPPC acyl chains from the highly ordered, low 
energy level all- t ra n s  conformation to the g a u c h e  conformation. In Liposome DC, 
due to the insertion of CPE-215® molecules in the DPPC lipid bilayer, not all the 
DPPC acyl chains are packed in t ra n s  conformation in the lamellar gel phase, 
which increases the energy level of the gel phase of Liposome DC and results in 
less enthalpy change during the phase transition.
Thermal data from Figure 47 further supported the above explanation. 
After calculation, we found that with CPE-215® diffusing into the DPPC 
liposomes, the Liposome D phase transition enthalpy change decreased 
gradually from 37 kJ/mol to 22 kJ/mol after 25 cycles of heating and cooling 
(Figure 51).
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Number of heating cycles
Figure 51 Change of phase transition AH of DPPC in Liposome D (DPPC 
liposome) with CPE-215® insertion.
Table 6 DSC study summary table
To (°C) Transition width AH of DPPC 
(kJ/mol)
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4.2.5. Conclusion
With the help of the powerful modulated DSC technique, we carried out a 
series of liposome phase transition studies. We found that adding CPE-215® into 
the lipid bilayer could reduce the phase transition temperature of liposomes. 
Adding both CPE-215® and cholesterol into the lipid bilayer can broaden the 
phase transition of DPPC liposomes, but CPE-215® has less peak broadening 
effect than cholesterol, which may be due to the rigidity of cholesterol and the 
flexibility of CPE-215®. When inserted into the lipid bilayers, CPE-215® was 
evenly distributed in the bilayers. With CPE-215® gradually inserted into the lipid 
bilayers, the liposome phase transition temperature was gradually shifted to 
lower temperatures, and the liposome phase transition enthalpy change also 
decreased gradually.
4.3. Insulin Interaction with Liposome (Membrane)
Depending on the surface properties and the distribution of hydrophilic or 
hydrophobic regions on the surface, different proteins interact with liposomes in 
different ways. Usually there are three types of interaction between 
protein/peptide and lipid bilayer: adsorption, insertion and penetration (Figure 
52).
133




Figure 52 The interaction modes between protein and lipid bilayer 
membrane.
Understanding the interaction between insulin and liposomes is important 
to our mechanism study of insulin release from liposomes and permeation 
enhancing effect of CPE-215®. Zhang, et al. studied the interaction between 
insulin and liposome by fluorescence spectra and microcalorimetry methods.115 
They found that the interaction between insulin and liposome was weak; there 
was no protein insertion or penetration, probably only weak adsorption; the heat 
effect of the interaction AH= -1.98 kcal/mol, which indicates weak non-covalent 
binding.
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4.3.1. Centrifugal Extraction to Determine the Insulin Adsorption Coefficient 
on Membrane
From our experience in handling insulin molecules during the release 
experiments, we learned that insulin molecules can adsorb on the surface of 
liposomes; otherwise, we would not have needed to perform the multiple 
centrifugal extractions to ensure the outside surface of liposomes was insulin- 
free before the release experiments.
Each of the 20 amino acids can be distinguished by the R-group 
substitution on the a-carbon atom. There are two broad classes of amino acids 
based upon whether the R-group is hydrophobic or hydrophilic. Usually the 
hydrophilic amino acids tend to interact with the aqueous environment and are 
often found on the exterior surface of proteins, but some hydrophobic amino 
acids also exist on the exterior surface, which accounts for the hydrophilic 
regions and hydrophobic regions on the protein surface. Under the hydrophilic 
surface, liposomes have the hydrophobic layer to isolate the inside from outside 
environment. Protein can adsorb on the liposome surface by letting its hydrophilic 
regions contact the liposome hydrophilic layer.
Our insulin adsorption isotherm is based on three assumptions: adsorption 
cannot proceed beyond monolayer coverage; all liposome surface sites are 
equivalent and can accommodate, at most, one adsorbed protein; the ability of a 
protein molecule to adsorb at a given site is independent of the occupation of 
neighboring sites. As one can see, our isotherm is similar to a Langmuir 
isotherm.116
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The dynamic equation is: Insulin + Surface <-> Insulin-Surface 
Rate of adsorption V a -  k xC (  1 -  0 )
where 0  is the fractional liposome surface coverage, k i  is the insulin adsorption 
rate constant, C is the insulin solution concentration.
Rate of desorption V d - k _ x6
where k . i  is the insulin desorption rate constant.
At equilibrium, the rate of adsorption is equal to the rate of desorption.
Then
We carried out a precise centrifugal extraction experiment to determine 
the insulin adsorption coefficient, K,  on the liposome surface. After the normal 
procedure of making 400 nm 4:1 (w/w) DPPC/Cholesterol liposomes in insulin 
solution at pH 7, we performed the centrifugal extraction at 4 °C. We used the 
DYNAC centrifuge at 2000 rpm, which was slow compared to the ultracentrifuge, 
but fair enough to concentrate the liposomes to the bottom of the tube. We 
allowed 1 hour for the insulin desorption and adsorption to reach equilibrium for 
each centrifugal extraction process. We wanted to see the insulin adsorption
k xC { \ - 6 )  =  k_xe [4.5]
k _ K
with ^  -  ,
k _  i
1+  K C  '
[4.6]
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equilibrium at 37 °C, but the lipid bilayer surface is not a solid sphere, and its 
fluidity depends on its temperature. If we perform the centrifugal extraction at 
high temperature, for example 37 °C, not only could the liposomes break during 
the centrifugation, but the inside insulin could come out to interfere with the 
outside insulin concentration. In that case, this experiment had to be carried out 
at low temperature, to ensure the hardness of the liposome sphere and minimize 
the leakage of insulin from inside of liposomes.
Following each centrifugal extraction, we recorded the volume of insulin 
solution in the centrifuge tube (excluding the volume of liposomes), and used 
fluorescence to detect the insulin concentration of the supernatant (before the 
fluorescence measurement, centrifuge filtration with 50 KDa MWCO membrane 
filters was used to separate insulin solution from liposomes); then we recorded 
the volume of supernatant that we took out and the volume of fresh buffer we 
added in. We used the calibration curve to convert the fluorescence signal to 
insulin concentration.
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Figure 53 The fluorescence signal of the supernatant was measured after 
each centrifugal extraction for 8 times. Note the fluorescence signal is on 
a log scale.
Figure 53 shows the decrease of fluorescence signal of the supernatant with the 
increase of centrifugal extraction times. Since the decrease in the signal was so 
drastic for the first couple extractions, the fluorescence signal is shown on a log 
scale, which indicates that the insulin adsorption on the liposome surface is not a 
strong interaction. After 3 extractions, the fluorescence signal was near that of 
the background.
After the ith centrifugal extraction, the insulin concentration, C,, is the result 
of dilution and insulin desorption from the liposomes. Therefore, the remaining 
solution volume (excluding the liposome volume) after removing the supernatant,
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] / „ , and the final solution volume after adding fresh buffer, V,, are two important 
parameters. Then according to the mass balance
Cl_xVri+a0 i_x= C iVl +ae i [4.7]
where a is the amount of insulin adsorbed on the liposome surface when 
0=100%.
Table 7 Centrifugal extraction data
/ C, (mg/ml) Vri (ml) Vi (ml)
0 0.11 N/A N/A
1 3.78 x 10'* 0.33 11.40
2 2.64 x 10'4 0.11 11.28
3 5.39 x 10"& 0.17 11.38
Table 7 listed the information from the centrifugal extraction experiment, 
which were used to calculate the adsorption coefficient, K .
From the equations of
CqV,.j +  u0o — CXVX + <20j
CxVr 2 +  adx =  C2V2 + a02 
1 + KC0
4
1 1 + KCX
2 1 + k c 2
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we can calculate the values of K , a , 0*. 02, 03-
We solved this system of equations and obtained two possible 
mathematical solutions, one was K -  97 ml/mg, the other was K  = 7.13 * 105 
ml/mg. Based on the solutions we got, when K -  97 ml/mg, 0o = 0.914, 9 i  =  
0.268, 02 = 0.025, a = 0.0105 mg; when K =  7.13 *105 ml/mg, 0O = 0.999987, 6 1 
=  0.99963, 02 = 0.9947, a = 18.99 mg. However, the total amount of insulin we 
put into the system when we prepared the liposomes, both inside and outside of 
liposomes, was less than 1.4 mg of insulin; hence, it is impossible to have 18.99 
mg of insulin adsorbed on the liposome surface. Therefore, K  = 7.13 *105 ml/mg 
is only a mathematical solution, with no physical reality, and was discarded. K  = 
97 ml/mg is the reasonable equilibrium constant for insulin to adsorb on a 
DPPC/Cholesterol liposome membrane.
Our calculation showed that if the liposome surface was 100% covered by 
insulin, the amount of insulin on the liposomes surface was 0.0105 mg. In our 
experiment, after the liposome extrusion process, there were 0.067 g of DPPC 
and 0.017 g cholesterol in the liposomes. Since cholesterol has a much smaller 
hydrophilic group than DPPC, we only used the DPPC amount to estimate the 
liposome surface area. Since the liposomes we made were 400 nm large 
unilamellar liposomes, we assumed there was no curvature effect and the overall 
surface area of liposomes was equal to the one side surface of one planar lipid 
bilayer. A phosphatidylcholine’s hydrophilic head group has an average surface 
area of 50 A2,117 the total liposome surface in our experiment S = 0.067 g + 734 
g/mol + 2 x 6.02 * 1023 /mol * 50 A2 = 1.37 x 1021 A2. Therefore, when the
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liposome surface was 100% covered by insulin (0 = 1), the area occupied by 
each insulin molecule was 1.37 * 1021 A2 + (0.0105 x 10'3 g + 5800 g/mol * 6.02 
x 1023 /mol) = 1.26 x 1 o6 A2, which is similar to a square of 112 nm x 112 nm. As 
we know, the diameter of insulin monomer is less than 3 nm; therefore, even at 
100% coverage, the liposome surface was loosely occupied by insulin molecules, 
which is another proof of weak interaction. When 0 = 1, on the inner surface of 
each 400 nm liposome, the average number of insulin monomer is 3.14 x (4000 
A)2 + 1.26 x 10® A2 = 40; most likely, insulin would exist as dimer when 0 = 1, 
then there would be 20 insulin dimer adsorbed on the inner surface of each 400 
nm liposome. This particularly low number of adsorbed insulin molecules 
indicates that insulin has a very low affinity for the outside of the lipid bilayer.
All these results confirmed that there is interaction between insulin and 
liposome, but such interaction is weak, most likely through electrostatic 
interaction.
4.3.2. ITC Experiment of Insulin Titration on Liposome
Isothermal Titration Calorimetry (ITC) is a thermodynamic technique for 
monitoring any chemical reaction initiated by the addition of a binding 
component, and has become a method of choice for characterizing biomolecular 
interactions.118,119 When substances bind, heat is either generated or absorbed. 
Measurement of this heat allows accurate determination of binding constants, 
reaction stoichiometry, enthalpy and entropy, thereby providing a complete 
thermodynamic profile of the molecular interaction in a single experiment.
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Injection of a ligand into the target molecule (which is accommodated in the 
calorimeter cell) will result in an endothermic, or exothermic, enthalpic event 
which will be observed as a heat pulse.
When we used ITC to study the insulin adsorption on liposome surface, 
insulin was the titrating ligand and the liposome was the target substance. Since 
the interaction was expected to be weak, insulin solution with high concentration 
was used to obtain enough signal strength. We prepared 5 mg/ml (0.86 mM) 
insulin solution and two kinds of liposomes with the lipid content of 5 mg/ml at pH 
3.1 in 30mM citrate buffer to study the interaction of insulin with liposomes, i.e. 
400 nm 6:1.5:1 (weight) DPPC/Cholesterol/CPE-215® unilamellar liposome and 
400 nm 4:1 (weight) DPPC/Cholesterol unilamellar liposome. We also sealed 
insulin solution and liposome solutions into dialysis tubes and put them into the 
pH3.1 30 mM citrate buffer overnight to make sure they all had the same pH and 
ionic strength. The dialysis membrane had a molecular weight cutoff of 3500 to 
make sure insulin and liposome can not pass through.
MicroCal, Inc. kindly agreed to perform the titration experiment for us 
using their VP-ITC at 37 °C. Besides two liposome sample titrations, a control run 
was also carried out, i.e. using insulin to titrate pH 3.1 citrate buffer.
Before the titration, the liposomes were placed in the calorimeter cell 
(1.428 ml cell volume) at 37 °C. The insulin solution was loaded in the syringe, 
and the titration program adjusted for 10 pl/injection (2 pi for 1st injection), 3.5 min 
interval between injections, 20 sec per injection.
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Figure 54 The VP-ITC raw data of two liposome sample titrations and one 
control run (endo up). Two liposome samples (400 nm 6:1.5:1 (weight) 
DPPC/Cholesterol/CPE-215 unilamellar liposome and 400 nm 4:1 
(weight) DPPC/Cholesterol unilamellar liposome) were titrated by insulin 
(5 mg/ml; 0.86 mM) in 30 mM pH 3.1 citrate buffer at 37 °C. 10 pl/injection 
(2 pi for 1st injection), 3.5 min interval between injections, 20 sec per 
injection, 280 rpm stirring.
Figure 54 shows the ITC raw data for two sample titrations and one 
control run. The heat effects for the control (upper curve) were endothermic and 
its magnitude decreased quite rapidly as the titration proceeded. Near the end of 
the titration, the heat effects became very small and constant. These data 
appeared to be the result of the heat of dilution of a concentrated insulin solution 
(0.86 mM) injected into a buffer. Due to our dialysis treatment of the samples
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before the titration, the large endothermic heat observed for the control run could 
not be due to pH mismatch. Additionally, a likely source for these endothermic 
heat effects is the insulin dimer to monomer dissociation when the insulin 
solution was diluted into the buffer. The heat effects for the two liposome sample 
titrations are very similar to that of the control, though their endothermic heat 
effects were slightly smaller than those of the control due to the weak binding of 
insulin to the liposome surface.
The integrated heats for three titration experiments are shown in Figure 55 
after normalizing by the insulin concentration (using 0.86 mM). The differences in 
the integrated heats between the liposome samples and the control are small. It 
appears that the sample of DPPC/Cholesterol/CPE-215® liposome has a slight 
larger exothermic net heat than that of DPPC/Cholesterol sample.
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Figure 55 VP-ITC heat data after auto baseline integration, normalized on 
insulin concentration (0.86 mM). 400 nm 6 :1.5:1 (weight) 
DPPC/Cholesterol/CPE-215® unilamellar liposome and 400 nm 4:1 
(weight) DPPC/Cholesterol unilamellar liposome) were titrated by insulin 
(5 mg/ml; 0.86 mM) in 30 mM pH 3.1 citrate buffer at 37 °C. 10 pl/injection 
(2 pi for 1st injection), 3.5 min interval between injections, 20 sec per 
injection, 280 rpm stirring, x, control titration; • , DPPC/Cholesterol 
liposome; □, DPPC/Cholesterol/CPE-215® liposome. Positive heat value 
means endothermal process.
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Figure 56 VP-ITC heat data after the sample runs subtracted the control run 
point by point. • , DPPC/Cholesterol liposome; □, DPPC/Cholesterol/CPE^IS* 
liposome. Negative heat value means exothermal process.
In order to clearly show the net heat effects of insulin adsorption on 
different liposome surfaces, the heat data of the control run were subtracted from 
that of liposome samples point by point, and Figure 56 shows the subtraction 
results. In Figure 56, we can see that DPPC/Cholesterol/CPE-215® liposomes
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have a larger exothermic net heat than DPPC/Cholesterol liposomes. The net 
exothermic heat from insulin adsorption on DPPC/Cholesterol/CPE-215® 
liposomes is almost twice that of DPPC/Cholesterol liposomes, which clearly 
indicates a higher affinity of insulin to the surface of DPPC/Cholesterol/CPE-215® 
liposome than to the surface of DPPC/Cholesterol liposome.
4.4. Mechanistic Hypothesis for the Insulin Release from Liposome
4.4.1. Diffusion through Lipid Bilayer Membrane
Since the permeability of lipid bilayer membranes to small molecules is a 
well-studied field,120,121 at the beginning of our mechanistic study of permeability 
of insulin through lipid bilayers, we started by testing the mechanism of small 
molecules crossing lipid bilayer membrane first.
The ability of a small solute molecule to cross the lipid membrane is 
quantified by its permeability coefficient. For a molecule to cross the bilayer, it 
must (1) enter the membrane, overcoming any interfacial resistance or free 
energy barrier to do this, (2) diffuse across the bilayer, and (3) exit the membrane 
on the opposite side, again, overcoming any possible interfacial resistance. Any 
of these steps could, in principle, be rate limiting. The permeability of most 
nonelectrolytes through lipid bilayer membranes can be successfully analyzed by 
the s o lu b i l i ty -d i f fu s io n  model, which makes the assumption that the rate-limiting 
step is the diffusion within the lipid bilayer and that interfacial barriers for 
membrane entry and exit are negligible. This allows one to assume a rapid
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partition equilibrium between the aqueous and membrane phases (step 1 and 3 
in Figure 57). The partition coefficient, K p, is defined by
K  = i £ n = i s i
'  [C?] [ C f ]  1 1
(1) (2) (3)
Figure 57 Simple schematic representation of the solute concentration 
change while crossing a lipid bilayer membrane according to the solubility- 
diffusion model. The solute concentrations at locations in the membrane 
(m) and aqueous (aq) phase are indicated. The numbers at the bottom 
refer to the steps required for a solute to cross the membrane from left to 
right.
The permeability coefficient, P, in terms of the net flux, from side 1 to side 
2, of solute across a m em brane of thickness of, is defined by
flux = P - { C “q - C a2q) [4.9]
This same flux can be expressed in terms of the diffusion coefficient describing 
the flux of solute within the membrane, D m, using Fick’s first law.
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[4.10]
where the concentration gradient is assumed to be linear across the bilayer. 
Substituting from equation 4.8 into equation 4.10 yields
Comparing equation 4.9 and 4.11 gives
The permeability coefficient is a product of the partition coefficient and diffusion 
coefficient within the membrane, divided by the width of the membrane.
We have already obtained the insulin diffusion coefficient in aqueous
hydrophobic layer of the bilayer membrane is made of long hydrocarbon chains, 
we tried to estimate D m from the insulin diffusion coefficient in decane. Due to the 
extremely low solubility of insulin in decane, it is very hard to obtain the insulin 
diffusion coefficient in decane experimentally. According to Stokes-Einstein 
equation (equation 4.1), the diffusion coefficient is determined by temperature, 
the viscosity of the liquid and the hydrodynamic radius of the molecule. The 
viscosity of decane at 20 °C is 0.92 cP, which is very similar to that of water at 20 
°C (1 cP). In that case, at the same temperature, the insulin diffusion coefficient 
in decane should be very similar to that in water, or at least in the same 
magnitude of 10'6 cm2/s. However, the hydrocarbon chains of the lipids in the 
lipid bilayer are lined up and orderly packed, which is not like the free decane
p [4.11]
solution from NMR, which is 1.4 * 10'6 cm2/s at 37 °C for insulin dimer. Since the
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molecules. From insulin adsorption on the membrane surface to insulin insertion 
into the membrane, the movement of insulin is associated with the lateral 
movement of lipids molecules. Therefore, the lateral diffusion (diffusion is 
restricted to two dimensions) coefficient of lipid should also be considered.122 The 
lateral diffusion coefficient in unilamellar vesicles of DPPC at 50°C was 
measured to be 8 * 10"8 cm2/s .123 According to our DSC data of DPPC liposomes 
(Figure 43), 37 °C and 50 °C are all in the phase transition range, therefore, the 
lateral diffusion coefficient in unilamellar vesicles of DPPC at 37°C should be of 
the order of 10'8 cm2/s. We would use 10'8 cm2/s to estimate the insulin diffusion 
coefficient in DPPC lipid bilayer at 37 °C.
The thickness of one lipid bilayer is about 4 -5  nm. If we assume the 
insulin permeation through lipid bilayer is a diffusion-controlled process like the 
small nonelectrolytes, then according to the relation between the diffusion 
coefficient and the mean-square displacement, <x2>,
< * 2 >D
It ’ [4.13]
the time required for insulin molecule to cross the lipid bilayer would be
<=(j^>=J 4 x lO -W  ^
2 D m 2 x 1 0  cm ■ j
This calculation indicates that once insulin is in the lipid bilayer, it takes 
almost no time for insulin to cross the membrane, but our insulin release 
experiment data did not show such a fast insulin release rate. Therefore, we can 
see diffusion is not the rate-limiting step for the insulin release from liposome,
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and we cannot ignore the large electric potential energy increase caused by 
protein surface charges in the bilayer membrane. The partition coefficient, K p 
(Equation[4.8]), of insulin in lipid bilayer must be very low. With both low K p and 
D m, it is not surprising that insulin has low permeability in lipid bilayers (Equation
[4.12]).
Insulin in water is stabilized by the favorable interaction of the water 
dipoles, the hydration energy. Moving insulin between media of different 
dielectric constants, e.g., from an aqueous phase to the bilayer membrane 
interior, is unfavorable because of the loss of this hydration energy.
4.4.2. The Role of CPE-215® as a Membrane Permeation Enhancer
From our release experiments, we know that at 37 °C, insulin has a small 
leakage rate from liposomes even without the addition of CPE-215®; the addition 
of CPE-215® greatly increased the insulin release rate from liposomes. 
Therefore, our mechanism hypothesis should at least explain these two 
phenomena.
Liposome leakage has been studied for decades. There are several 
competing theories, focusing on defects in the packing order of the bilayer. 
These defects are postulated to form spontaneously, like fluctuating holes124, or 
possibly along boundaries between coexisting lipid gel and liquid crystalline 
phases125. Liposome leakage is maximal at the transition temperature between 
the gel and liquid crystalline phases126, which indicates that the leakage is not 
due to a simple increase in molecular motion at higher temperatures, but is due
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to a transient structural disorder of the lipid packing induced by the phase 
separation.
Based on this information, we propose that the rate-limiting step for insulin 
release from liposome is the probability for an insulin molecule to find a 
appropriate defect in the lipid bilayer to cross the membrane, and the rate of
insulin release, V, can be expressed a s V  oc P . • P d t where P,is the probability of 
insulin molecules adsorbed on the lipid bilayer surface, Pd is the probability of 
defects in the lipid bilayer.
Our ITC experimental data show a larger net insulin adsorption exothermic 
heat on DPPC/Cholesterol/CPE-215® liposome surface than on 
DPPC/Cholesterol liposome surface, which indicates a higher affinity and larger 
adsorption coefficient of insulin on the surface of DPPC/Cholesterol/CPE-215® 
liposome than on the surface of DPPC/Cholesterol liposome. Therefore, with the 
addition of CPE-215® in the lipid bilayer, more insulin can be adsorbed on the 
liposome surface, that is, the addition of CPE-215® can increase P,.
Although the hydrophobic CPE-215® likes to go into the interior 
hydrophobic region of the bilayer membrane, there is a hydrophilic layer at the 
outmost surface of liposome and CPE-215® has to cross that layer first to go 
inside of the bilayer. It is clear that the bilayer is a remarkably good barrier 
against both hydrophilic and hydrophobic molecules. However, the defects in the 
liposome surface are perfect places for CPE-215® to enter the bilayer. Once 
CPE-215® molecules go into the defect, they stabilize the defect and make a 
hydrophobic region on the liposome surface attract more CPE-215® to make
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larger defect. As a result, CPE-215® can increase P d. However, the size of the 
stabilized defect is limited by the energy cost associated with the creation of a 
large CPE-215®/water interface.
The above analysis shows that CPE-215® has positive effect on the two 
major factors in the rate-limiting step of insulin release. That is our rational on 
how CPE-215® can facilitate the insulin release from liposomes.
Compared to the totally hydrophobic hydrocarbon chains of the lipids, 
CPE-215® has a better affinity to the insulin molecule due to its polar ester group. 
Figure 58 shows the insulin dimer surface property region distribution. The insulin 
dimer structure was obtained from RCSB Protein Data Bank, and was displayed 
by Swiss-PdbViewer. Those regions are determined by the property of amino 
acid side groups: the polar regions are red, the non-polar regions are blue, the 
acidic/basic regions are yellow. The non-polar regions are ready to be in the 
hydrophobic environment; although the polar regions are not as good as the non­
polar regions in the hydrophobic environment, they are much better than the 
acidic/basic regions; the acidic/basic regions do not want to stay in the 
hydrophobic environment at all, because they can lose the hydration energy once 
they move from hydrophilic phase to the hydrophobic phase within the lipid 
bilayer.
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Figure 58 Insulin dimer surface property region distribution: the polar 
regions are red, the non-polar regions are blue, the acidic/basic regions 
are yellow.
When insulin dimer enters the defect in the liposome, the CPE-215® 
molecules in the defect can cover the non-polar and polar regions on the dimer 
surface, some may even cover the acid/basic regions because insulin prefers 
CPE-215® to hydrocarbon chains of lipid anyway. Then the whole insulin dimer 
molecule can be shielded by CPE-215® molecules and cross the bilayer with less 
energy barrier. This is another possible role of CPE-215® as a membrane 
permeation enhancer, though this may not be the major facilitating effect of CPE- 
215® on the insulin release from liposome process.
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4.4.3. Proposed Hypothesis for the Whole Insulin Release Process
From our release data with different formulations and different conditions, 
we found one similar phenomenon—different formulations can initiate different 
initial release rates, but high insulin release rates only appeared at early release 
time, later on all the release rates were similar and independent of enhancer 
formulation. Figure 59 is an example of this phenomenon that has been 
systematically observed.
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Figure 59 Insulin release from a DPPC/Cholesterol liposome at 37 °C
Figure 59 shows the insulin release from a DPPC/cholesterol (4:1 w/w) 
liposome at 37 °C. In this experiment, three release tubes contained the same
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amount of DPPC/cholesterol (4:1 w/w) liposomes. One tube was used as blank 
control, one tube received a CPE-215®/cottonseed oil (3:1 w/w) mixture, and the 
other received a CPE-215®/cottonseed oil (3:1 w/w) mixture with p-cyclodextrin 
(1%). The release data showed that the insulin release rate of the blank control 
almost remained the same throughout the whole experiment, which showed the 
intrinsic leakage rate of a DPPC/cholesterol liposome. After the addition of CPE- 
215®/cottonseed oil mixture, the release rate was about twice the release rate of 
the blank control at the beginning, three hours later, the release rate began to 
slow down, and finally the release rate was equal to the one of the blank control. 
The formulation containing P-cyclodextrin really boosted the initial insulin release 
rate (about 8 times from the blank control rate, and 4 times from the formulation 
containing only CPE-215® and cottonseed oil). Later this rate also slowed down 
to equate to the rate of blank control release. In Figure 59, we divided the release 
data into three phases: Phase I, when the high initial release rates occur; Phase 
II, when the release rates begin to decrease; Phase III, when the release rates 
are all equal to the rate of the blank control.
Figure 60 shows a molecular level illustration of our proposed hypothesis 
for the whole insulin release process with CPE-215®. According to our DSC data 
(Figure 44), 37 °C is in the phase transition range of DPPC/cholesterol liposome, 
and there are defects existing in liposome. Due to the reason we discussed 
earlier, the oil mixture prefers being inserted into the defects of lipid bilayer. Once 
CPE-215® molecules go into the defect, they stabilize the defect and make a 
hydrophobic region on the liposome surface to attract more CPE-215® to form a
156
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
domain of CPE-215®, probably a few nanometers in diameter, which is not 
detectable by MDSC. As a result, high stress is generated at the outer surface of 
the liposome, and a transient CPE-215® “pore” is formed to facilitate the protein 
transport through the membrane. That is Phase I in Figure 59 and 60.
Defect
CFO OLiposome
Low insulin leak rate High insulin leak rate Medium insulin leak rate Low insu|in |eak rate
T=0 Phase I Phase II Phase III
Figure 60 Scheme of Immediate Impact theory
Large CPE-215® domains are not favored thermodynamically; entropy 
causes CPE-215® to distribute evenly in the bilayers. When CPE-215® molecules 
begin to diffuse out of the CPE-215® rich domain, the transport “pores” begin to 
disappear, and the insulin release rate starts to decrease. This is what we call 
Phase II in Figure 59 and 60.
When all the CPE-215® molecules in the domains are evenly distributed in 
the lipid bilayers, no more “pores” exist and the release rate goes back to the 
blank control leakage rate. We define this mode as Phase III in Figure 59 and 60.
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This hypothesis implies that the CPE-215®-evenly-distributed liposomes 
should have a similar leakage rate comparable to the blank control liposomes, 
and should be able to be reactivated by CPE-215®/cottonseed oil droplets. In 
order to test the validity of the theory, we designed a new release experiment. 
Two kinds of liposomes were made, one was 4:1 (weight ratio) DPPC/cholesterol 
liposome, and the other was DPPC/CPE-215®/cholesterol liposome. In the 
DPPC/CPE-215®/cholesterol liposome, CPE-215® was evenly distributed in the 
lipid bilayers, DPPC/CPE-215® molar ratio was 2:1 (weight ratio 6:1), and 
DPPC/cholesterol weight ratio was still 4:1. According to our theory and the 
release data of Figure 59, after 6 hours, CPE-215® should be evenly distributed 
in the lipid bilayers; if another dose of formulation was added then, there should 
be another enhanced insulin release rate. In this set of experiments, there were 
five release tubes, two of them were used for controlling the leakage rate of 
DPPC/cholesterol liposome and DPPC/CPE-215®/cholesterol liposome, two of 
them were used to see the enhanced release effect of adding oil mixture into 
DPPC/cholesterol liposome and DPPC/CPE-215®/cholesterol liposome at time 
zero, the last one was subjected to a second oil mixture “injection” after 6 hours 
to see if there would be renewed release boost.
Figure 61 shows the insulin release results of this set of experiments and 
Figure 62 is a close-up of Figure 61 at early times. The leakage rate of 
DPPC/CPE-215®/cholesterol liposome was similar to that of DPPC/cholesterol 
liposome, sometimes even slower than that of DPPC/cholesterol liposome, which 
is in good agreement with our hypothesis theory. Although the third point of the
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DPPC/cholesterol liposome release curve was a little low, it was still within the 
experimental error. Release from the DPPC/CPE-215®/cholesterol liposomes 
was activated by CPE-215®/cottonseed oil mixture, similar to what CPE- 
215®/cottonseed oil mixture did to DPPC/cholesterol liposome. Again this agrees 
with our theory. We think that evenly distributed CPE-215® has a function similar 
to cholesterol in membrane barrier. In DPPC/CPE-215®/cholesterol liposome, 
there was already a large amount of CPE-215® evenly distributed in the lipid 
bilayers, the impact by outside oil mixture should not be as significant as in 
DPPC/cholesterol liposome, and the “pore” disappearing process should be 
slower due to reduced driving forces, which explained why in Figure 61 the 
“DPPC/CPE/Chol C&C” curve had a lower slope than the “DPPC/Chol C&C” 
curve at the beginning and took longer time to go back to the control leakage 
rate. The “DPPC/Chol 2C&C" curve showed another boost after a second 
addition of oil mixture at Hour 6, which is a very strong argument for our theory. 
All in all, this set of experiment proves the validity of our hypothesis on the 
membrane permeation enhancing effect of CPE-215®.
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Figure 61 Insulin release at 37°C from different liposomes.
Note that the “DPPC/Chol 2C&C” and “DPPC/Chol C&C” samples were 
having the exact same condition during the first 6 hours, so their release data in 
the first 6 hours should be the same, and they ARE the same in Figure 61, which 
shows the reproducibility of our experimental technique and sample handling.
DPPC/Chol Blank 
* -  DPPC/Chol C&C  
DPPC/Chol 2C&C  
x DPPC/CPE/Chol Blank 
• * -  DPPC/CPE/Chol C&C
2nd injection for 
DPPC/Chol m
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Figure 62 Close-up of Figure 61 at early times.
An important implication of this permeation mechanism is that CPE-215® 
is a SAFE membrane permeation enhancer. There are many kinds of membrane 
permeation enhancers out in the market. Some of these enhancers cause 
irritations, but what patients and the FDA are concerned most with is whether 
they are safe to use, whether they destroy the integrity of the membranes and let 
everything flow into the human body at the same time as the drug is delivered. 
Based on our theory, CPE-215® can only form transient “pores” in the membrane 
for a short period of time, and then the barrier function of the membrane is re­
established. In our in vitro study, the time from “pore” formation to “pore" 
resorption was about 6 hours; while in human body, cell metabolism is carried
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out at all times, so the in vivo time from “pore” formation to “pore” resorption 
should be less than 6 hours, which makes CPE-215® safer to use than other 
membrane permeation enhancers.
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CHAPTER 5
QUANTITATIVE RELEASE MODEL
We have proposed a theory to describe the process of protein release 
from liposomes and carried out a set of testing experiments to prove the validity 
of this theory. In this chapter we developed a mathematical model based on this 
theory to quantify the release results. A semi-empirical nonlinear equation 
involving four parameters effectively fits the protein release profiles. Finally we 
used a neural network approach to correlate the different release condition 
parameters and the four semi-empirical fitting parameters based on our limited 
data sets.
5.1. Mathematical Model
Based on our theory, the whole release process is simplified to be the 
combination of two steps: at the beginning it is the boost release triggered by the 
permeation enhancers; after the permeation enhancers are evenly distributed 
inside of the lipid bilayer, it is the self-leakage of liposome.
The part of the triggered boost release can be empirically expressed as a 
simple linear time dependent event
y  =  a - t  +  b  [5.1]
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where y  is the percentage of protein released from liposome, a is the boost 
release rate, b  represents the systematic error of the experiment (theoretically, b 
should be zero, but due to the temperature change at time zero and the sample 
processing time between taking the sample and finishing the separation of 
protein and liposome, b  is always a little bit more than zero).
The self-leakage of liposomes can also be empirically expressed as a 
simple linear time dependent event
y  =  c  • t  +  d  [5.2]
where y  is the percentage of protein released from liposome, c is the liposome
self-leakage rate.
We introduced another parameter, t*, which is the transition time between 
the triggered boost release and the self-leakage of liposomes 
where a - t * + b  =  c - t * + d  [5.3]
then d  -  ( a - c ) - t * + b  [5.4]
and the self-leakage of liposome can be expressed as 
y  =  c - t  +  ( a - c ) - t * + b  [5.5]
Mathematically, we combined both release steps [5.1] and [5.2] through 
the following equation
1
y  = 1 1 [5.6]
a - t  +  b  c - t  +  ( a -  c ) - t * + b  
or alternatively
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which could smoothly link the two release steps and represent the whole release 
process. Practically Equation 5.7 is a better fit than Equation 5.6 to all 
experimental data. Equation 5.7 was used to express the whole release process.
We used the “Solver” function of Excel® to estimate the best a,  b,  c  and t *  
values to make the Equation 5.7 fit the experimental data through a least square 
non-linear curve fit. Figure 63 is an example of the fitting. The complete fitting 
results for all release curves can be found in Appendix.
The experimental data used in Figure 63 are from the “CPE215” sample in 
Chapter 3.2.2, shown as square dots. The lines of “a t+ b ” and “cf+aT are shown in 
blue and pink colors respectively, and the t* value can be found in the cross point 
of these two lines.
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Figure 63 Modeling curves and the experimental release data of the 
“CPE215” sample in Chapter 3.2.2. The blue line is the " a t+ b ” , which 
represents the boost release; the pink line is “ c t+ d ” , which represents the 
later self-leakage of liposome. The time value of the cross point of the two 
lines is t* . The experimental data points are shown as square dots.
Equation 5.7 was used as the modeling equation for all the release 
experiments, and a, b , c, t *  were obtained from the Excel® “Solver” function 
within reasonable range to generate the best fits. Most modeling curves fit well 
with the experimental data, which, to some extent, contributes to the validity of 
our theory. With the values of a, b , c , t* , we can generate the whole release 
profile. Table 8 shows the fitting results with Equation 5.7.
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Table 8 Modeling parameters for the release experiments.
Chapter # Sample a (%»hour'1) b (%) c (%*hour'1) t* (hour)
3.2.2 Blank 1.66 10.41 0.48 6.79
3.2.2 CPE215 3.29 3.43 0.42 6.01
3.3.1 B-CD 4.14 12.93 0.15 5.32
3.3.1 CPE&CSO 6.72 8.68 0.19 3.54
3.3.1 B-CD+CPE&CSO 10.65 9.02 0.33 2.20
3.3.1 a-CD+CPE&CSO 15.25 23.07 0.09 3.47
3.3.2 C&C+20X B-CD 14.68 16.79 0.23 2.12
3.3.2 C&C+1x a-CD 9.94 9.86 0.20 2.51
3.3.2 C&C+20x a-CD 14.08 10.43 0.19 1.94
3.3.3 Blank 0.71 49.44 0.20 10.00
3.3.3 CSO+B-CD 11.83 55.55 0.02 1.00
3.3.3 CPE+B-CD 6.57 51.72 0.16 0.65
3.3.3 CPE+CSO+B-CD 11.87 40.41 0.28 0.94
3.4.1 Blank 0.90 2.14 0.70 10.00
3.4.1 CPE-215 2.90 0.41 0.62 2.60
3.4.1 Cottonseed Oil 4.26 0.65 0.30 5.78
3.4.1 CPE+B-CD 4.90 1.34 0.58 6.47
3.4.1 CSO+B-CD 7.11 1.67 0.83 5.14
3.4.2 Blank 0.91 4.02 0.71 54.29
3.4.2 B-CD 4.17 5.59 0.50 5.01
3.4.2 1xCPE&CSO 8.58 3.21 0.45 4.04
3.4.2 3xCPE&CSO 10.20 5.11 0.20 4.22
3.4.2 1 xCPE&CSO+B-CD 23.96 9.34 0.39 2.35
3.4.2 3xCPE&CSO+B-CD 29.26 13.66 0.54 1.63
3.5.1 pH7 Blank 0.66 -0.07 0.62 2.45
3.5.1 pH7 C&C+B-CD 20.62 -2.33 0.70 2.53
3.5.2 Blank 0.32 -0.14 0.36 21.75
3.5.2 C&C 1.16 -1.91 0.89 9.04
3.5.2 C&C+B-CD 5.02 -2.33 0.79 14.09
3.5.3 Blank 0.36 -0.73 0.23 16.91
3.5.3 C&C 0.46 -0.37 0.20 23.42
3.5.3 C&C+B-CD 4.16 2.15 1.30 7.87
3.6 Blank 1.32 0.29 0.40 49.04
3.6 CPE 2.10 -0.81 0.50 29.68
3.6 CPE&CSO 4.13 -2.36 0.23 18.83
One can observe that the a value, representing the burst release rate, is 
system dependant and fluctuates widely based on the release conditions from
0.32 %/hour to almost 30 %/hour. The c value reflects the leakage rate and 
should be small and reasonably the same for all systems; in our case, it ranges
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from 0.02 %/hour to 1.3 %/hour. Here, c < a. Although t *  has a physical meaning 
in the model, which is system dependant and related to the time needed for the 
liposomes to restore the barrier function, it is hard to find a reasonable 
explanation to the wild fluctuation of t *  values given by the model in Table 8. The 
meaning of t *  in the model may need further modification.
5.2. Neural Network
5.2.1. Introduction to Neural Network
A neural network is an information processing paradigm that is inspired by 
the way biological nervous systems, such as the brain, process information.127 
The key element of this paradigm is the novel structure of the information 
processing system. It is composed of a large number of highly interconnected 
processing elements (neurons) working in parallel to solve specific problems. 
Neural networks, like people, learn by example. A neural network is configured 
for a specific application, such as pattern recognition or data classification, 
through a learning process. Learning in biological systems involves adjustments 
to the synaptic connections that exist between the neurons, which is true for 
neural networks as well.
The field of neural network was established before the advent of 
computers, but many important advances did not appear until the use of fast and 
inexpensive computers.
Neural networks take a different approach to problem solving than that of 
conventional computers. Conventional computers use an algorithmic approach,
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i.e. the computer follows a set of instructions in order to solve a problem. Unless 
the specific steps that the computer needs to follow are known, the computer 
cannot solve the problem. But computers would be so much more useful if they 
could do things that we don't exactly know how to do. Neural networks process 
information in a similar way the human brain does. They cannot be programmed 
to perform a specific task. The examples must be selected carefully otherwise 
useful time is wasted or even worse the network might be functioning incorrectly. 
The disadvantage is that because the network finds out how to solve the problem 
by itself, its operation can be unpredictable.
An artificial neuron (Figure 64) is a device with many inputs and one 
output. The neuron has two modes of operation; the training mode and the 
predictive mode. In the training mode, the neuron can be trained to fire (or not), 
for particular input patterns. In the predictive mode, when a taught input pattern is 








Figure 64 A simple artificial neuron in Neural Network.
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The most common type of artificial neural network consists of three layers 
of neurons: a layer of "input" elements is connected to a layer of "hidden" 
neurons, which is connected to a layer of "output" neurons (Figure 65). The 
activity of the input units represents the raw information that is fed into the 
network. The activity of each hidden unit is determined by the activities of the 
input units and the weights on the connections between the input and the hidden 
units. The behavior of the output units depends on the activity of the hidden units 
and the weights between the hidden and output units.
Hidden layer Outputs
Figure 65 An example of a fully connected feed-forward network.
Every neural network possesses knowledge which is contained in the 
values of the connections weights (Figure 66). Modifying the knowledge stored in 
the network as a function of experience implies a learning (training) rule for 
changing the values of the weights. Information is stored in the weight matrix W  
of a neural network. Learning (training) is the determination of the weights.
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Incoming neural activations (A,) 
multiplied by individual 
connection weights (W jj)
Output activation (Ay) multiplied 
by individual connection weights 
(Wjk) sent to other neurons
I » ' r
. 1 = 1
Figure 66 Activation (output) of Neuron j, Aj. W  is the individual 
connection weight; 0j is the offset or threshold.
Since neural networks are best at identifying patterns or trends in data, 
they are well suited for prediction or forecasting needs including sales 
forecasting, industrial process control, customer research, data validation, risk 
management, target marketing, etc. The ability to learn by example makes neural 
network very flexible and powerful. Furthermore, there is no need to devise an 
algorithm in order to perform a specific task; i.e. there is no need to understand 
the internal mechanisms of that task.
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5.2.2. Application of Neural Network Model
One major purpose of modeling is to have the ability to forecast. Although 
we have proposed a theory and mathematical model for the process of protein 
release from liposomes with permeation enhancers, we would like to use a 
neural network to predict the release process, i.e. to predict a, b , c , t *  values, 
based on given conditions.
There are nine major factors that affect the protein release profile, which 
means there are nine inputs for our neural network. These inputs are AT (T-Tc), 
cholesterol content in lipid bilayer, molecular weight of protein, amount of CPE- 
215®, amount of cottonseed oil, ratio of total oil (CPE-215® and cottonseed oil) to 
lipid content (DPPC and cholesterol), percent of (3-cyclodextrin in the aqueous 
phase, percent of a-cyclodextrin in the aqueous phase, and pH.
We listed all nine factors and a, b , c, t *  values for each experimental 
release curve in Table 9. In order to easily trace back to the experiment, the 
number of chapter where the experiment was mentioned in this thesis and the 
sample name were also shown in Table 9. According to our liposome DSC data, 
the phase transition temperature for 4:1 (w/w) DPPC/Cholesterol liposome is 46 
°C, which is the reason why when using DPPC/Cholesterol liposomes at 37 °C, 
the AT is shown as -9. We used insulin dimer for the insulin molecular weight 
because we know at the release concentration and condition inside of liposomes, 
insulin mostly existed as dimers, and probably penetrated the liposomes as 
dimers. Since Table 9 was used for the training of our neural network, two sets of
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data (randomly selected), which were used to test the prediction, are not listed 
here.




























3.2.2 Blank 0 0 11600 0 0 0 0 0 7.4 1.66 10.41 0.48 6.79
3.2.2 CPE215 0 0 11600 0.25 40.9 0 0 0 7.4 3.29 3.43 0.42 6.01
3.2.2 3-CD 0 0 11600 0 0 0 0.3 0 7 4.14 12.93 0.15 5.32
3.3.1 CPE&CSO 0 0 11600 0.258 54.5 0.086 0 0 7 6.72 8.68 0.19 3.54
3.3.1 6-CD+CPE&CSO 0 0 11600 0.258 54.5 0.086 0.3 0 7 10.65 9.02 0.33 2.20
3.3.1 a-CD+CPE&CSO 0 0 11600 0.258 54.5 0.086 0 2.1 7 15.25 23.07 0.09 3.47
3.3.2 C&C+20X 3-CD 0 0 11600 0.046 8.7 0.015 1 0 7 14.68 16.79 0.23 2.12
3.3.2 C&C+1x a-CD 0 0 11600 0.046 8.7 0.015 0 0.05 7 9.94 9.86 0.20 2.51
3.3.2 C&C+20x a-CD 0 0 11600 0.046 8.7 0.015 0 0.9 7 14.08 10.43 0.19 1.94
3.3.3 Blank 0 0 11600 0 0 0 0 0 7 0.71 49.44 0.20 10.00
3.3.3 CS0+3-CD 0 0 11600 0 0.6 0.0032 1 0 7 11.83 55.55 0.02 1.00
3.3.3 CPE+3-CD 0 0 11600 0.0095 1.6 0 1 0 7 6.57 51.72 0.16 0.65
3.3.3 CPE+CSO+3-CD 0 0 11600 0.0095 2.2 0.0032 1 0 7 11.87 40.41 0.28 0.94
3.4.1 Blank -9 20 11600 0 0 0 0 0 7 0.90 2.14 0.70 10.00
3.4.1 CPE-215 -9 20 11600 0.0084 1 0 0 0 7 2.90 0.41 0.62 2.60
3.4.1 Cottonseed Oil -9 20 11600 0 1.1 0.0096 0 0 7 4.26 0.65 0.30 5.78
3.4.1 CPE+3-CD -9 20 11600 0.0084 1 0 1.3 0 7 4.90 1.34 0.58 6.47
3.4.2 Blank -9 20 11600 0 0 0 0 0 7 0.91 4.02 0.71 54.29
3.4.2 3-CD -9 20 11600 0 0 0 1.7 0 7 4.17 5.59 0.50 5.01
3.4.2 1xCPE&CSO -9 20 11600 0.009 1.4 0.003 0 0 7 8.58 3.21 0.45 4.04
3.4.2 3xCPE&CSO -9 20 11600 0.027 4.1 0.009 0 0 7 10.20 5.11 0.20 4.22
3.4.2 1 XCPE&CSO+3-CD -9 20 11600 0.009 1.4 0.003 1.7 0 7 23.96 9.34 0.39 2.35
3.4.2 3xCPE&CSO+3-CD -9 20 11600 0.027 4.1 0.009 1.7 0 7 29.26 13.66 0.54 1.63
3.5.1 pH7 Blank -9 20 11600 0 0 0 0 0 7 0.66 -0.07 0.62 2.45
3.5.2 Blank -9 20 11600 0 0 0 0 0 10 0.32 -0.14 0.36 21.75
3.5.2 C&C -9 20 11600 0.0084 1.3 0.0028 0 0 10 1.16 -1.91 0.89 9.04
3.5.2 C&C+3-CD -9 20 11600 0.0084 1.3 0.0028 1.7 0 10 5.02 -2.33 0.79 14.09
3.5.3 Blank -9 20 11600 0 0 0 0 0 4 0.36 -0.73 0.23 16.91
3.5.3 C&C -9 20 11600 0.0084 1.3 0.0028 0 0 4 0.46 -0.37 0.20 23.42
3.5.3 C&C+3-CD -9 20 11600 0.0084 1.3 0.0028 1.7 0 4 4.16 2.15 1.30 7.87
3.6 Blank -9 20 66000 0 0 0 0 0 7 1.32 0.29 0.40 49.04
3.6 CPE -9 20 66000 0.013 1 0 0 0 7 2.10 -0.81 0.50 29.68
3.6 CPE&CSO -9 20 66000 0.013 1.4 0.0043 0 0 7 4.13 -2.36 0.23 18.83
The neural network software we are using is FORECASTER XL™ from 
ALYUDA Research, Inc, which is a MS Excel add-in program for forecasting and 
data analysis using neural network method. We used this program to form the 
network and forecast a , b , c, t *  values one at a time. In that case, we have nine
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inputs and one output each time. We have 33 sets of data to form the network, in 
which 85% (28) of the data sets would be used for network training and 15% (5) 
of the data sets would be used for testing purposes by the program; the program 
requires the data sets should be at least three times more than the number of 
inputs, and we barely met this minimum requirement.
5.2.3. Neural Network Model Analysis
For neural network modeling, the major task for users is to form the input 
and output matrix, then the rest is all automatic calculation. We did the 
calculation for a , b , c  and t *  one by one. After each calculation, the program gave 
a report on the neural network formed.
For the network formed for the purpose of predicting the value of a, the 
program gave some figures to visualize the deviation of the forecasted value 
from the actual result. From Figure 67, we can see the forecasted value did not 
deviate from the actual value significantly, except for a few rows. Given the 
limited number of experimental data sets, this is a reasonable network model for 
the prediction the value of a.
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Figure 68 Input importance for each parameter in the network for 
predicting a. C6 is AT (T-Tc), D6 is the cholesterol content in lipid bilayer, 
E6 is the molecular weight of protein, F6 is the amount of CPE-215®, H6 
is the amount of cottonseed oil, G6 is the ratio of total oil (CPE-215® and 
cottonseed oil) to lipid content (DPPC and cholesterol), 16 is the percent of 
(3-cyclodextrin in the aqueous phase, J6 is the percent of a-cyclodextrin in 
the aqueous phase, and K6 is pH.
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Figure 68 shows that the parameters of temperature, cholesterol content 
in lipid bilayer, (B-cyclodextrin concentration and pH have significant influence on 
the a value, which is the rate of triggered boost release at the beginning of the 
protein release. Based on our knowledge of our protein release system, the 
major factors that the network picked seem reasonable: the temperature and 
cholesterol content have significant influence on liposome properties; (3- 
cyclodextrin is an efficient phase transfer agent to transport CPE-215® to the 
membrane; pH would affect the surface charge character of proteins and as a 
result greatly alter the permeation ability of proteins.
For the neural network formed for the purpose of predicting the value of c, 
the program also gave some figures to visualize the deviation of the forecasted 
value from the actual result. From Figure 69, we can see the forecasted value did 
not deviate from the actual value too much. Again, this is a reasonable network 
model for the prediction of c value.
176



















H6 —  7.446%





o% 20% 40% 60% 80% 100%
Figure 70 Input importance for each parameter in the network for 
predicting c. C6 is AT (T-Tc), D6 is the cholesterol content in lipid bilayer, 
E6 is the molecular weight of protein, F6 is the amount of CPE-215®, H6 
is the amount of cottonseed oil, G6 is the ratio of total oil (CPE-215® and 
cottonseed oil) to lipid content (DPPC and cholesterol), 16 is the percent of 
P-cyclodextrin in the aqueous phase, J6 is the percent of a-cyclodextrin in 
the aqueous phase, and K6 is pH.
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Figure 70 shows that temperature, cholesterol content in lipid bilayer, (3- 
cyclodextrin concentration and pH have significant influence on the c value, 
which is similar to what the previous neural network picked for a value. The value 
of c represents the self-leakage rate of liposomes. Again, this is a reasonable 
pick of major parameters for the similar reasons.
For the neural network formed for the purpose of predicting the value of t*, 
the program also gave some figures to visualize the deviation of the forecasted 
value from the actual result. The value of t *  represents the time when the 
permeation enhancers starts to diffuse evenly within the lipid bilayer and the 
system starts to change from the triggered boost release to liposome self­
leakage. From Figure 71, we can see the forecasted value did not deviate from 
the actual value too much, except for one and actually that one is a “Blank” 
sample. As to “Blank” samples, f*does not have meanings for them, because 
they actually do not have a transition time point. Therefore, this is an effective 
network model for the prediction of t *  value for non-“Blank” samples.
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Figure 72 Input importance for each parameter in the network for 
predicting t*. C6 is AT (T-Tc), D6 is the cholesterol content in lipid bilayer, 
E6 is the m olecular weight of protein, F6 is the am ount of CPE-215®, H6 
is the amount of cottonseed oil, G6 is the ratio of total oil (CPE-215® and 
cottonseed oil) to lipid content (DPPC and cholesterol), 16 is the percent of 
(3-cyclodextrin in the aqueous phase, J6 is the percent of a-cyclodextrin in 
the aqueous phase, and K6 is pH.
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Figure 72 shows that temperature, cholesterol content in lipid bilayer, 
protein molecular weight and pH have significant influence on the t *  value. It is 
easy to understand the influence of temperature and cholesterol content in lipid 
bilayer on the t *  value, but it is hard to relate t* to protein molecular weight and 
pH. Maybe this is due to the limitation in the number of data sets.
Neural network training was performed for b , but the result was not useful 
as expected. The parameter b  has the meaning of systemic error; therefore, 
there is no real meaning in predicting b  value. For the purpose of forecasting, we 
used b  = 0 .01, since the b  value can not be zero.
5.2.4. Neural Network Prediction
After we formed the neural networks for a, c and t* , we wanted to see if 
the neural networks can predict reasonable values for a, c and t *  for other 
release experiments. Table 10 shows the data sets we used to test the neural 
network prediction. Table 11 gives out the result of neural network prediction 
values versus the mathematical fit values of a , c  and t*.





















3.4.1 CSO+B-CD -9 20 11600 0 1.1 0.0096 1.3 0 7
3.5.1 C&C+B-CD -9 20 11600 0.009 1.4 0.003 1.7 0 7
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Table 11 Neural network prediction compared with the math model result.
CSO+B-CD C& C+B-CD
Math Fit Neural Network 
Prediction
Math Fit Neural Network 
Prediction
a (% 'hour'1) 7.11 7.88 20.61 24.03
b ( % ) 1.67 0.01T -2.33 0.01T
c  (%‘ hour1) 0.83 0.68 0.70 0.54
t *  (hour) 5.14 2.39 2.53 2.07
t  The value ol b  in Neural Network is not pred icted, but arbitrarily put as 0.01
Figure 73 and Figure 74 show the deviation of the forecasted model curve 
from the real experimental data. One neural network prediction fits well with the 
experimental data, while the other only fits the early data. Given the fact that the 
neural network forecast was based on a,  c, and t *  values that were from the 
empirical mathematical model, which was not exactly the same as the real data, 
and the limited number of data sets, the prediction are acceptable, though we 
recognize that they are far from ideal.
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Figure 74 Neural network forecast for “C&C+B-CD” sample in Chapter
Among the three major parameters a, c, and t*, a  is the one that we are 
most interested in to do predictions since it is the triggered boost release rate. 
Based on the neural network we formed, we wanted to know under what 
conditions the highest a value could be achieved. Figure 68 shows the individual 
connection weight for each input condition — temperature, cholesterol content in 
lipid bilayer, (3-cyclodextrin concentration and pH have significant influence on 
the a value. The neural network predicted the maximum a value could be 
reached at 37 °C in pH 7 from 4:1 DPPC/Cholesterol liposome with the highest 
concentrations of phase transfer agents, CPE-215® and cottonseed oil. In
3.5.1.
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practical situations, phase transfer agents have their solubility limit and the 
amount of CPE-215® and cottonseed oil added does have limit. Under the 
conditions of 37 °C, pH 7, 4:1 DPPC/Cholesterol liposome, insulin dimer, 0.06 g 
CPE-215®, 0.02 g cottonseed oil, 1.7% P-cyclodextrin, 2.1% a-cyclodextrin, the 
neural network predicted the boost release rate, a value, to be 31.9 %*hour"1, 
which is more than 40 times faster than the liposome leakage rate (0.73 %*hour'
184
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CHAPTER 6
CONCLUSION
In our study of the enhancement effect of cyclopentadecanolide (CPE- 
215®) on protein permeation through lipid membranes, we successfully designed 
and developed a novel in vitro membrane permeability model -  liposome. This 
model system can not only be used to perform in vitro protein release 
experiments, but also can be used as a tool to select promising intranasal 
formulations before the expensive animal tests. We effectively labeled the 
proteins (insulin and BSA) with fluorescein to increase their detection sensitivity 
at low concentrations. By utilizing the extrusion technique, we can prepare 
“mono-dispersed” 400 nm large unilamellar vesicles/liposomes; when using 1% 
(weight) lipid content to make 400 nm unilamellar DPPC liposomes, the 
encapsulation efficiency is 10%. We prepared different liposomes with DPPC, 
cholesterol and CPE-215®, among which DPPC was the major lipid component. 
We utilized liposomes to encapsulate fluorescein labeled insulin, fluorescein 
labeled BSA and calcein. We used the centrifugal extraction method to clean the 
unencapsulated molecules and the molecules adsorbed on the outside surface of 
liposomes, so that the fluorescence signal outside of liposome was close to the 
background signal of the buffer solution. We utilized this model to perform a
185
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series of protein release kinetics experiments from liposomes at 37 °C, 42 °C, at 
pH 7, pH 4, pH 10, in the presence of CPE-215®, cottonseed oil, cyclodextrins.
The experimental results show that CPE-215® is an effective membrane 
permeation enhancer for proteins; because of the limited solubility of hydrophobic 
CPE-215® in water, a phase transfer agent, for example, cyclodextrins, can 
further enhance the permeation effect of CPE-215®. The pH of the solution has a 
huge impact on the protein release profile due to the protein surface charge 
change caused by the pH change. Proteins permeate through lipid bilayers 
easier at pH levels around its isoelectric point.
Studies on insulin solution properties (self-diffusion and self-association 
states), the interaction between insulin and liposome, and the interaction 
between CPE-215® and liposomes were carried out to understand the 
mechanism behind the fact that CPE-215® facilitates the protein transport 
through lipid bilayers. We determined insulin diffusion coefficient at pH 3 at 37 °C 
to be 1.4 x 10'10 m2/s, or 1.4 x 10'6 cm2/s by the pulsed field gradient NMR 
technique. We determined the binding constant of insulin on a DPPC/Cholesterol 
liposome surface to be K  = 97 ml/mg, which indicates that insulin only has weak 
interactions with liposomes. However, we identified that CPE-215® almost 
doubled the insulin adsorption energy on liposome surface by ITC. Based on our 
calculation, there would be 20 insulin dimers adsorbed on the inner surface of 
each 400 nm liposome in our release conditions. By modulated DSC, we 
determined that CPE-215® could diffuse across the aqueous phase into the 
bilayer through limited number of thermal cycles from 10 °C to 90 °C; 20%
186
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
(weight) CPE-215® can broaden the Tc range, lower the Tc of DPPC liposome by 
8 °C and the Tc of DPPC/Cholesterol liposome by 9 °C, and reduce the AH of 
DPPC transition from 37 kJ/mol to 20 kJ/mol.
Based on the mechanism study, our release data and the current 
liposome leakage theory, we proposed a hypothesis that CPE-215® would form a 
transient “pore” in the lipid bilayer at the beginning of the release experiment; 
after CPE-215® evenly diffused within the bilayer, the barrier function of the lipid 
bilayer was restored. We performed one set of testing experiments and the result 
supported our hypothesis theory.
Mathematical modeling approach was used based on our theory. The 
release kinetics was modeled with Equation 5.7,
1
v ( a  • t  +  b ) 2 ( c - t  +  ( a - c ) - t *  + b )2,
where y  is the percentage of protein released from liposome, a, c, t *  are 
adjustable parameters: a is the boost release rate, b  represents the systemic 
error of the experiment, c is the liposome self-leakage rate, t *  is the transition 
time between the triggered boost release and the self-leakage of liposomes.
Most release data fit well with this model, which further supported our hypothesis 
theory.
We used the neural network approach to find the internal connections 
between different release condition parameters based on our limited data sets 
and tried to predict the protein release profile at new conditions. The values of a, 
c, f*were correlated to experimental conditions (temperature difference between
187
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the release temperature and the phase transition temperature of liposome, the 
cholesterol content in the liposome, the protein molecular weight, the amount of 
CPE-215®, the amount of cottonseed oil, the weight ratio of oil (CPE-215® and 
cottonseed oil) to lipid (DPPC and cholesterol), the amount of p-cyclodextrin and 
a-cyclodextrin, and pH) through neural networks. Neural network predicted the 
values of a and c  within 20% error, and t *  with a 20% to 50% error. The initial 
boost release rate is the most concerned parameter when the model is used to 
determine the promising intranasal formulations. The prediction result shows that 
reasonable neural networks were successfully formed for the major parameters 
of the mathematical model. The neural network predicted the maximum value of 
a of 31.9 %»hour'1, for the condition of 37 °C, 4:1 DPPC/Cholesterol liposome at 
pH 7 with 1.7% of P-cyclodextrin and 2.1 % a-cyclodextrin, 0.06 g CPE-215® and 
0.02 g cottonseed oil, which is more than 40 times faster than the liposome 
leakage rate.
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APPENDIX
In Chapter 5.1, we developed a mathematical model, based on our theory 
of protein release from liposomes, to quantify the release results. Equation 5.7 
was used as the modeling equation to express the whole protein release process.
We used the “Solver” function of Excel® to estimate the best a, b , c  and t *  
values to make the Equation 5.7 fit the experimental data through a least square 
non-linear curve fit. Table 6 listed the result of the curving fitting. The figures in 
the Appendix show the detail curve fitting for each release curve: the diamond 
dots are the experimental data points and the line is the fitting curve. The R2 
value was also given by
where y. is the experimental protein percent release value, y. is the predicted 
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